Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | |
Dec. 31, 2018 | Feb. 05, 2021 | |
Document Information Line Items | ||
Entity Registrant Name | NUTRA PHARMA CORP | |
Document Type | 10-K | |
Current Fiscal Year End Date | --12-31 | |
Entity Common Stock, Shares Outstanding | 6,855,197,214 | |
Entity Public Float | $ 2,385,792 | |
Amendment Flag | false | |
Entity Central Index Key | 0001119643 | |
Entity Current Reporting Status | No | |
Entity Voluntary Filers | No | |
Entity Filer Category | Non-accelerated Filer | |
Entity Well-known Seasoned Issuer | No | |
Document Period End Date | Dec. 31, 2018 | |
Document Fiscal Year Focus | 2018 | |
Document Fiscal Period Focus | FY | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity File Number | 003-32141 | |
Entity Interactive Data Current | Yes |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 |
Current assets: | ||
Cash | ||
Accounts receivable | 17,065 | 15,143 |
Inventory | 35,302 | 20,142 |
Due from officer | 269,772 | |
Prepaid expenses and other current assets | 63,000 | 52,500 |
Total current assets | 115,367 | 357,557 |
Property and equipment, net | 10,500 | 16,463 |
Security deposit | 15,550 | 15,550 |
Total assets | 141,417 | 389,570 |
Current liabilities: | ||
Accounts payable | 475,409 | 393,043 |
Accrued expenses | 831,849 | 949,396 |
Accrued payroll due to officers | 1,050,993 | 836,493 |
Deferred revenue | 22,490 | |
Accrued interest to related party | 141,808 | 126,036 |
Due to officer | 186,497 | |
Derivative warrant liability | 1,468 | 5,903 |
Other debt, net of discount | 3,338,576 | 3,466,403 |
Total current liabilities | 6,026,600 | 5,799,764 |
Promissory note, less current portion | 51,410 | |
Total liabilities | 6,078,010 | 5,799,764 |
Commitments and Contingencies | ||
Stockholders' deficit: | ||
Preferred stock, $0.001 par value, 20,000,000 shares authorized: 3,000,000 Series A Preferred shares issued and outstanding at December 31, 2018 and 2017 | 3,000 | 3,000 |
Common stock, $0.001 par value, 8,000,000,000 shares authorized: 4,046,746,110 and 2,032,233,701 shares issued and outstanding at December 31, 2018 and 2017 | 4,046,746 | 2,032,234 |
Additional paid-in capital | 51,286,503 | 49,942,719 |
Accumulated deficit | (61,272,842) | (57,388,147) |
Total stockholders' deficit | (5,936,593) | (5,410,194) |
Total liabilities and stockholders' deficit | $ 141,417 | $ 389,570 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - $ / shares | Dec. 31, 2018 | Dec. 31, 2017 |
Preferred stock par value (in Dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock shares authorized | 20,000,000 | 20,000,000 |
Common stock par value (in Dollars per share) | $ 0.001 | $ 0.001 |
Common stock shares authorized | 8,000,000,000 | 8,000,000,000 |
Common stock shares issued | 4,046,746,110 | 2,032,233,701 |
Common stock shares outstanding | 4,046,746,110 | 2,032,233,701 |
Series A Preferred Stock [Member] | ||
Series A Preferred shares issued | 3,000,000 | 3,000,000 |
Series A Preferred shares outstanding | 3,000,000 | 3,000,000 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Income Statement [Abstract] | ||
Net sales | $ 130,596 | $ 120,979 |
Cost of sales | (68,777) | (26,903) |
Change in reserve for supplier advances for purchases | (47,757) | |
Gross profit | 14,062 | 94,076 |
Operating expenses: | ||
Selling, general and administrative - including stock based compensation of $70,000 and $73,576 for the years ended December 31, 2018 and 2017, respectively | 1,387,454 | 1,476,016 |
Bad debt expense - officer loans | 505,470 | |
Total operating expenses | 1,892,924 | 1,476,016 |
Loss from operations | (1,878,862) | (1,381,940) |
Other income (expenses) | ||
Interest expense | (574,334) | (343,194) |
Interest expense to related parties | (15,772) | (15,457) |
Change in fair value of convertible notes and derivatives | (2,146,950) | (2,273,968) |
Stock issued for loan modification | (174,535) | |
Gain (Loss) on settlement of debt and accounts payable, net | 905,758 | (14,189) |
Total Other income (expenses) | (2,005,833) | (2,646,808) |
Loss before income taxes | (3,884,695) | (4,028,748) |
Provision for income taxes | ||
Net loss | $ (3,884,695) | $ (4,028,748) |
Net loss per share - basic and diluted (in Dollars per share) | $ 0 | $ 0 |
Weighted average number of shares outstanding during the year - basic and diluted (in Shares) | 3,187,272,679 | 1,048,283,386 |
Consolidated Statements of Op_2
Consolidated Statements of Operations (Parentheticals) - USD ($) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Income Statement [Abstract] | ||
Stock based compensation | $ 70,000 | $ 73,576 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Net loss | $ (3,884,695) | $ (4,028,748) |
Change in reserve for supplier advances for purchases | 47,757 | |
Bad debt expense - officer loans | 505,470 | |
Accrued interest expense for amount due to officer | 7,674 | |
(Gain) loss on settlement of debt and accounts payable | (905,758) | 14,189 |
Depreciation | 5,963 | 6,286 |
Stock-based compensation | 70,000 | 73,576 |
Stock-based loan modification cost | 174,535 | 5,140 |
Change in fair value of convertible notes and derivatives | 2,146,950 | 2,273,968 |
Amortization of loan discount | 378,754 | 117,325 |
Changes in operating assets and liabilities: | ||
Decrease (Increase) in accounts receivables | (1,922) | 15,482 |
Decrease (Increase) in inventory | (15,160) | 5,420 |
Increase in prepaid expenses and other current assets | (8,257) | (8,486) |
Increase in accounts payable | 86,567 | 111,961 |
Increase in accrued expenses | 184,391 | 5,593 |
Increase in accrued payroll due to officers | 214,500 | 232,000 |
Increase (Decrease) in deferred revenue | (22,490) | 22,490 |
Increase in accrued interest to related party | 15,772 | 15,457 |
Net cash used in operating activities | (999,949) | (1,138,347) |
Cash flows from investing activities: | ||
Acquisition of property and equipment | (9,113) | |
Net cash used in investing activities: | (9,113) | |
Cash flows from financing activities: | ||
Loans from officer | 105,900 | 330,350 |
Repayment of officers loans | (162,775) | (266,900) |
Repayments of notes payable-related party | (15,209) | |
Proceeds from convertible notes | 1,101,800 | 595,500 |
Repayment of convertible notes | (3,000) | (40,000) |
Proceeds from other notes payable, net of debt discount of $28,723 in 2017 | 690,500 | |
Repayments of other notes payable | (41,976) | (178,024) |
Net cash provided by financing activities | 999,949 | 1,116,217 |
Net decrease in cash | (31,243) | |
Cash - beginning of year | 31,243 | |
Cash - end of year | ||
Supplemental Cash Flow Information: | ||
Cash paid for interest | 5,425 | 75,207 |
Cash paid for income taxes | 0 | 0 |
Non cash Financing and Investing: | ||
Note and stock issued in settlement of notes and accounts payable | 348,050 | |
Shares issued to satisfy debt | 2,434,452 | 2,619,101 |
Shares issued to satisfy debt-related party | 348,050 | |
Discounts on notes payable | 32,146 | 28,815 |
Debt discount for beneficial conversion features | $ 249,113 | 5,241 |
Related Party [Member] | ||
Non cash Financing and Investing: | ||
Note and stock issued in settlement of notes and accounts payable | 400,000 | |
Shares issued to satisfy debt-related party | $ 400,000 |
BASIS OF PRESENTATION AND SUMMA
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2018 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Significant Accounting Policies [Text Block] | 1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® Basis of Presentation and Consolidation The accompanying Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Adjustments have been made to the Consolidated Balance sheets for the year ended December 31, 2017, to reclassify accrued interest to related parties, accrued payroll due to officers, and accrued payroll taxes. An adjustments has been made to Consolidated Statement of operations for the year ended December 31, 2017, to reclassify interest expense to related parties. These changes in classification also affected cash flows from operating activities for the year ended December 31, 2017 in the Consolidated Statements of Cash Flows. Liquidity and Going Concern Our Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $61,272,842 at December 31, 2018. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $5,911,233 and a stockholders’ deficit of $5,936,593 at December 31, 2018. There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from SBA to fund our request for a PPP loan for $64,895. We intended to use the proceeds primarily for payroll costs. During April and June 2020, we obtained the loan in the amount of $154,900 from SBA under its Economic Injury Disaster Loan assistance program. We intended to use the proceeds primarily for working capital purpose (See Note 13). The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the development of widespread testing or a vaccine. Use of Estimates The accompanying Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and warrant liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers, originally effective for public business entities with annual reporting periods beginning after December 15, 2016. On August 12, 2015, the FASB issued an Accounting Standards Update (“ASU”), Revenue From Contracts With Customers (Topic 606): Deferral of the Effective Date, which deferred the effective date of ASC 606 for one year. ASC 606 provides accounting guidance related to revenue from contracts with customers. For public business entities, ASC 606 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. This new revenue recognition standard (new guidance) has a five-step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; and e) Recognize revenue when (or as) performance obligations are satisfied. The Company has evaluated the impact of ASC 606 and determined that there is no change to the Company's accounting policies, except for the recording of certain product sales to a distributor, in which a portion of the cash proceeds received is remitted back to the distributor. Under ASC 606, the Company determined that these sales should be recorded on a gross basis. Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon delivery of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor. Adoption of ASC 606, Revenue from Contracts with Customers On January 1, 2018, we adopted ASC 606 using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic revenue recognition methodology under ASC 605, Revenue Recognition. The cumulative impact of adopting ASC 606 resulted in no changes to retained earnings at January 1, 2018. The impact to revenue for the year ended December 31, 2018 was an increase of $4,403 as a result of applying ASC 606 to certain revenues generated through online distributors which are now presented gross as we have control over providing the products related to such revenues. For the year ended December 31, 2018, the revenue recognized from contracts with customers was $130,596. The impact of adoption of ASC 606 on our consolidated statement of operations was as follows: With Implementation of ASC 606 Before Implementation of ASC 606 Effect of Implementation Revenue $ 130,596 $ 126,193 $ 4,403 Costs of sales (68,777) (64,374) (4,403) Net effect of ASC 606 implementation $ - There was no balance sheet impact. Accounting for Shipping and Handling Costs We record shipping and handling costs incurred in cost of sales. Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivables. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. Management believes that the receivables are fully collectable. Therefore, no allowance for doubtful account is deemed to be required at December 31, 2018 and 2017. Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand. If necessary it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at December 31, 2018, and increased the reserve on supplier advances for future venom purchases included in the prepaid expenses and other current assets by $47,757. At December 31, 2018, the total valuation allowance for prepaid venom is $200,911. Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2018, there were two customers that accounted for 32% and 27% of the total revenues, respectively. For the year ended December 31, 2017, there were two customers that accounted for 38% and 15% of the total revenues, respectively. For the years ended December 31, 2018 and 2017, 84% and 85% of the accounts receivable balance are reserves due from two payment processors. Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature ("BCF"). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging Property and Equipment and Long-Lived Assets Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years. Income Taxes We compute income taxes in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 740, Income Taxes On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position. At December 31, 2018 and 2017, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions. Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation Net Loss Per Share Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share December 31, 2018 December 31, 2017 Options and warrants 12,600,000 13,540,000 Convertible notes payable 4,448,128,953 2,467,512,550 Total 4,460,728,953 2,481,052,550 Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases In June 2018, the FASB issued ASU 2018-07, “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). ASU No 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance also specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and is effective for the Company as of January 1, 2019. The Company noted that all share based payments were settled as of the date of the adoption, so there was no impact on the Company's financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable. |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 12 Months Ended |
Dec. 31, 2018 | |
Fair Value Disclosures [Abstract] | |
Fair Value Disclosures [Text Block] | 2. FAIR VALUE MEASUREMENTS Certain assets and liabilities that are measured at fair value on a recurring basis at December 31, 2018 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements The statement requires fair value measurement be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The following table summarizes our financial instruments measured at fair value at December 31, 2018 and December 31, 2017: Fair Value Measurements at December 31, 2018 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,468 $ - $ - $ 1,468 Convertible notes at fair value $ 1,156,341 $ - $ - $ 1,156,341 Fair Value Measurements at December 31, 2017 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 5,903 $ - $ - $ 5,903 Convertible notes at fair value $ 1,925,959 $ - $ - $ 1,925,959 The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the years ended December 31, 2018 and 2017: Description 2018 2017 Beginning balance $ 5,903 $ 48,504 Purchases, issuances, and settlements - 24,017 Day one loss on value of hybrid instrument - - Total (gain) loss included in earnings (1) (4,435) (66,618) Ending balance $ 1,468 $ 5,903 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. We valued our warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 2.59% to 2.81% risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 256% (4) zero expected dividends (5) exercise price set forth in the agreements (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted. The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at December 31, 2018 and 2017: Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back 2018 $1,340,026 8%-12% 18%-20% 25.95-27.95 $0.0002-$0.20 40%-60% 3 to 25 Days 2017 $682,099 8%-12% 18% 23.95-27.95 $0.0002-$0.20 40%-60% 3 to 25 Days Using the stated assumptions summarized in table above, we calculated the inception date and reporting period fair values of each note issued. The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the year ended December 31, 2018 and 2017: Description 2018 2017 Beginning balance $ 1,925,959 $ 1,672,728 Purchases and issuances 472,029 580,143 Day one loss on value of hybrid instrument (1) 2,021,041 999,228 Loss from change in fair value (1) 130,344 1,314,325 Gain on settlement (958,581) - Conversion to common stock (2,434,451) (2,594,100) Repayment in cash - (46,365) Ending balance $ 1,156,341 $ 1,925,959 (1) The losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
INVENTORIES
INVENTORIES | 12 Months Ended |
Dec. 31, 2017 | |
Inventory Disclosure [Abstract] | |
Inventory Disclosure [Text Block] | 3. INVENTORIES Inventories are valued at the lower of cost or net realizable value on an average cost basis. At December 31, 2018 and 2017, inventories were as follows: December 31, 2018 December 31, 2017 Raw Materials $ 33,431 $ 13,704 Finished Goods 1,871 6,438 Total Inventories $ 35,302 $ 20,142 |
PROPERTY AND EQUIPMENT
PROPERTY AND EQUIPMENT | 12 Months Ended |
Dec. 31, 2018 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment Disclosure [Text Block] | 4. PROPERTY AND EQUIPMENT Property and equipment consists of the following at December 31, 2018 and 2017: December 31, 2018 December 31, 2017 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 53,711 53,711 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 216,033 216,033 Less: Accumulated depreciation (205,533) (199,570) Property and equipment, net $ 10,500 $ 16,463 We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At December 31, 2018, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the years ended December 31, 2018 and 2017 was $5,963 and $6,286, respectively. |
DUE FROM_TO OFFICERS
DUE FROM/TO OFFICERS | 12 Months Ended |
Dec. 31, 2018 | |
Due to Officers [Abstract] | |
Due to Officers [Text Block] | 5. DUE TO/FROM OFFICER At December 31, 2018, the balance due to our President and CEO, Rik Deitsch, is $186,497, which is an unsecured demand loan that bears interest at 4%. During the year ended December 31, 2018, we advanced $162,775 to and collected $105,900 from Mr. Deitsch and the Companies owned by him. Additionally, accrued interest on the demand loan was $7,674 and is included in the due to officer account. As of December 31, 2018, we recorded a bad debt expense of $505,470 which represents a full valuation allowance for amounts owed by these Companies. At December 31, 2017, the balance due from our officer and Companies owned by him is $269,772. Included within this balance is an unsecured demand loan due to Mr. Deitsch, in the amount of $134,549. The loan bears interest at 4%. During the year ended December 31, 2017, we borrowed $330,350 and repaid $266,900 to Mr. Deitsch and the Companies owned by him . |
DEBTS
DEBTS | 12 Months Ended |
Dec. 31, 2018 | |
Debt Disclosure [Abstract] | |
Debt Disclosure [Text Block] | 6. DEBTS Debts consist of the following at December 31, 2018 and 2017: December 31, 2018 December 31, 2017 Note payable– Related Party (Net of discount of $2,400 and $2,000, $ 12,000 $ 202,974 Notes payable – Unrelated third parties (Net of discount of $17,870 1,469,690 1,337,470 Convertible notes payable – Unrelated third parties (Net of discount of 751,955 594 Convertible notes payable, at fair value (4) 1,156,341 1,925,365 Ending balances 3,389,986 3,466,403 Less: Current portion (3,338,576) (3,466,403) Long-term portion-Notes payable-Unrelated third parties $ 51,410 $ - (1) During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At December 31, 2018 and 2017, we owed this director accrued interest of $141,808 and $126,036. The interest expense for the years ended December 31, 2018 and 2017 was $15,772 and $15,457. In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by one of our directors. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At December 31, 2018 and 2017, we owed principal balance of $192,974, and accrued interest of $40,033 and $16,876, respectively. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020 (See Note 12) In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. At December 31, 2018 and 2017, the principal balance of the loan is $12,000. The Note was settled in June 2020. (2) At December 31, 2018 and 2017, the balance of $1,469,690 and $1,337,470 net of discount of $17,870 and $28,723, respectively, consisted of the following loans: ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $2,739 and $1,465. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the outstanding principal balance is $50,000 and accrued interest is $37,801 and $25,567. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2018 and 2017, the outstanding principal balance is $50,000 and accrued interest is $31,000 and $18,767. ● In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest were restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest were restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. The note is in default and negotiation of settlement. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018 (See Note 7). The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest were restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and will be due June 17, 2019. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $329 and the debt discount at December 31, 2018 is $3,616. At December 31, 2018 and 2017, the principal balance is $282,983 and $180,250, respectively, and the accrued interest is $2,830 and $38,455, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $17,271 and $7,708. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $27,300 and $15,067. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $1,944 and $670. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of December 31, 2018. At December 31, 2017, the principal balance of the loan was $191,329 and in negotiation of settlement. During June 2018, the loan was settled for $170,402 with scheduled repayments of approximately $7,000 per month through July 2020. We recorded a gain on settlement of debt in other income for $20,927. The Company repaid $34,976 during the third and fourth quarter of 2018. At December 31, 2018, the principal balance is $135,426. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the principal balance of the note is $50,000. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $51,000 with original issue discount of $8,500. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The Company repaid $8,500 in cash in November 2017. In May 2018, the Noteholder received a total of 187,500,000 shares of our restricted common stock with a fair value of $243,750 in satisfaction of the remaining balance of $42,500. We recorded a loss on settlement of debt in other expense for $201,250 (See Note 7). As of December 31, 2018 and 2017, the principal balance of the note is $0 and $42,500. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 each due in September 2019 and 2020, respectively. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and is due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the year ended December 31, 2018 and 2017 was $4,000 and $2,000, respectively. The debt discount at December 31, 2018 and 2017 is $6,000 and $4,000. Repayments of $1,500 and $7,000 have been made in 2017 and 2018, respectively. The Note is under personal guarantee by Mr. Deitsch. At December 31, 2018 and 2017, the principal balance of the note is $27,500 and $34,500, respectively. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment (See Note 7). The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the year ended December 31, 2018 was $4,127. As of December 31, 2018, the amount due is $61,746, net of discount of $8,254. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. 1,500,000 shares of common stocks were issued due to the default of repayments with a fair value of $2,250 (See Note 7). At December 31, 2018 and 2017, the principal balance of the loan is $120,000. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600 (See Note 7). At December 31, 2018 and 2017, the principal balance of the note is $18,000. ● In December 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in one year from the execution and funding of the note. During August 2018, the Note holder sold the debt of $60,000 to a non-related party. The subsequent note holder received a total of 145,000,000 shares of our restricted common stock with a fair value of $101,500 in satisfaction of the Note of $60,000 in full. We recorded a loss on settlement of debt in other expense for $41,500 (See Note 7). As a result of the settlement of the note, the debt discount has been fully amortized as of December 31, 2018. At December 31, 2018 and 2017, the principal balance of the note is $0 and $60,000. (3) At December 31, 2018 and 2017, the balance of $751,955 and $594 net of discount of $29,371 and $0, respectively, consisted of the following convertible loans: ● On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. The first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014. The notes carry interest at 8% and were due on March 19, 2018. The note holders have the right to convert the notes into shares of Common Stock at a price of $0.20. At December 31, 2017, these convertible notes payable, at fair value, was recorded at $594. During 2018, repayment of $3,000 was made. At December 31, 2018, the principal balance of the note is $27,000 and the accrued interest is $11,412. The two outstanding Notes were settled in connection with issuance of the convertible note in the amount of up to $1,000,000 in February 2019 (See Note 13). ● During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and is due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The note is under personal guarantee by Mr. Deitsch. At December 31, 2018, the convertible note payable was recorded at $75,126, net of discount of $950. The accrued interest as of December 31, 2018 is $8,177. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500 (See Note 7). At December 31, 2018 and 2017, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock (See Note 7). The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. Amortization for the year ended December 31, 2018 was $290,184. At December 31, 2018, the principal balance of the notes, net of discount of $28,421 is $589,829. $264,150 of the above mentioned convertible notes payable to nine of the unrelated third parties with original issue discount of $24,915 are in default and in negotiation of settlement. (4) At December 31, 2018 and 2017, the balance of $1,156,341 and $1,925,365, respectively, consisted of the following convertible loans: ● During December 2015, Mr. Deitsch, assigned $80,000 of his outstanding loan to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 4% and was due on December 7, 2016. The Note reverted back as the promissory note upon maturity date. On June 27, 2017, the Company owed principal balance of $80,000 plus accrued interest of $4,971. The total of $84,971 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note (See Note 7(2)). The note carries interest at 8% and was due on June 27, 2018, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of lowest closing bid prices of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. During July and August 2017, the Note holder made conversions of a total of 164,935,000 shares of our restricted common stock satisfying the principal balance of $55,325 with a fair value of $225,143. At December 31, 2017, the convertible note payable, at fair value, was recorded at $95,369. During February 2018, the Note holder made conversions of a total of 109,876,500 shares of our restricted common stock with a fair value of $462,625 in satisfaction of the remaining principal balance of $29,646 in full. ● On March 31, 2017, we issued a convertible denture in the amount of $80,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 8% and was due on March 30, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note into shares of Common Stock at a fifty-five percent (55%) of the of the lowest closing bid price of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. At December 31, 2017, the convertible note payable, at fair value, was recorded at $256,043. During February 2018, the Noteholder made a conversion of 70,123,500 shares of our restricted common stock with a fair value of $294,885 in satisfaction of a portion of the Note in the amount of $30,854 (See Note 7). The noteholder sold and assigned the remaining balance of $49,146 with accrued interest of $3,276 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During April and May 2018, the Note holder made conversions of a total of 65,885,713 shares of our restricted common stock with a fair value of $145,161 in satisfaction of the remaining principal balance of $49,146 and accrued interest in full (See Note 7). ● On July 18, 2017, we issued a convertible denture in the amount of $150,000 to Coventry. The note carries interest at 8% and was due on July 18, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note into shares of Common Stock at a fifty-five percent (55%) of the of the lowest closing bid price of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. At December 31, 2017, the convertible note payable, at fair value, was recorded at $483,092. During February 2018, the noteholder sold and assigned the balance of $150,000 with accrued interest of $6,000 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During May and June 2018, the Noteholder made conversions of a total of 120,891,284 shares of our restricted common stock with a fair value of $200,475 in partial satisfaction of the note in the amount of $70,000 (See Note 7). During July through September 2018, the Note holder made conversions of a total of 206,988,570 shares of our restricted common stock with a fair value of $176,655 in satisfaction of the remaining principal balance $86,000 and accrued interest in full (See Note 7). ● On March 28, 2016, we signed an expansion agreement with Brewer and Associates Consulting, LLC (“B+A”) to the original consulting agreement dated on October 15, 2015 for consulting services for twelve months for a monthly fee of $7,000. To relieve our cash obligation of $36,000 per original agreement, we issued three convertible notes for a total of $120,000 which includes the fees due under the original agreement and the new monthly fees due under the expansion agreement. The $40,000 and $60,000 of the Notes were paid in full as of December 31, 2016 and December 31, 2017, respectively. The remaining balance of $20,000 Notes is in default and negotiation of settlement. The conversion price is equal to 55% of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. At December 31, 2018 and 2017, the convertible notes payable with principal balance of $20,000, at fair value, were recorded at $47,481 and $52,948, respectively. ● During June 2016, we issued a Convertible Debenture in the amount of $72,000 to an unrelated third party as a result of debt sale. The Note carries interest at 8% and was due on June 20, 2017, unless previously converted into shares of restricted common stock. The convertible note holder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of the average of the three lowest volume weighted average prices (the VWAP) of our restricted common stock for the fifteen trading days preceding the conversion date. At December 31, 2017, the convertible notes payable, at fair value, was recorded at $237,121. During August 2018, a Note holder received a total of 300,000,000 shares of our restricted common stock in satisfaction of the principal balance of $72,000 with accrued interest in full (See Note 9). ● During June 2016, the notes payable of $50,000 originating in January 2016 with accrued interest of $4,800 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note (See Note 7(2)). The note carries interest at 8% and was due on June 16, 2017, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of the average of the three lowest VWAP prices of our restricted common stock for the fifteen trading days preceding the conversion date. At December 31, 2017, the balance of $54,800, at fair value, was recorded at $180,868. During May 2018, the Note holder made a conversion of 228,000,000 shares of our restricted common stock with a fair value of $319,200 in satisfaction of the principal balance of $54,800 in full (See Note 7). ● In April 2017, we issued a Convertible Promissory Note for $33,000 to an unrelated third party. The note carries interest at 12% annually and was due on January 30, 2018. The Holder has the right to convert the loan, beginning on the date which is one hundred eighty (180) days following the date of the Note, into common stock at a price of sixty percent (60%) of the average of the three lowest trading prices of our restricted common stock for the fifteen trading days preceding the conversion date. During October 2017, the Noteholder made the conversions of a total of 50,125,000 of our restricted common stock satisfying the principal balance of $16,040 with a fair value of $35,596. At December 31, 2017, the convertible note payable, at fair value, was recorded at $48,213. During June 2018, the Note holder made a conversion of 150,000,000 shares of our restricted common stock with a fair value of $180,000 in satisfaction of the remaining principal balance of $16,960 with accrued interest in full (See Note 7). ● During May and October 2017, we issued two Convertible Debenture for a total of $90,000 ($45,000 each) to Labrys. The notes carrie interest at 12% and were due on July 19, 2017 and November 3, 2017, respectively, unless previously converted into shares of restricted common stock. Labrys has the right to convert the notes into shares of Common Stock at sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty-five trading days preceding the conversion date. During November 2017, the Note holder made a conversion of 62,059,253 shares of stock satisfying the principal balance of $11,057 and accrued interest for a fair value of $51,732. At December 31, 2017, the convertible notes payable, at fair value, was recorded at $236,349. During February 2018, we issued 45,000,000 shares of our restricted common stock with a fair value of $247,500 to Labrys in settlement of the remaining balance of $78,943 and accrued interest in full (See Note 7). Based on the conversion methodology, the debt was valued at $1,206,081 prior to conversion, and the Company recorded a gain on settlement of $958,581, which is recorded within gain (loss) on settlement of debt, net, within the statement of operations. ● During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carries interest at 12% and matures on September 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 179,800,000 shares of stock satisfying the principal balance of $63,001 and accrued interest for a fair value of $298,575. At December 31, 2017, the convertible note payable, at fair value, was recorded at $147,314. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. During February and July, 2018, we issued a total of 105,157,409 shares of our restrict |
STOCKHOLDERS' DEFICIT
STOCKHOLDERS' DEFICIT | 12 Months Ended |
Dec. 31, 2018 | |
Stockholders' Equity Note [Abstract] | |
Stockholders' Equity Note Disclosure [Text Block] | 7 . STOCKHOLDERS' DEFICIT Authorized Shares On March 7, 2018, we obtained written consents from stockholders holding a majority of our outstanding voting stock to approve an amendment of the Company’s articles of incorporation, as amended, to increase the number of authorized shares of common stock from 2,000,000,000 to 8,000,000,000. Series A Preferred Stock Effective October 30, 2017, pursuant to authority of its Board of Directors, the Company filed a Certificate of Determination for its Series A Preferred Stock. There are 20,000,000 authorized shares of Series A Preferred Stock. The Series A Preferred Stock votes with the Company’s common stock as a single class on all matters or consents for the Company’s common stockholders. Each share of Series A Preferred Stock is entitled to one thousand votes per share. In 2017, 3,000,000 shares of Series A Preferred Stock was issued to Rik J. Deitsch, the Company’s Chairman, to discharge four hundred thousand dollars ($400,000) of Mr. Deitsch’s loan to the Company (See Note 5). Common Stock Issued with Indebtedness In January 2017, in connection with the restatement of a convertible note payable of $56,567, we issued 300,000 shares of our common stock with a fair value of $2,413. In April 2017, in connection with the restatement of a promissory note payable of $180,250, we issued 500,000 shares of our common stock with a fair value of $2,413. During April 2017, 1,000,000 warrants were exercised via cashless exercise into 615,230 shares with a fair value of $3,015. In July 2017, in connection with the issuance of a promissory note payable of $50,000, we issued 2,000,000 shares of our common stock with a fair value of $4,912. In August 2017, in connection with the restatement of a promissory note payable of $56,567, we issued 300,000 shares of our common stock with a fair value of $417. In September 2017, in connection with the issuance of a promissory note payable of $51,000, we issued 4,000,000 shares of our common stock with a fair value of $3,656. In October through November 2017, in connection with the issuance of four promissory notes payable, we issued a total of 25,000,000 shares of our common stock with a fair value of $15,000. In January and February 2018, in connection with four notes payable, we issued a total of 4,250,000 shares of our restricted common stock with a fair value of $9,887 (See Note 6). In April 2018, in connection with a note payable, we issued a total of 5,000,000 shares of our restricted common stock with a fair value of $8,678 (See Note 6). In August 2018, in connection with a note payable, we issued a total of 5,000,000 shares of our restricted common stock with a fair value of $3,800 (See Note 6). In October through December, 2018, in connection with a note payable, we issued a total of 25,500,000 shares of our restricted common stock with a fair value of $9,781 (See Note 6). Common Stock Issued for Conversion of Convertible Debt During October 2017, the Noteholder made the conversions of a total of 50,125,000 of our restricted stock satisfying the principal balance of $16,040 with a fair value of $35,596. During July and August 2017, a Note holder received 164,935,000 shares of our restricted stock with a fair value of $225,143 upon conversion of $55,325 of an $84,971 Note originated in June 2017. Date Number of Fair Value of shares converted Debt Converted 7/18/2017 50,000,000 $81,016 7/27/2017 37,000,000 56,236 8/8/2017 60,000,000 73,159 8/23/2017 17,935,000 14,732 During August 2017, a Noteholder received 85,491,054 of our restricted stock with a fair value of $90,976 upon conversion of a $53,000 Note originated in February 2017. Date Number of Fair Value of shares converted Debt Converted 8/10/2017 70,426,471 78,859 8/21/2017 15,064,583 12,117 In June through October 2017, B+A received 83,125,164 shares of our restricted stock with a fair value of $107,970 upon conversion of $60,000 of an $80,000 Note originated in April 2016. Date Number of Fair Value of shares converted Debt Converted 6/8/2017 23,715,415 56,303 7/6/2017 17,044,486 11,166 10/9/2017 42,365,263 40,501 During April, 2017, a Note holder received 5,000,000 shares of our restricted stock with a fair value of $25,000 upon conversion of $25,000 of a $75,000 promissory Note originated in May 2016. During March and May 2017, Coventry received 47,011,483 shares of our restricted stock with a fair value of $214,795 upon conversion of a $100,000 Note. Date Number of Fair Value of shares converted Debt Converted 3/7/2017 15,500,000 $78,909 3/31/2017 15,000,000 66,000 5/25/2017 16,511,483 69,886 During March, April, and May 2017, the Note holder received 25,558,744 shares of our restricted stock with a fair value of $108,452 upon conversion of a $45,000 Note originated in August 2016. Date Number of Fair Value of shares converted Debt Converted 3/2/2017 2,300,000 $ 9,982 3/28/2017 5,700,000 21,186 4/18/2017 5,700,000 31,057 4/24/2017 5,700,000 26,717 5/11/2017 6,158,744 19,510 During February and March 2017, a Noteholder received 20,971,375 of our restricted stock with a fair value of $94,857 upon conversion of a $52,500 Note originated in August 2016. Date Number of Fair Value of shares converted Debt Converted 2/26/2017 2,681,327 $18,381 3/6/2017 4,633,425 20,760 3/13/2017 3,059,501 16,016 3/24/2017 10,597,122 39,700 During May and June 2017, a Noteholder received 43,244,572 of our restricted stock with a fair value of $106,000 upon conversion of a $52,500 Note originated in February 2017. Date Number of Fair Value of shares converted Debt Converted 5/4/2017 11,473,225 $55,549 5/24/2017 8,603,866 25,108 6/26/2017 23,167,481 25,343 During August 2017, a Noteholder received 106,713,358 of our restricted stock with a fair value of $96,261 upon conversion of a $52,500 Note originated in March 2017. Date Number of Fair Value of shares converted Debt Converted 8/4/2017 37,138,936 $42,923 8/21/2017 69,574,422 53,338 During February and March 2017, a Noteholder received 19,573,258 of our restricted stock with a fair value of $98,147 upon conversion of a $51,000 Note originated in August 2016. Date Number of Fair Value of shares converted Debt Converted 2/27/2017 6,250,000 $42,171 3/8/2017 8,000,000 38,234 3/28/2017 5,323,258 17,742 During April through July 2017, a Noteholder received 138,541,668 shares of the company’s restricted stock with a fair value of $218,353 upon conversion of a Note of $66,500 and default penalty of $22,617. Date Number of Fair Value of shares converted Debt Converted 4/25/2017 13,631,346 $60,202 6/15/2017 10,679,950 20,949 6/21/2017 27,429,600 38,401 6/26/2017 27,429,750 30,173 6/29/2017 26,171,885 28,789 7/6/2017 33,199,136 39,839 During July through September 2017, a Note holder received 249,809,724 shares of the company’s restricted stock with a fair value of $270,716 upon conversion of a Note of $66,500 and default penalty of $5,000. Date Number of Fair Value of shares converted Debt Converted 7/13/2017 50,650,959 $117,179 8/10/2017 21,275,000 23,486 9/13/2017 9,711,900 5,062 9/19/2017 82,122,533 65,229 10/10/2017 86,049,332 59,760 During November 2017, the Note holder made a conversion of 62,059,253 shares of stock with a fair value of $51,732 satisfying the principal balance of $11,057 of a $45,000 Note originated in May 2017. During November 2017, the Note holder made a conversion of 31,532,125 shares of stock with a fair value of $21,399 satisfying the principal balance of $856 and penalty of $6,400 of a $64,000 Note originated in May 2017. During June and July 2017, a Noteholder received 179,800,000 shares of our restricted stock with a fair value of $298,575 upon conversion of $63,001 of a $110,000 Note originated in December 2016. Date Number of Fair Value of shares converted Debt Converted 6/12/2017 19,000,000 $33,123 6/20/2017 19,000,000 26,231 6/30/2017 19,000,000 19,992 7/13/2017 19,000,000 49,517 7/19/2017 53,800,000 96,005 7/31/2017 50,000,000 73,707 During June and July 2017, a Noteholder received 31,582,547 shares of our restricted stock with a fair value of $53,979 upon conversion of a $22,500 Note originated in December 2016. Date Number of Fair Value of shares converted Debt Converted 6/6/2017 9,000,000 $27,051 6/20/2017 9,000,000 11,872 7/5/2017 13,582,547 15,056 During June and July 2017, the Note holder made conversions of a total of 116,386,819 shares of stock satisfying the principal balance and accrued interest in full for a fair value of $123,121 upon conversion of a $50,000 Note originated in December 2016. Date Number of Fair Value of shares converted Debt Converted 6/28/2017 11,560,500 $10,158 6/29/2017 30,352,771 32,450 7/5/2017 32,252,381 43,664 7/10/2017 42,221,167 36,849 During June and July 2017, the Note holder made conversions of a total of 222,707,390 shares of stock satisfying the principal balance and accrued interest in full for a fair value of $304,050 upon conversion of $41,925 of a $67,500 Note originated in December 2016. Date Number of Fair Value of shares converted Debt Converted 6/19/2017 20,000,000 $28,858 6/23/2017 28,000,000 34,433 6/27/2017 30,000,000 27,747 6/30/2017 33,000,000 32,781 7/5/2017 42,960,000 55,666 7/13/2017 45,000,000 115,625 7/31/2017 23,747,390 8,941 During May 2017, the Note holder received 5,432,195 shares of our restricted stock with a fair value of $26,412, satisfying the convertible notes payable of $11,951 originated in September 2016. During January 2017, the Note holder received 5,980,861 shares of our restricted stock with a fair value of $47,569 upon conversion of the remaining $25,000 of the $50,000 Note originated in April 2016. During February 2018, a Note holder made conversions of a total of 70,123,500 shares of our restricted common stock with a fair value of $294,885 in satisfaction of the principal balance of $30,854 of an $80,000 Note originated in March 2017 (See Note 6). During February 2018, a Note holder received 45,000,000 of our restricted common stock with a fair value of $247,500 upon conversion of the remaining balance of $78,943 of $90,000 Notes originated in May and October 2017 (See Note 6). During April and May 2018, a Note holder made conversions of a total of 65,885,713 shares of our restricted common stock with a fair value of $145,161 in satisfaction of the remaining principal balance of $49,146 assigned and purchased from a Note originated in March 2017 (See Note 6). During May and June 2018, a Note holder made conversions of a total of 120,891,284 shares of our restricted common stock with a fair value of $200,475 in satisfaction of the balance of $70,000 of a $156,000 Note assigned and purchased from a Note originated in July 2017 (See Note 6). During May 2018, a Note holder received a total of 228,000,000 shares of our restricted common stock with a fair value of $319,200 in satisfaction of the remaining principal balance of $54,800 assigned and purchased from a Note originated in June 2016 (See Note 6). During June 2018, a Note holder made a conversion of 150,000,000 shares of our restricted common stock with a fair value of $180,000 in satisfaction of the remaining principal balance of $16,960 of $33,000 Notes originated in May 2017 (See Note 6). During June 2018, a Note holder made a conversion of 50,670,000 shares of our restricted common stock with a fair value of $70,938 in satisfaction of the principal balance of $34,060 and accrued interest of $6,476 assigned and purchased from a Note originated in May 2017 (See Note 6). During July through September 2018, a Note holder made conversions of a total of 206,988,570 shares of our restricted common stock with a fair value of $176,655 in satisfaction of the remaining principal balance $86,000 and accrued interest in full from a Note originated in February 2018(See Note 6). During September 2018, a Note holder made a conversion of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full from a Note originated in February 2018 (See Note 6). During August 2018, a Note holder received a total of 300,000,000 shares of our restricted common stock with a fair value of $300,000 in satisfaction of the principal balance of $72,000 with accrued interest in full for a Note originated in July 2016 (See Note 6). Common Stock Issued for Conversion of Promissory Note During May 2018, a Note holder received a total of 187,500,000 shares of our restricted common stock with a fair value of $243,750 in satisfaction of the remaining balance of $42,500 from a Note originated in September 2017 in full. We recorded a loss on settlement of debt in other expense for $201,250 (See Note 6). During August 2018, a Note holder received a total of 145,000,000 shares of our restricted common stock with a fair value of $101,500 in satisfaction of the Note of $60,000 originated in December 2017 in full. We recorded a loss on settlement of debt in other expense for $41,500 (See Note 6). Common Stock Issued for Account Payable During August 2018, the Company issued a total of 2,800,000 shares of the Company’s restricted common stock to settle the outstanding fees of $4,200 with a fair value of $2,800. We recorded a gain on settlement of accounts payable in other expense for $1,400. Common Stock Issued for Settlement of Default Penalty During February and July, 2018, in connection with the settlement of a default penalty of debt, we issued a total of 105,157,409 shares of our restricted common stock with a fair value of $147,220 to the Note holder (See Note 6). Common Stock Issued for Default Payments During January 2017, we issued a total of 300,000 restricted shares to a Note holder due to the default on repayment of the convertible note of $50,000 originated in July 2016. The shares were valued at fair value of $2,520. During March 2017, we issued a total of 50,000 restricted shares to a Note holder due to the default on repayment of the convertible note of $150,000 originated in August 2016. The shares were valued at fair value of $275. In March 2017, the amendment was signed to waive Labrys’ obligation to return the 4,532,810 Returnable Shares issued as a commitment fee. During April 2017, we issued a total of 350,000 restricted shares to a Note holder due to the default on repayment of the promissory note of $50,000 originated in October 2016. The shares were valued at fair value of $1,645. During October and November 2017, we issued a total of 450,000 restricted shares to Note holders due to the default on repayment of three promissory notes. The shares were valued at fair value of $700. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment of the promissory note of $50,000 originated in October 2017 (See Note 6). The shares were valued at fair value of $1,700. During April through December, 2018, we issued a total of 33,625,000 restricted shares to 14 Note holders due to the default on repayment of the promissory notes. The shares were valued at fair value of $25,615 (See Note 6). Common Stock Issued for Services During February 2017, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 1,500,000 shares of our restricted common stock were issued. The shares were valued at $0.0075 per share. We recorded an equity compensation charge of $11,250 during the year ended December 31, 2017. During January 2017, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 1,000,000 shares of our restricted common stock were issued. The shares were valued at $0.0087 per share. We recorded an equity compensation charge of $8,700 during the year ended December 31, 2017. During June 2018, the Company signed an agreement with a consultant for investor relation services for twelve months. In connection with the agreement, 100,000,000 shares of the Company’s restricted common stocks were issued. The share was valued at $0.0012 per share. The Company recorded an equity compensation charge of $70,000 during the year ended December 31, 2018. The remaining unrecognized compensation cost of $50,000 for the period from January through June 2019 will be recognized by the Company over the remaining service period. Beneficial Conversion Features During 2018, the Company has recorded a beneficial conversion feature in the amount of $249,113 as additional paid-in capital due to the difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes (See Note 6). |
STOCK WARRANTS
STOCK WARRANTS | 12 Months Ended |
Dec. 31, 2018 | |
Stock Options and Warrants [Abstract] | |
Stock Options and Warrants [Text Block] | 8. STOCK WARRANTS Common Stock Warrants During March, 2013, the Company issued a total of 65,000 warrants to purchase common stock at an exercise price of $0.01 per share in connection with issuance of a convertible note payable to Coventry. The warrants expired on March 22, 2018. On September 3, 2013 and September 12, 2013, the Company issued 500,000 and 375,000 warrants, respectively, to purchase common stock at an exercise price of $0.025 and $0.01 per share in connection with issuances of convertible notes payable to Coventry. The warrants expired on September 3, 2018 and September, 12, 2018, respectively. On March 31, 2017, in connection with the issuance of an $80,000 Note, we granted three-year warrants to purchase an aggregate of 6,000,000 shares of our common stock at an exercise price of $0.005 per share. The warrants were valued at their fair value of $977 and $3,536 using the Black-Scholes method on December 31, 2018 and 2017. The warrants expire on March 30, 2020 (See Note 5). On March 3, 2016, in connection with the issuance of a convertible note, we granted five-year warrants to purchase an aggregate of 2,500,000 shares of our common stock at an exercise price of $0.03 per share. The warrants were valued at their fair value of $491 and $1,502 using the Black-Scholes method at December 31, 2018 and 2017. The warrants expire on March 3, 2021. On April 4, 2016, in connection with the issuance of convertible notes, we granted three-year warrants to purchase an aggregate of 4,000,000 shares of our common stock at an exercise price of $0.05 per share. The warrants were valued at their fair value of $0 and $862 using the Black-Scholes method at December 31, 2018 and 2017. The warrants expire on April 4, 2019. During April, 2014, the Company issued a total of 100,000 warrants to purchase common stock at an exercise price of $1.00 per share in connection with issuance of a convertible note payable to Coventry. The warrants were valued at their fair value of $0 and $5 using the Black-Scholes method at December 31, 2018 and 2017. The warrants expire on April 9, 2019. During July 2015, we issued a total of 4,400,000 shares of our restricted stock and 4,400,000 warrants to settle outstanding commissions’ payable in aggregate of $59,000 with TCN. The shares were valued at $0.185 per share and the warrants were valued at $0.1009 per share. The warrants expired on June 30, 2016. During October, 2016, warrants were re-priced from exercise prices from $0.20 per share to an exercise price of $0.05 per share, the warrants expired on March 31, 2017. During October, 2016, we repriced 15,285,000 from exercise prices from $0.20 per share to an exercise price of $0.05 per share, the warrants expired on March 31, 2017. During March 2016, we issued 916,667 warrants to purchase common stock at an exercise price of $0.10 per share. The warrants expired on March 31, 2017. During April 2015, we issued a total of 1,000,000 two year warrants to the notes holders to purchase common stock at an exercise price of $0.35 per share. During April 2017, 1,000,000 warrants were exercised via cashless exercise into 615,230 shares with a fair value of $3,015 (See Note 7). A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the years ended December 31, 2018 and 2017: Number Of shares Weighted average exercise price Balance December 31, 2016 29,141,667 $ 0.03 Exercised (1,000,000) 0.35 Issued 6,000,000 $ 0.005 Forfeited (20,601,667) - Balance December 31, 2017 13,540,000 $ 0.023 Exercised - - Issued - $ - Forfeited (940,000) 0.015 Balance December 31, 2018 12,600,000 $ 0.026 The following table summarizes information about fixed-price warrants outstanding as of December 31, 2018 : Exercise Price Weighted Average Number Outstanding Weighted Average Contractual Life Weighted Average Exercise Price 2018 $ 0.005-0.05 12,600,000 1.11 years $ 0.024 2017 $ 0.005-1.00 13,540,000 1.75 years $ 0.023 At December 31, 2018, the aggregate intrinsic value of all warrants outstanding and expected to vest was $0. The intrinsic value of warrant share is the difference between the fair value of our restricted common stock and the exercise price of such warrant share to the extent it is “in-the-money”. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money warrants had they exercised their warrants on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $0.0003, closing stock price of our restricted common stock on December 31, 2018. There were no in-the-money warrants at December 31, 2018. |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2018 | |
Income Tax Disclosure [Abstract] | |
Income Tax Disclosure [Text Block] | 9. INCOME TAXES The Company’s tax expense differs from the “expected” tax expense for the years ended December 31, 2018 and 2017, (computed by the following blended rate), are approximately as follows. 2018 2017 Tax Rate Reconciliation: Federal tax rate 21.00% 34.00% Add: State taxes 5.50% 5.50% Permanent difference -1.20% -1.90% Valuation allowance and change in federal tax rate -25.35% -37.63% Tax rate - - December 31, 2018 2017 Computed “expected” tax expense (benefit) - Federal $ (793,340) $ (1,345,175) Computed “expected” tax expense (benefit) - State (164,145) (230,267) Permanent differences 571,235 771,881 Change in federal tax rate 4,134,665 - Change in valuation allowance (3,748,415) 803,561 Provision for income taxes $ - $ - 2018 2017 Net deferred income tax assets: Reserve for prepaid inventory $ 12,104 $ - Accrued salary 296,834 347,674 Net operating loss carryforwards 9,083,135 12,792,814 Valuation allowance (9,392,073) (13,140,488) Net deferred income tax asset $ - $ - Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, we have provided a valuation allowance to fully reserve such assets. The valuation allowances (decreased) increased by approximately ($3,748,000) and $803,000 for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2017, the Company has net operating loss carryforwards of approximately $35.4 million available to offset future taxable income in various years through December 31, 2037. As of December 31, 2018, the Company has net operating loss carryforwards of approximately $35.8 million available to offset future taxable income with no expiration date. In December 2017, the United States Government passed new tax legislation that, among other provisions, lowered the corporate tax rate from 34% to 21%. In addition to applying the new lower corporate tax rate in 2018 and thereafter to any taxable income the Company may have, the legislation affects the way the Company can use and carryforward net operating losses previously accumulated and results in a revaluation of deferred tax assets and liabilities recorded on the balance sheet. Given that current deferred tax assets are offset by a full valuation allowance, these changes will have no net impact on the balance sheet. However, when the Company becomes profitable, the Company will receive a reduced benefit from such deferred tax assets. The Company’s 2017 and 2018 tax returns are subject to examination by the Internal Revenue Services and various state authorities. |
ACCRUED EXPENSES
ACCRUED EXPENSES | 12 Months Ended |
Dec. 31, 2018 | |
Payables and Accruals [Abstract] | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 10. ACCRUED EXPENSES Accrued expenses consisted of the following: December 31, 2018 2017 Accrued consulting fees $ 161,550 $ 161,550 Accrued settlement expenses 347,400 315,000 Accrued payroll taxes 120,182 72,452 Accrued interest 180,509 133,865 Accrued legal fees - 239,020 Accrue others 22,208 27,509 Total $ 831,849 $ 949,396 |
PREPAID EXPENSES
PREPAID EXPENSES | 12 Months Ended |
Dec. 31, 2018 | |
Prepaid Expenses [Abstract] | |
Prepaid Expenses [Text Block] | 11. PREPAID EXPENSES Prepaid expenses and other current assets consist of the following: December 31, December 31, Supplier advances for future purchases $ 200,911 $ 189,154 Reserve for supplier advances (200,911) (153,154) Net supplier advances - 36,000 Prepaid professional fees 13,000 16,500 Deferred stock compensation 50,000 - Total $ 63,000 $ 52,500 We performed an evaluation of our inventory and related accounts at December 31, 2018, and increased the reserve on supplier advances for future venom purchases by $47,757. At December 31, 2018, the total valuation allowance for prepaid venom is $200,911. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2018 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | 12. COMMITMENTS AND CONTINGENCIES Operating Leases In February 2016, we entered into our current three-year operating lease for monthly payments of approximately $3,200 which expired in February 2019. The lease is currently month-to-month. ReceptoPharm leases a lab and renewed its operating lease agreement for five years in July of 2012. The lease required monthly payments of approximately $6,400 from August 1, 2012 through August 1, 2017. The lease was renewed in February 2016 for another five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year. Future minimum payments under these lease agreements are as follows: Total 2019 $ 84,765 2020 87,991 2021 99,163 2022 54,490 $ 326,409 Rent expense for the years ended December 31, 2018 and 2017 approximated $128,897 and $127,400, respectively. Consulting Agreements During July 2015, we signed an agreement with a company to provide for consulting services for five years. In connection with the agreement, 500,000 shares of our restricted common stock and a one year 8% note of $50,000 were granted. The shares were valued at $0.18 per share. As the services provided were in dispute, the shares and note payable have not been issued as of December 31, 2018. We have accrued the $142,500 in accrued expense and equity compensation. During October 2015, the Company signed an agreement with a consultant for consulting services for a year. In connection with the agreement, 2,500,000 shares of the Company’s restricted common stock were granted and the Company was to make monthly cash payments of $3,000. As of December 31, 2016, the Company recorded an equity compensation charge of $31,750, however, only 1,000,000 of the shares have been issued. As of December 31, 2018, $19,150 has been recorded in accrued expense to account for the 1,500,000 shares of common stock that have not been issued. Litigation Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc. On June 1, 2015, ReceptoPharm entered into a settlement agreement with Patricia Meding, a former officer and shareholder of ReceptoPharm. The settlement relates to a lawsuit filed by Ms. Meding against ReceptoPharm (Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc., Index No.: 18247/06, New York Supreme Court, Queens County) in which she claimed to own certain shares of ReceptoPharm stock and claimed to be owed amounts on a series of promissory notes allegedly executed in 2001 and 2002. The settlement agreement executed on June 1, 2015 provides that ReceptoPharm will pay Ms. Meding a total of $360,000 over 35 months. The first payment of $20,000 was made on July 1, 2015. A second payment of $20,000 was made on August 17, 2015 with 32 subsequent monthly $10,000 payments due on the 15th of every month thereafter. To date, ReceptoPharm has made all monthly payments due under the agreement. In the event of default on any of the payments due under the settlement agreement, the settlement amount would increase by an additional $200,000. As of December 31, 2018, all payments were made and the settlement is concluded. We have recorded $200,000 in gain on settlement of debt on the consolidated statements of operations upon payments in full in April 2018. Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik “Rik” Deitsch On April 21, 2011, Nutra Pharma Corp. and its CEO, Erik Deitsch, were named as defendants in Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik “Rik” Deitsch, Superior Court of Fulton County, Georgia, Civil Action No. 2011–CV–199562. Liquid Packaging Resources, Inc. (“LPR”) claimed that Nutra Pharma Corp. and Mr. Deitsch, directly or through other companies, placed orders with LPR that required LPR to purchase components from third parties. LPR sought reimbursement for those third party expenses in the amount of not less than $359,826.85 plus interest. LPR also sought punitive damages in the amount of not less than $500,000 and attorney's fees. Mr. Deitsch and Nutra Pharma Corp. then removed the action to the United States District Court, Northern District of Georgia, Civil Action No. 11–CV–01663–ODE. After removal, LPR amended the Complaint to assert that Nutra Pharma Corp. and Mr. Deitsch were the alter egos of the alleged other companies through whom the subject orders were placed and therefore should be considered one and the same. At LPR's request, the parties mediated the dispute. At the mediation, the parties worked out an agreement whereby Nutra Pharma Corp. would purchase from LPR the components LPR purchased from third parties at an amount slightly less than the principal amount of the suit and on terms acceptable to us. The agreed price was $350,000 payable over 7 months in equal $50,000 amounts. The litigation was dismissed in August of 2011. Following several payments under the parties’ agreement, the parties entered into two amended payment schedules as accommodations to Nutra Pharma Corp. to allow it to make payments that had been missed. Nutra Pharma Corp. did not make a payment in March 2012 and LPR subsequently called Nutra Pharma Corp. in default of the parties’ agreement. On June 11, 2012, LPR sold its debt to Southridge Partners, LLP in an agreement to be paid out over time. In August 2013, LPR cancelled their agreement with Southridge Partners, LLP. LPR filed a notice of intent to administratively dissolve in May 2015 (with the dissolution becoming effective in December 2015) and has not pursued its claimed default against Nutra Pharma Corp. in any court or other formal proceeding since that date. Paul Reid et al. v. Nutra Pharma Corp. et al. On August 26, 2016, certain of former ReceptoPharm employees and a former ReceptoPharm consultant filed a lawsuit in the 17th Judicial Circuit in and for Broward County, Florida (Case No. CACE16–015834) against Nutra Pharma and Receptopharm to recover $315,000 allegedly owing to them under a settlement agreement reached in an involuntary bankruptcy action that was brought by the same individuals in 2012 and for payment of unpaid wages/breach of written debt confirms. Nutra Pharma and Receptopharm believe that the lawsuit is without merit, especially in light of gross misconduct by these former employees that was discovered after execution of the aforementioned settlement agreement. On October 9, 2020, the Court entered an Order denying the plaintiffs’ motion for summary judgment with respect to Count I of the Complaint (for alleged breach of the aforementioned settlement agreement), and the parties continue to engage in discovery regarding their respective claims and defenses. The case is currently set for trial during the period from May 10, 2021 to May 28, 2021, but it is unclear at this time with the ongoing COVID-19 pandemic (and the resultant cessation of jury trials in Broward County) whether the trial will proceed at that time. Get Credit Healthy, Inc. v. Nutra Pharma Corp. and Rik Deitsch, Case No. CACE 18-017055 On August 1, 2018, Get Credit Healthy, Inc. filed a lawsuit against Nutra Pharma Corp. and Rik Deitsch (collectively the “Defendants”) in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-017055) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. On September 10, 2018, the Defendants filed their Answer and Affirmative Defenses to the Complaint. One of Defendants’ primary defenses to the Complaint was that the majority owner of Get Credit Healthy, Inc. violated the terms of a Binding Memorandum of Understanding by failing to invest in Nutra Pharma Corp. and fraudulently inducing Defendants to enter into the subject amended promissory note. Counsel for Get Credit Healthy, Inc. requested an early mediation conference in an attempt to resolve our dispute. We agreed to this request, and mediation took place on February 15, 2019. At December 31, 2018, we owed principal balance of $101,818 and accrued interest of $21,023 (See Note 6). At mediation, Get Credit Healthy, Inc. claimed that the individual that breached the binding memorandum of understanding with Nutra Pharma Corp. was never an owner of Get Credit Healthy, Inc., but rather, a close friend that encouraged Get Credit Healthy, Inc. to make the subject loan to Nutra Pharma Corp. Ultimately, the parties were able to reach a Confidential Settlement Agreement to resolve the dispute, and an Agreed Order was entered dismissing the lawsuit. The lawsuit was settled on February 15, 2019 for $104,000 with scheduled payments. The repayments were made in full as of November 2020 (See Note 13). CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150 On October 12, 2018, CSA 8411, LLC filed a lawsuit against Nutra Pharma Corp. (“Defendant”) in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-023150) to recover $100,000.00 allegedly owed under an amended promissory note dated April 12, 2017. On November 1, 2018, the Defendant filed its Answer and Affirmative Defenses to the Complaint. Defendant believes that this lawsuit is without merit. Moreover, Defendant believes that it has a number of valid defenses to this claim. Among other things, the owner of CSA 8411, LLC violated the terms of a Binding Memorandum of Understanding by failing to invest in Nutra Pharma Corp. and fraudulently inducing Defendant to enter into the subject amended promissory note (contrary to the Get Credit Healthy lawsuit discussed above, we are certain that this individual is the majority owner of CSA 8411, LLC). Opposing counsel reached out to schedule mediation, and mediation was set for June 21, 2019 in Plantation, FL however the mediation was unsuccessful. At December 31, 2018, we owed principal balance of $91,156 and accrued interest of $19,010 (See Note 6) if the defenses and our new claims are deemed to be of no merit. Defendant also filed affirmative claims against the Plaintiff, its owner Dan Oran and several relate entities. The case has not been set for trial as of this date. Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus On September 28, 2018, the United States Securities and Exchange Commission (the “SEC”) filed a lawsuit in the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against Nutra Pharma, Mr. Deitsch, and Mr. McManus. The lawsuit alleges that, from July 2013 through June 2018, Nutra Pharma and the other defendants defrauded investors by making materially false and misleading statements about Nutra Pharma and violated anti-fraud and other securities laws. The violations alleged against Nutra Pharma by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which Nutra Pharma failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose Nutra Pharma’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about Nutra Pharma, that Mr. Deitsch engaged in manipulative trades of Nutra Pharma’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief. On May 29, 2019 (following each of the defendants filing motions to dismiss), the SE filed a First Amended Complaint which generally alleged the same conduct as its original Complaint, but accounted for certain guidance provided by the United States Supreme Court in a case that had been recently decided. Each of the defendants then moved to dismiss the SEC’s First Amended Complaint. On March 31, 2020, the Court entered an Order granting in part and denying in part the various motions to dismiss. Following that Order, the SEC filed a Second Amended Complaint (the operative pleading) and the defendants have filed their answers which generally deny liability. At this time, discovery is closed and the SEC has indicated an intent to file a summary judgment motion regarding certain non-fraud claims asserted in its Second Amended Complaint. The defendants have opposed the SEC’s request to file such motion(s), and a hearing on that request is set for February 23, 2021. Nutra Pharma disputes the allegations in this lawsuit and continues to vigorously defend against the SEC’s claims. Mr. Deitsch and Mr. McManus have similarly defended the lawsuit since its filing and each contest liability. Nutra Pharma does not believe that it engaged in any fraudulent activity or made any material misrepresentations concerning Nutra Pharma and/or its products. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2018 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | 13. SUBSEQUENT EVENTS Convertible Notes Payable During February 2019, we issued convertible promissory notes to unrelated third parties for a total of $55,000 with original issuance discount of $5,000. The notes were due six months from the execution and funding of the notes. During December 2019, $22,000 of the Note was amended to extend the maturity date to June 2020. During August 2020, $38,500 of the Notes was amended with additional original issuance discount of $7,550 due February 2021. During October 2020, $16,500 of the Notes was amended with additional original issuance discount of $1,650 due April 2021.The Noteholders have the right to convert the note into shares of Common Stock at a conversion price of $0.0005. In connection with the issuance of convertible notes and amendments, the Company granted the following warrants at an exercise price of $0.001 per share. The warrants were valued using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. No warrants have been exercised. Month of Issuance Number of Fair Value of Month of Expiration Warrants Warrants February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 7,370 August, 2020 August, 2020 92,100,000 22,879 August, 2021 October, 2020 39,930,000 9,497 October, 2022 During January 2019, the Company received an advance from a non-related party of $15,000. The advance was non-interest bearing, unsecured and due on demand. The advance was repaid in December 2019 in connection with the settlement agreement. During February 2019, we issued a convertible promissory note to an unrelated third party in the amount up to $1,000,000 paid upon tranches. The note is due two years from the execution and funding of the note per tranche. The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion. A portion of the Note in the amount of $389,572 has been funded during 2019 through October 2020. In connection with issuance of the convertible note, the Noteholder agreed to eliminate two outstanding Notes of $27,000 and the accrued interest of $11,412 that were held by the Noteholder’s defunct entities. During May 2019 through February 2020, the Note holder received a total of 1,250,000,000 shares of our restricted common stock in satisfaction the $275,000 of the Note with a fair value of $700,000. As of December 31, 2019, $114,572 remains outstanding and is due between March 2021 through September 2022. Date Number of Fair Value of shares converted Debt Converted 5/6/2019 250,000,000 $75,000 5/31/2019 250,000,000 100,000 6/6/2019 250,000,000 100,000 1/21/2020 250,000,000 150,000 2/18/2020 250,000,000 275,000 During June 2019, we issued a convertible promissory note to an unrelated third party for $240,000 with original issuance discount of $40,000. The note was due one year from the execution and funding of the notes. In connection with the issuance of this note, we issued 16,000,000 shares of our restricted common stock. The common stock was valued at $4,688 and recorded as a debt discount that was amortized over the life of the note. The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion. The Note is in default and negotiation of settlement. During November 2019, we issued a convertible promissory note to an unrelated third party for $137,500 with original issuance discount of $12,500. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.000275. The Note is in default and negotiation of settlement. During December 2019, we issued a convertible promissory note to an unrelated third party for $22,000 with original issuance discount of $2,000. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0002. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature (BCF) in the amount of $20,000. The BCF was recorded as a debt discount that was amortized over the life of the notes. The Note is in default and negotiation of settlement. During January and March 2020, we issued convertible promissory notes to an unrelated third party for a total of $68,750 with original issuance discount of $6,250. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $5,500. The BCF was recorded as a debt discount that was amortized over the life of the notes. The Notes are due in January and March 2021. During February and March 2020, we issued convertible promissory notes to an unrelated third party for a total of $22,000 with original issuance discount of $2,000. The notes were due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0003. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $20,000. The BCF was recorded as a debt discount that was amortized over the life of the notes. The Notes are in default and negotiation of settlement. During March 2020, we issued a convertible promissory note to an unrelated third party for $5,500 with original issuance discount of $500. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0002. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $5,000. The BCF was recorded as a debt discount that was amortized over the life of the notes. The Note is in default and negotiation of settlement. During March 2020, we issued a convertible promissory note to an unrelated third party for $5,500 with original issuance discount of $500. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $3,300. The BCF was recorded as a debt discount that was amortized over the life of the notes. The Note is in default and negotiation of settlement. During August 2020, we issued a convertible promissory note to an unrelated third party for a $22,000 with original issuance discount of $2,000. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $13,200. The BCF was recorded as a debt discount that was amortized over the life of the notes. The note is due August 2021. During July 2020, we issued a convertible promissory note to an unrelated third party for $20,900 with original issuance discount of $1,900. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.00052. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $15,273. The BCF was recorded as a debt discount that was amortized over the life of the notes. The note is due January 2021. During August 2020, we issued convertible promissory notes to an unrelated third party for $5,500 with original issuance discount of $500. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $1,100. The BCF was recorded as a debt discount that was amortized over the life of the notes. The note is due February 2021. PPP Loan During May 2020, we entered into a long-term loan agreement with the U. S. Small Business Administration for a Payroll Protection Program (PPP) loan, for $64,895 with an annual interest rate of one percent (1%), with a term of twenty-four (24) months, whereby a portion of the loan proceeds have been used for certain labor costs, office rent costs and utilities, which may be subject to a loan forgiveness, pursuant to the terms of the SBA/PPP program. Economic Injury Disaster Loan During April and June 2020, the Company executed the standard loan documents required for securing a loan from the SBA under its Economic Injury Disaster Loan assistance program (the “EIDL Loan”) considering the impact of the COVID-19 pandemic on the Company’s business. Pursuant to the Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan was $154,900, with proceeds to be used for working capital purposes. Interest accrues at the rate of 3.75% per annum. Installment payments, including principal and interest, are due twelve months from the date of the SBA Loan Agreement in the amount of $731. The balance of principal and interest is payable over a 360 month period from the date of the SBA Loan Agreement. In connection therewith, the Company received a $5,000 advance, which does not have to be repaid. The SBA requires that the Company collateralize the loan to the maximum extent up to the loan amount. If business fixed assets do not “fully secure” the loan the lender may include trading assets (using 10% of current book value for the calculation), and must take available equity in the personal real estate (residential and investment) of the principals as collateral. Common Stock Issued for Services During April 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 120,000,000 shares of our restricted common stock were issued. The shares were valued at $24,000. During June 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 15,000,000 shares of our restricted common stock were issued. The shares were valued at $6,000. Restatement of Convertible Promissory Notes During May 2019, the Notes of $48,000 with original issuance discount of $8,000 amended in October 2018 were restated. The $8,000 original issuance discount from the Note restated in October was repaid May 2019. The restated principal balance of $40,000 plus the original issuance discount of $8,000 were due August 2019. In connection with this restated note, we issued 3,000,000 shares of our common stock. The common stock was valued at $900 and recorded as a debt discount that was amortized over the life of the restated note. The Note is in default and negotiation of settlement. During May 2019, the Notes of $24,000 with original issuance discount of $4,000 amended in November 2018 were restated. The restated principal balance of $24,000 plus the original issuance discount of $2,400 were due August 2019. In connection with this restated note, we issued 3,000,000 shares of our common stock. The common stock was valued at $900 and recorded as a debt discount that was amortized over the life of the restated note. The Note is in default and negotiation of settlement. Restatement of Promissory Notes During September 2019, the Notes of $282,983 plus accrued interest amended in December 2018 were restated. The restated principal balance of $333,543 were due September 2020. In connection with this restated note, we issued 20,000,000 shares of our common stock. The common stock was valued at $5,090 and recorded as a debt discount that was amortized over the life of the note. The Note is in default and negotiation of settlement. During September 2019, the Note of $36,000 with original issuance discount of $6,000 amended in September 2018 was restated. The $6,000 original issuance discount from the Note amended in September 2018 has been repaid in full as of September 2019. The restated principal balance was $36,000 with the original issuance discount of $6,000 and was due September 2020. The $6,000 original issuance discount from the Note amended in September 2019 has been repaid in full as of September 2020. The Note was further restated in September 2020. The restated principal balance was $36,000 with the original issuance discount of $6,000 and is due March 2021. During January 2020, the Note of $60,000 with original issuance discount of $10,000 amended in November 2018 and the Note of $88,225 plus accrued interest at a rate of 2.5% monthly to an unrelated third party were combined and restated. The restated principal balance was $148,225 that carries interest at a rate of 2.0% monthly due July 2020. During July 2020, the restated Note of $148,225 plus accrued interest of $18,701 was further restated. The new principal balance was $166,926 that carries interest at a rate of 2.0% monthly and was due January 2021. The Note is in negotiation of restatement. Settlement of Convertible Promissory Notes During January 2019, in connection with the settlement of a default penalty of the debt originated in December 2016, we issued a total of 81,000,000 shares of our restricted common stock to the original Note holder with a fair value of $32,400. During August 2019, the Note of $12,000 with original issuance discount of $2,000 originated in December 2019 was settled for $12,000 with scheduled payments through December 1, 2019. In connection with this settlement, we issued 1,500,000 shares of common stocks with a fair value of $450. Repayment of $3,500 was made as of December 2020. The remaining balance of $8,500 is in default and in negotiation of settlement. During December 2019, two Notes for a total of $9,900 with original issuance discount of $900 originated in February 2018 were settled with 40,000,000 shares of common stocks. The shares were valued at fair value of $24,000. During December 2019, three Notes for a total of $49,684 with original issuance discount of $2,700 originated in May 2017, January and September 2018, respectively, were settled with 260,000,000 shares of common stocks. The shares were valued at fair value of $130,000. During December 2019, two Notes for a total of $46,500 originated in October and November 2018 and the accounts payable of $39,000 for consulting fees were settled with 500,0000,000 shares of common stocks. The shares were valued at fair value of $300,000, and have not been issued. During February through August 2018, we issued seven convertible promissory notes to an unrelated third party due one year from the execution dates. The principal balance of these Notes on December 31, 2018 was $511,319. During September 2020, a Note holder received a total of 107,133,333 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,140. During October 2020, the Note holder received a total of 107,817,770 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,345. During October 2020, the Note holder sold the remaining debt of $467,000 and accrued interest of $166,168 for $250,000 to a non-related party. Date Number of Fair Value of shares converted Debt Converted 9/22/2020 107,133,333 $171,413 10/5/2020 107,817,770 64,691 Settlement and Restatement of Promissory Notes During March 2020, $50,000 of the Note of $120,000 with original issuance discount of 20,000 originated in November 2017 was settled for 125,000,000 shares. An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $119,700. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. Settlement of a Related-Party Note During June 2020, the Note of $14,400 with original issuance discount of $2,400 to a related party amended in December 2018 was settled with cash payment of $14,400 and 5,000,000 shares of common stocks. The shares were valued at fair value of $3,000. Advances During the periods from May 2019 through May 2020, the Company received a total of $175,000 in deposits from a third party in connection with a Joint Venture proposal. The deposits were considered as payments towards the purchase of equity in the joint venture. The joint venture is currently on hold pending the outcome of the lawsuit with the SEC. Common Stock Issued for Default Payments During May 2019, we issued a total of 3,000,000 restricted shares to two Note holders due to the default on repayments of the convertible note of $48,000 originated in October 2018 and $24,000 originated in November 2018. The shares were valued at fair value of $900. During August 2019, we issued a total of 2,000,000 additional restricted shares to the two Note holders due to default on repayments. These shares were valued at fair value of $700. During June 2019, we issued a total of 500,000 restricted shares to a Note holder due to the default on repayments of the convertible note of $12,000 originated in December 2018. The shares were valued at fair value of $150. During July 2019, we issued a total of 5,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $282,983 plus accrued interest amended in December 2018. The shares were valued at fair value of $1,500. During September 2019, we issued a total of 10,000,000 restricted shares to a Note holder due to the default on repayments of the original issuance discount of $10,000 for the convertible promissory notes of $60,000 amended in November 2018. The shares were valued at fair value of $4,000. During January 2020, we issued a total of 75,000,000 restricted shares to a Note holder due to the default on repayments of the convertible promissory note of a total of $148,225 amended in August and November 2018. The shares were valued at fair value of $45,000. During July 2020, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $22,000 originated in December 2019. The shares were valued at fair value of $700. During September 2020, we issued a total of 10,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $333,543 plus accrued interest amended in September 2019. The shares were valued at fair value of $6,000. During October 2020, we issued a total of 1,500,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $84,000 amended in March 2020. The shares were valued at fair value of $900. |
Accounting Policies, by Policy
Accounting Policies, by Policy (Policies) | 12 Months Ended |
Dec. 31, 2018 | |
Accounting Policies, by Policy (Policies) [Line Items] | |
Business Description and Accounting Policies [Text Block] | Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | Basis of Presentation and Consolidation The accompanying Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation. |
Liquidity and Going Concern [Policy Text Block] | Liquidity and Going Concern Our Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $61,272,842 at December 31, 2018. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $5,911,233 and a stockholders’ deficit of $5,936,593 at December 31, 2018. There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The accompanying Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and warrant liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. |
Revenue Recognition, Dividends [Policy Text Block] | Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers, originally effective for public business entities with annual reporting periods beginning after December 15, 2016. On August 12, 2015, the FASB issued an Accounting Standards Update (“ASU”), Revenue From Contracts With Customers (Topic 606): Deferral of the Effective Date, which deferred the effective date of ASC 606 for one year. ASC 606 provides accounting guidance related to revenue from contracts with customers. For public business entities, ASC 606 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. This new revenue recognition standard (new guidance) has a five-step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; and e) Recognize revenue when (or as) performance obligations are satisfied. The Company has evaluated the impact of ASC 606 and determined that there is no change to the Company's accounting policies, except for the recording of certain product sales to a distributor, in which a portion of the cash proceeds received is remitted back to the distributor. Under ASC 606, the Company determined that these sales should be recorded on a gross basis. Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon delivery of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor. |
Shipping and Handling Cost, Policy [Policy Text Block] | Accounting for Shipping and Handling Costs We record shipping and handling costs incurred in cost of sales. |
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] | Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivables. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. Management believes that the receivables are fully collectable. Therefore, no allowance for doubtful account is deemed to be required at December 31, 2018 and 2017. |
Inventory, Policy [Policy Text Block] | Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand. If necessary it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at December 31, 2018, and increased the reserve on supplier advances for future venom purchases included in the prepaid expenses and other current assets by $47,757. At December 31, 2018, the total valuation allowance for prepaid venom is $200,911. |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2018, there were two customers that accounted for 32% and 27% of the total revenues, respectively. For the year ended December 31, 2017, there were two customers that accounted for 38% and 15% of the total revenues, respectively. |
Derivatives, Reporting of Derivative Activity [Policy Text Block] | Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks |
Debt, Policy [Policy Text Block] | Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature ("BCF"). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. |
Fair Value Measurement, Policy [Policy Text Block] | The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment and Long-Lived Assets Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years. |
Income Tax, Policy [Policy Text Block] | Income Taxes We compute income taxes in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 740, Income Taxes On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position. At December 31, 2018 and 2017, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions. |
Stockholders' Equity, Policy [Policy Text Block] | Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation |
Earnings Per Share, Policy [Policy Text Block] | Net Loss Per Share Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share December 31, 2018 December 31, 2017 Options and warrants 12,600,000 13,540,000 Convertible notes payable 4,448,128,953 2,467,512,550 Total 4,460,728,953 2,481,052,550 |
Reclassification, Comparability Adjustment [Policy Text Block] | Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Adjustments have been made to the Consolidated Balance sheets for the year ended December 31, 2017, to reclassify accrued interest to related parties, accrued payroll due to officers, and accrued payroll taxes. An adjustments has been made to Consolidated Statement of operations for the year ended December 31, 2017, to reclassify interest expense to related parties. These changes in classification also affected cash flows from operating activities for the year ended December 31, 2017 in the Consolidated Statements of Cash Flows. |
Impact of COVID-19 [Policy Text Block] | Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from SBA to fund our request for a PPP loan for $64,895. We intended to use the proceeds primarily for payroll costs. During April and June 2020, we obtained the loan in the amount of $154,900 from SBA under its Economic Injury Disaster Loan assistance program. We intended to use the proceeds primarily for working capital purpose (See Note 13). The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the development of widespread testing or a vaccine. |
Accounting Standards Update 2016-10 [Member] | |
Accounting Policies, by Policy (Policies) [Line Items] | |
New Accounting Pronouncements, Policy [Policy Text Block] | Adoption of ASC 606, Revenue from Contracts with Customers On January 1, 2018, we adopted ASC 606 using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic revenue recognition methodology under ASC 605, Revenue Recognition. The cumulative impact of adopting ASC 606 resulted in no changes to retained earnings at January 1, 2018. The impact to revenue for the year ended December 31, 2018 was an increase of $4,403 as a result of applying ASC 606 to certain revenues generated through online distributors which are now presented gross as we have control over providing the products related to such revenues. For the year ended December 31, 2018, the revenue recognized from contracts with customers was $130,596. The impact of adoption of ASC 606 on our consolidated statement of operations was as follows: With Implementation of ASC 606 Before Implementation of ASC 606 Effect of Implementation Revenue $ 130,596 $ 126,193 $ 4,403 Costs of sales (68,777) (64,374) (4,403) Net effect of ASC 606 implementation $ - There was no balance sheet impact. |
Accounting Standards Update 2016-02 [Member] | |
Accounting Policies, by Policy (Policies) [Line Items] | |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases In June 2018, the FASB issued ASU 2018-07, “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). ASU No 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance also specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and is effective for the Company as of January 1, 2019. The Company noted that all share based payments were settled as of the date of the adoption, so there was no impact on the Company's financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable. |
BASIS OF PRESENTATION AND SUM_2
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Accounting Policies [Abstract] | |
Accounting Standards Update and Change in Accounting Principle [Table Text Block] | The impact of adoption of ASC 606 on our consolidated statement of operations was as follows: With Implementation of ASC 606 Before Implementation of ASC 606 Effect of Implementation Revenue $ 130,596 $ 126,193 $ 4,403 Costs of sales (68,777) (64,374) (4,403) Net effect of ASC 606 implementation $ - |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | As of December 31, 2018 and 2017, the following items were not included in dilutive loss as the effect is anti-dilutive: December 31, 2018 December 31, 2017 Options and warrants 12,600,000 13,540,000 Convertible notes payable 4,448,128,953 2,467,512,550 Total 4,460,728,953 2,481,052,550 |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Fair Value Disclosures [Abstract] | |
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] | The following table summarizes our financial instruments measured at fair value at December 31, 2018 and December 31, 2017: Fair Value Measurements at December 31, 2018 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,468 $ - $ - $ 1,468 Convertible notes at fair value $ 1,156,341 $ - $ - $ 1,156,341 Fair Value Measurements at December 31, 2017 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 5,903 $ - $ - $ 5,903 Convertible notes at fair value $ 1,925,959 $ - $ - $ 1,925,959 |
Fair Value Measurements, Nonrecurring [Table Text Block] | The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the years ended December 31, 2018 and 2017: Description 2018 2017 Beginning balance $ 5,903 $ 48,504 Purchases, issuances, and settlements - 24,017 Day one loss on value of hybrid instrument - - Total (gain) loss included in earnings (1) (4,435) (66,618) Ending balance $ 1,468 $ 5,903 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
Debentures [Table Text Block] | The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at December 31, 2018 and 2017: Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back 2018 $1,340,026 8%-12% 18%-20% 25.95-27.95 $0.0002-$0.20 40%-60% 3 to 25 Days 2017 $682,099 8%-12% 18% 23.95-27.95 $0.0002-$0.20 40%-60% 3 to 25 Days |
Convertible Debt [Table Text Block] | The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the year ended December 31, 2018 and 2017: Description 2018 2017 Beginning balance $ 1,925,959 $ 1,672,728 Purchases and issuances 472,029 580,143 Day one loss on value of hybrid instrument (1) 2,021,041 999,228 Loss from change in fair value (1) 130,344 1,314,325 Gain on settlement (958,581) - Conversion to common stock (2,434,451) (2,594,100) Repayment in cash - (46,365) Ending balance $ 1,156,341 $ 1,925,959 (1) The losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
INVENTORIES (Tables)
INVENTORIES (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory, Current [Table Text Block] | Inventories are valued at the lower of cost or net realizable value on an average cost basis. At December 31, 2018 and 2017, inventories were as follows: December 31, 2018 December 31, 2017 Raw Materials $ 33,431 $ 13,704 Finished Goods 1,871 6,438 Total Inventories $ 35,302 $ 20,142 |
PROPERTY AND EQUIPMENT (Tables)
PROPERTY AND EQUIPMENT (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment [Table Text Block] | Property and equipment consists of the following at December 31, 2018 and 2017: December 31, 2018 December 31, 2017 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 53,711 53,711 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 216,033 216,033 Less: Accumulated depreciation (205,533) (199,570) Property and equipment, net $ 10,500 $ 16,463 |
DEBTS (Tables)
DEBTS (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Debt Disclosure [Abstract] | |
Schedule of Debt [Table Text Block] | Debts consist of the following at December 31, 2018 and 2017: December 31, 2018 December 31, 2017 Note payable– Related Party (Net of discount of $2,400 and $2,000, $ 12,000 $ 202,974 Notes payable – Unrelated third parties (Net of discount of $17,870 1,469,690 1,337,470 Convertible notes payable – Unrelated third parties (Net of discount of 751,955 594 Convertible notes payable, at fair value (4) 1,156,341 1,925,365 Ending balances 3,389,986 3,466,403 Less: Current portion (3,338,576) (3,466,403) Long-term portion-Notes payable-Unrelated third parties $ 51,410 $ - (1) During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At December 31, 2018 and 2017, we owed this director accrued interest of $141,808 and $126,036. The interest expense for the years ended December 31, 2018 and 2017 was $15,772 and $15,457. In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by one of our directors. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At December 31, 2018 and 2017, we owed principal balance of $192,974, and accrued interest of $40,033 and $16,876, respectively. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020 (See Note 12) In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. At December 31, 2018 and 2017, the principal balance of the loan is $12,000. The Note was settled in June 2020. (2) At December 31, 2018 and 2017, the balance of $1,469,690 and $1,337,470 net of discount of $17,870 and $28,723, respectively, consisted of the following loans: ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $2,739 and $1,465. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the outstanding principal balance is $50,000 and accrued interest is $37,801 and $25,567. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2018 and 2017, the outstanding principal balance is $50,000 and accrued interest is $31,000 and $18,767. ● In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest were restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest were restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. The note is in default and negotiation of settlement. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018 (See Note 7). The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest were restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and will be due June 17, 2019. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $329 and the debt discount at December 31, 2018 is $3,616. At December 31, 2018 and 2017, the principal balance is $282,983 and $180,250, respectively, and the accrued interest is $2,830 and $38,455, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $17,271 and $7,708. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $27,300 and $15,067. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $1,944 and $670. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of December 31, 2018. At December 31, 2017, the principal balance of the loan was $191,329 and in negotiation of settlement. During June 2018, the loan was settled for $170,402 with scheduled repayments of approximately $7,000 per month through July 2020. We recorded a gain on settlement of debt in other income for $20,927. The Company repaid $34,976 during the third and fourth quarter of 2018. At December 31, 2018, the principal balance is $135,426. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the principal balance of the note is $50,000. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $51,000 with original issue discount of $8,500. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The Company repaid $8,500 in cash in November 2017. In May 2018, the Noteholder received a total of 187,500,000 shares of our restricted common stock with a fair value of $243,750 in satisfaction of the remaining balance of $42,500. We recorded a loss on settlement of debt in other expense for $201,250 (See Note 7). As of December 31, 2018 and 2017, the principal balance of the note is $0 and $42,500. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 each due in September 2019 and 2020, respectively. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and is due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the year ended December 31, 2018 and 2017 was $4,000 and $2,000, respectively. The debt discount at December 31, 2018 and 2017 is $6,000 and $4,000. Repayments of $1,500 and $7,000 have been made in 2017 and 2018, respectively. The Note is under personal guarantee by Mr. Deitsch. At December 31, 2018 and 2017, the principal balance of the note is $27,500 and $34,500, respectively. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment (See Note 7). The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the year ended December 31, 2018 was $4,127. As of December 31, 2018, the amount due is $61,746, net of discount of $8,254. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. 1,500,000 shares of common stocks were issued due to the default of repayments with a fair value of $2,250 (See Note 7). At December 31, 2018 and 2017, the principal balance of the loan is $120,000. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600 (See Note 7). At December 31, 2018 and 2017, the principal balance of the note is $18,000. ● In December 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in one year from the execution and funding of the note. During August 2018, the Note holder sold the debt of $60,000 to a non-related party. The subsequent note holder received a total of 145,000,000 shares of our restricted common stock with a fair value of $101,500 in satisfaction of the Note of $60,000 in full. We recorded a loss on settlement of debt in other expense for $41,500 (See Note 7). As a result of the settlement of the note, the debt discount has been fully amortized as of December 31, 2018. At December 31, 2018 and 2017, the principal balance of the note is $0 and $60,000. (3) At December 31, 2018 and 2017, the balance of $751,955 and $594 net of discount of $29,371 and $0, respectively, consisted of the following convertible loans: ● On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. The first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014. The notes carry interest at 8% and were due on March 19, 2018. The note holders have the right to convert the notes into shares of Common Stock at a price of $0.20. At December 31, 2017, these convertible notes payable, at fair value, was recorded at $594. During 2018, repayment of $3,000 was made. At December 31, 2018, the principal balance of the note is $27,000 and the accrued interest is $11,412. The two outstanding Notes were settled in connection with issuance of the convertible note in the amount of up to $1,000,000 in February 2019 (See Note 13). ● During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and is due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The note is under personal guarantee by Mr. Deitsch. At December 31, 2018, the convertible note payable was recorded at $75,126, net of discount of $950. The accrued interest as of December 31, 2018 is $8,177. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500 (See Note 7). At December 31, 2018 and 2017, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock (See Note 7). The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. Amortization for the year ended December 31, 2018 was $290,184. At December 31, 2018, the principal balance of the notes, net of discount of $28,421 is $589,829. $264,150 of the above mentioned convertible notes payable to nine of the unrelated third parties with original issue discount of $24,915 are in default and in negotiation of settlement. (4) At December 31, 2018 and 2017, the balance of $1,156,341 and $1,925,365, respectively, consisted of the following convertible loans: ● During December 2015, Mr. Deitsch, assigned $80,000 of his outstanding loan to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 4% and was due on December 7, 2016. The Note reverted back as the promissory note upon maturity date. On June 27, 2017, the Company owed principal balance of $80,000 plus accrued interest of $4,971. The total of $84,971 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note (See Note 7(2)). The note carries interest at 8% and was due on June 27, 2018, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of lowest closing bid prices of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. During July and August 2017, the Note holder made conversions of a total of 164,935,000 shares of our restricted common stock satisfying the principal balance of $55,325 with a fair value of $225,143. At December 31, 2017, the convertible note payable, at fair value, was recorded at $95,369. During February 2018, the Note holder made conversions of a total of 109,876,500 shares of our restricted common stock with a fair value of $462,625 in satisfaction of the remaining principal balance of $29,646 in full. ● On March 31, 2017, we issued a convertible denture in the amount of $80,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 8% and was due on March 30, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note into shares of Common Stock at a fifty-five percent (55%) of the of the lowest closing bid price of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. At December 31, 2017, the convertible note payable, at fair value, was recorded at $256,043. During February 2018, the Noteholder made a conversion of 70,123,500 shares of our restricted common stock with a fair value of $294,885 in satisfaction of a portion of the Note in the amount of $30,854 (See Note 7). The noteholder sold and assigned the remaining balance of $49,146 with accrued interest of $3,276 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During April and May 2018, the Note holder made conversions of a total of 65,885,713 shares of our restricted common stock with a fair value of $145,161 in satisfaction of the remaining principal balance of $49,146 and accrued interest in full (See Note 7). ● On July 18, 2017, we issued a convertible denture in the amount of $150,000 to Coventry. The note carries interest at 8% and was due on July 18, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note into shares of Common Stock at a fifty-five percent (55%) of the of the lowest closing bid price of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. At December 31, 2017, the convertible note payable, at fair value, was recorded at $483,092. During February 2018, the noteholder sold and assigned the balance of $150,000 with accrued interest of $6,000 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During May and June 2018, the Noteholder made conversions of a total of 120,891,284 shares of our restricted common stock with a fair value of $200,475 in partial satisfaction of the note in the amount of $70,000 (See Note 7). During July through September 2018, the Note holder made conversions of a total of 206,988,570 shares of our restricted common stock with a fair value of $176,655 in satisfaction of the remaining principal balance $86,000 and accrued interest in full (See Note 7). ● On March 28, 2016, we signed an expansion agreement with Brewer and Associates Consulting, LLC (“B+A”) to the original consulting agreement dated on October 15, 2015 for consulting services for twelve months for a monthly fee of $7,000. To relieve our cash obligation of $36,000 per original agreement, we issued three convertible notes for a total of $120,000 which includes the fees due under the original agreement and the new monthly fees due under the expansion agreement. The $40,000 and $60,000 of the Notes were paid in full as of December 31, 2016 and December 31, 2017, respectively. The remaining balance of $20,000 Notes is in default and negotiation of settlement. The conversion price is equal to 55% of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. At December 31, 2018 and 2017, the convertible notes payable with principal balance of $20,000, at fair value, were recorded at $47,481 and $52,948, respectively. ● During June 2016, we issued a Convertible Debenture in the amount of $72,000 to an unrelated third party as a result of debt sale. The Note carries interest at 8% and was due on June 20, 2017, unless previously converted into shares of restricted common stock. The convertible note holder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of the average of the three lowest volume weighted average prices (the VWAP) of our restricted common stock for the fifteen trading days preceding the conversion date. At December 31, 2017, the convertible notes payable, at fair value, was recorded at $237,121. During August 2018, a Note holder received a total of 300,000,000 shares of our restricted common stock in satisfaction of the principal balance of $72,000 with accrued interest in full (See Note 9). ● During June 2016, the notes payable of $50,000 originating in January 2016 with accrued interest of $4,800 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note (See Note 7(2)). The note carries interest at 8% and was due on June 16, 2017, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of the average of the three lowest VWAP prices of our restricted common stock for the fifteen trading days preceding the conversion date. At December 31, 2017, the balance of $54,800, at fair value, was recorded at $180,868. During May 2018, the Note holder made a conversion of 228,000,000 shares of our restricted common stock with a fair value of $319,200 in satisfaction of the principal balance of $54,800 in full (See Note 7). ● In April 2017, we issued a Convertible Promissory Note for $33,000 to an unrelated third party. The note carries interest at 12% annually and was due on January 30, 2018. The Holder has the right to convert the loan, beginning on the date which is one hundred eighty (180) days following the date of the Note, into common stock at a price of sixty percent (60%) of the average of the three lowest trading prices of our restricted common stock for the fifteen trading days preceding the conversion date. During October 2017, the Noteholder made the conversions of a total of 50,125,000 of our restricted common stock satisfying the principal balance of $16,040 with a fair value of $35,596. At December 31, 2017, the convertible note payable, at fair value, was recorded at $48,213. During June 2018, the Note holder made a conversion of 150,000,000 shares of our restricted common stock with a fair value of $180,000 in satisfaction of the remaining principal balance of $16,960 with accrued interest in full (See Note 7). ● During May and October 2017, we issued two Convertible Debenture for a total of $90,000 ($45,000 each) to Labrys. The notes carrie interest at 12% and were due on July 19, 2017 and November 3, 2017, respectively, unless previously converted into shares of restricted common stock. Labrys has the right to convert the notes into shares of Common Stock at sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty-five trading days preceding the conversion date. During November 2017, the Note holder made a conversion of 62,059,253 shares of stock satisfying the principal balance of $11,057 and accrued interest for a fair value of $51,732. At December 31, 2017, the convertible notes payable, at fair value, was recorded at $236,349. During February 2018, we issued 45,000,000 shares of our restricted common stock with a fair value of $247,500 to Labrys in settlement of the remaining balance of $78,943 and accrued interest in full (See Note 7). Based on the conversion methodology, the debt was valued at $1,206,081 prior to conversion, and the Company recorded a gain on settlement of $958,581, which is recorded within gain (loss) on settlement of debt, net, within the statement of operations. ● During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carries interest at 12% and matures on September 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 179,800,000 shares of stock satisfying the principal balance of $63,001 and accrued interest for a fair value of $298,575. At December 31, 2017, the convertible note payable, at fair value, was recorded at $147,314. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. During February and July, 2018, we issued a total of 105,157,409 shares of our restricted common |
STOCKHOLDERS' DEFICIT (Tables)
STOCKHOLDERS' DEFICIT (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Stockholders' Equity Note [Abstract] | |
Schedule of Stockholders Equity [Table Text Block] | Date Number of Fair Value of shares converted Debt Converted 7/18/2017 50,000,000 $81,016 7/27/2017 37,000,000 56,236 8/8/2017 60,000,000 73,159 8/23/2017 17,935,000 14,732 Date Number of Fair Value of shares converted Debt Converted 8/10/2017 70,426,471 78,859 8/21/2017 15,064,583 12,117 Date Number of Fair Value of shares converted Debt Converted 6/8/2017 23,715,415 56,303 7/6/2017 17,044,486 11,166 10/9/2017 42,365,263 40,501 Date Number of Fair Value of shares converted Debt Converted 3/7/2017 15,500,000 $78,909 3/31/2017 15,000,000 66,000 5/25/2017 16,511,483 69,886 Date Number of Fair Value of shares converted Debt Converted 3/2/2017 2,300,000 $ 9,982 3/28/2017 5,700,000 21,186 4/18/2017 5,700,000 31,057 4/24/2017 5,700,000 26,717 5/11/2017 6,158,744 19,510 Date Number of Fair Value of shares converted Debt Converted 2/26/2017 2,681,327 $18,381 3/6/2017 4,633,425 20,760 3/13/2017 3,059,501 16,016 3/24/2017 10,597,122 39,700 Date Number of Fair Value of shares converted Debt Converted 5/4/2017 11,473,225 $55,549 5/24/2017 8,603,866 25,108 6/26/2017 23,167,481 25,343 Date Number of Fair Value of shares converted Debt Converted 8/4/2017 37,138,936 $42,923 8/21/2017 69,574,422 53,338 Date Number of Fair Value of shares converted Debt Converted 2/27/2017 6,250,000 $42,171 3/8/2017 8,000,000 38,234 3/28/2017 5,323,258 17,742 Date Number of Fair Value of shares converted Debt Converted 4/25/2017 13,631,346 $60,202 6/15/2017 10,679,950 20,949 6/21/2017 27,429,600 38,401 6/26/2017 27,429,750 30,173 6/29/2017 26,171,885 28,789 7/6/2017 33,199,136 39,839 Date Number of Fair Value of shares converted Debt Converted 7/13/2017 50,650,959 $117,179 8/10/2017 21,275,000 23,486 9/13/2017 9,711,900 5,062 9/19/2017 82,122,533 65,229 10/10/2017 86,049,332 59,760 Date Number of Fair Value of shares converted Debt Converted 6/12/2017 19,000,000 $33,123 6/20/2017 19,000,000 26,231 6/30/2017 19,000,000 19,992 7/13/2017 19,000,000 49,517 7/19/2017 53,800,000 96,005 7/31/2017 50,000,000 73,707 Date Number of Fair Value of shares converted Debt Converted 6/6/2017 9,000,000 $27,051 6/20/2017 9,000,000 11,872 7/5/2017 13,582,547 15,056 Date Number of Fair Value of shares converted Debt Converted 6/28/2017 11,560,500 $10,158 6/29/2017 30,352,771 32,450 7/5/2017 32,252,381 43,664 7/10/2017 42,221,167 36,849 Date Number of Fair Value of shares converted Debt Converted 6/19/2017 20,000,000 $28,858 6/23/2017 28,000,000 34,433 6/27/2017 30,000,000 27,747 6/30/2017 33,000,000 32,781 7/5/2017 42,960,000 55,666 7/13/2017 45,000,000 115,625 7/31/2017 23,747,390 8,941 |
STOCK WARRANTS (Tables)
STOCK WARRANTS (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Stock Options and Warrants [Abstract] | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the years ended December 31, 2018 and 2017: Number Of shares Weighted average exercise price Balance December 31, 2016 29,141,667 $ 0.03 Exercised (1,000,000) 0.35 Issued 6,000,000 $ 0.005 Forfeited (20,601,667) - Balance December 31, 2017 13,540,000 $ 0.023 Exercised - - Issued - $ - Forfeited (940,000) 0.015 Balance December 31, 2018 12,600,000 $ 0.026 |
Summary of fixed-price warrants outstanding [Table Text Block] | The following table summarizes information about fixed-price warrants outstanding as of December 31, 2018: Exercise Price Weighted Average Number Outstanding Weighted Average Contractual Life Weighted Average Exercise Price 2018 $ 0.005-0.05 12,600,000 1.11 years $ 0.024 2017 $ 0.005-1.00 13,540,000 1.75 years $ 0.023 |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Income Tax Disclosure [Abstract] | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | The Company’s tax expense differs from the “expected” tax expense for the years ended December 31, 2018 and 2017, (computed by the following blended rate), are approximately as follows. 2018 2017 Tax Rate Reconciliation: Federal tax rate 21.00% 34.00% Add: State taxes 5.50% 5.50% Permanent difference -1.20% -1.90% Valuation allowance and change in federal tax rate -25.35% -37.63% Tax rate - - December 31, 2018 2017 Computed “expected” tax expense (benefit) - Federal $ (793,340) $ (1,345,175) Computed “expected” tax expense (benefit) - State (164,145) (230,267) Permanent differences 571,235 771,881 Change in federal tax rate 4,134,665 - Change in valuation allowance (3,748,415) 803,561 Provision for income taxes $ - $ - 2018 2017 Net deferred income tax assets: Reserve for prepaid inventory $ 12,104 $ - Accrued salary 296,834 347,674 Net operating loss carryforwards 9,083,135 12,792,814 Valuation allowance (9,392,073) (13,140,488) Net deferred income tax asset $ - $ - |
ACCRUED EXPENSES (Tables)
ACCRUED EXPENSES (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Expenses [Table Text Block] | Accrued expenses consisted of the following: December 31, 2018 2017 Accrued consulting fees $ 161,550 $ 161,550 Accrued settlement expenses 347,400 315,000 Accrued payroll taxes 120,182 72,452 Accrued interest 180,509 133,865 Accrued legal fees - 239,020 Accrue others 22,208 27,509 Total $ 831,849 $ 949,396 |
PREPAID EXPENSES (Tables)
PREPAID EXPENSES (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Prepaid Expenses [Abstract] | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] | Prepaid expenses and other current assets consist of the following: December 31, December 31, Supplier advances for future purchases $ 200,911 $ 189,154 Reserve for supplier advances (200,911) (153,154) Net supplier advances - 36,000 Prepaid professional fees 13,000 16,500 Deferred stock compensation 50,000 - Total $ 63,000 $ 52,500 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | Future minimum payments under these lease agreements are as follows: Total 2019 $ 84,765 2020 87,991 2021 99,163 2022 54,490 $ 326,409 |
SUBSEQUENT EVENTS (Tables)
SUBSEQUENT EVENTS (Tables) - Subsequent Event [Member] | 12 Months Ended |
Dec. 31, 2018 | |
SUBSEQUENT EVENTS (Tables) [Line Items] | |
Schedule of Derivative Instruments [Table Text Block] | Month of Issuance Number of Fair Value of Month of Expiration Warrants Warrants February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 7,370 August, 2020 August, 2020 92,100,000 22,879 August, 2021 October, 2020 39,930,000 9,497 October, 2022 |
Schedule of Stockholders Equity [Table Text Block] | Date Number of Fair Value of shares converted Debt Converted 5/6/2019 250,000,000 $75,000 5/31/2019 250,000,000 100,000 6/6/2019 250,000,000 100,000 1/21/2020 250,000,000 150,000 2/18/2020 250,000,000 275,000 Date Number of Fair Value of shares converted Debt Converted 9/22/2020 107,133,333 $171,413 10/5/2020 107,817,770 64,691 |
BASIS OF PRESENTATION AND SUM_3
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) | 12 Months Ended | |||
Dec. 31, 2018USD ($) | Dec. 31, 2017USD ($) | Jun. 30, 2020USD ($) | May 31, 2020USD ($) | |
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Number of Reportable Segments | 1 | |||
Retained Earnings (Accumulated Deficit) | $ (61,272,842) | $ (57,388,147) | ||
Capital Deficit | 5,911,233 | |||
Stockholders' Equity Attributable to Parent | (5,936,593) | (5,410,194) | ||
Deferred Revenue, Period Increase (Decrease) | 4,403 | |||
Contract with Customer, Liability, Revenue Recognized | 130,596 | |||
Increase (Decrease) in Deferred Revenue | (22,490) | 22,490 | ||
Deferred Tax Assets, Valuation Allowance | 200,911 | $ 189,154 | ||
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability | $ 281,175 | |||
Minimum [Member] | ||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Property, Plant and Equipment, Useful Life | 3 years | |||
Maximum [Member] | ||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Property, Plant and Equipment, Useful Life | 7 years | |||
PPP Loan [Member] | ||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Short-term Non-bank Loans and Notes Payable | $ 64,895 | |||
Economic Injury Disaster Loan [Member] | ||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Short-term Non-bank Loans and Notes Payable | $ 154,900 | |||
Payment processor 1 [Member] | ||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Concentration Risk, Percentage | 84.00% | |||
Payment processor 2 [Member] | ||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Concentration Risk, Percentage | 85.00% | |||
Customer 2 [Member] | ||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Concentration Risk, Customer | In addition, for the year ended December 31, 2018, there were two customers that accounted for 32% and 27% of the total revenues, respectively | |||
Concentration Risk, Percentage | 27.00% | 15.00% | ||
Customer 1 [Member] | ||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Concentration Risk, Percentage | 32.00% | 38.00% | ||
Prepaid Venom [Member] | ||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Increase (Decrease) in Deferred Revenue | $ 47,757 | |||
Deferred Tax Assets, Valuation Allowance | $ 200,911 |
BASIS OF PRESENTATION AND SUM_4
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Adoption of ASC 606, Revenue from Contracts with Customers | 12 Months Ended |
Dec. 31, 2018USD ($) | |
With ASC 606 [Member] | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |
Revenue | $ 130,596 |
Costs of sales | (68,777) |
Without ASC 606 [Member] | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |
Revenue | 126,193 |
Costs of sales | (64,374) |
Effect of ASC 606 [Member] | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |
Revenue | 4,403 |
Costs of sales | $ (4,403) |
BASIS OF PRESENTATION AND SUM_5
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities excluded from computation of Earnings Per Share - shares | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive Securities | 4,460,728,953 | 2,481,052,550 |
Warrant [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive Securities | 12,600,000 | 13,540,000 |
Convertible Debt Securities [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive Securities | 4,448,128,953 | 2,467,512,550 |
FAIR VALUE MEASUREMENTS (Detail
FAIR VALUE MEASUREMENTS (Details) | 12 Months Ended |
Dec. 31, 2018 | |
FAIR VALUE MEASUREMENTS (Details) [Line Items] | |
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate | 256.00% |
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate | 0.00% |
Minimum [Member] | |
FAIR VALUE MEASUREMENTS (Details) [Line Items] | |
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate | 2.59% |
Maximum [Member] | |
FAIR VALUE MEASUREMENTS (Details) [Line Items] | |
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate | 2.81% |
FAIR VALUE MEASUREMENTS (Deta_2
FAIR VALUE MEASUREMENTS (Details) - Schedule of Financial Instruments Measured at Fair Value - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 |
FAIR VALUE MEASUREMENTS (Details) - Schedule of Financial Instruments Measured at Fair Value [Line Items] | ||
Warrant liability | $ 1,468 | $ 5,903 |
Convertible notes at fair value | 1,156,341 | 1,925,959 |
Fair Value, Inputs, Level 1 [Member] | ||
FAIR VALUE MEASUREMENTS (Details) - Schedule of Financial Instruments Measured at Fair Value [Line Items] | ||
Warrant liability | ||
Convertible notes at fair value | ||
Fair Value, Inputs, Level 2 [Member] | ||
FAIR VALUE MEASUREMENTS (Details) - Schedule of Financial Instruments Measured at Fair Value [Line Items] | ||
Warrant liability | ||
Convertible notes at fair value | ||
Fair Value, Inputs, Level 3 [Member] | ||
FAIR VALUE MEASUREMENTS (Details) - Schedule of Financial Instruments Measured at Fair Value [Line Items] | ||
Warrant liability | 1,468 | 5,903 |
Convertible notes at fair value | $ 1,156,341 | $ 1,925,959 |
FAIR VALUE MEASUREMENTS (Deta_3
FAIR VALUE MEASUREMENTS (Details) - Schedule of Changes in Fair Value Measurements Using Significant Unobservable Inputs - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | ||
Schedule of Changes in Fair Value Measurements Using Significant Unobservable Inputs [Abstract] | |||
Beginning balance | $ 5,903 | $ 48,504 | |
Purchases, issuances, and settlements | 24,017 | ||
Total (gain) loss included in earnings | [1] | (4,435) | (66,618) |
Ending balance | $ 1,468 | $ 5,903 | |
[1] | The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
FAIR VALUE MEASUREMENTS (Deta_4
FAIR VALUE MEASUREMENTS (Details) - Schedule of Significant Terms of Each of the Debentures - USD ($) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
FAIR VALUE MEASUREMENTS (Details) - Schedule of Significant Terms of Each of the Debentures [Line Items] | ||
Face Amount (in Dollars) | $ 1,340,026 | $ 682,099 |
Default Interest Rate | 18.00% | |
Minimum [Member] | ||
FAIR VALUE MEASUREMENTS (Details) - Schedule of Significant Terms of Each of the Debentures [Line Items] | ||
Interest Rate | 8.00% | 8.00% |
Default Interest Rate | 18.00% | |
Discount Rate (in Dollars per share) | $ 25.95 | $ 23.95 |
Anti-Dilution Adjusted Price (in Dollars per share) | $ 0.0002 | $ 0.0002 |
% of stock price for look-back period | 40.00% | 40.00% |
Look-back Period | 3 days | 3 days |
Maximum [Member] | ||
FAIR VALUE MEASUREMENTS (Details) - Schedule of Significant Terms of Each of the Debentures [Line Items] | ||
Interest Rate | 12.00% | 12.00% |
Default Interest Rate | 20.00% | |
Discount Rate (in Dollars per share) | $ 27.95 | $ 27.95 |
Anti-Dilution Adjusted Price (in Dollars per share) | $ 0.20 | $ 0.20 |
% of stock price for look-back period | 60.00% | 60.00% |
Look-back Period | 25 days | 25 days |
FAIR VALUE MEASUREMENTS (Deta_5
FAIR VALUE MEASUREMENTS (Details) - Schedule of Changes in Fair Value Measurements Using Significant Unobservable Inputs for the Convertible Notes - Convertible Notes [Member] - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | ||
FAIR VALUE MEASUREMENTS (Details) - Schedule of Changes in Fair Value Measurements Using Significant Unobservable Inputs for the Convertible Notes [Line Items] | |||
Beginning balance | $ 1,925,959 | $ 1,672,728 | |
Purchases and issuances | 472,029 | 580,143 | |
Day one loss on value of hybrid instrument | [1] | 2,021,041 | 999,228 |
Loss from change in fair value | [1] | 130,344 | 1,314,325 |
Gain on settlement | (958,581) | ||
Conversion to common stock | (2,434,451) | (2,594,100) | |
Repayment in cash | (46,365) | ||
Ending balance | $ 1,156,341 | $ 1,925,959 | |
[1] | The losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
INVENTORIES (Details) - Schedul
INVENTORIES (Details) - Schedule of Inventories - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 |
Schedule of Inventories [Abstract] | ||
Raw Materials | $ 33,431 | $ 13,704 |
Finished Goods | 1,871 | 6,438 |
Total Inventories | $ 35,302 | $ 20,142 |
PROPERTY AND EQUIPMENT (Details
PROPERTY AND EQUIPMENT (Details) - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 |
Property, Plant and Equipment [Abstract] | ||
Property, Plant and Equipment, Other, Accumulated Depreciation | $ 5,963 | $ 6,286 |
PROPERTY AND EQUIPMENT (Detai_2
PROPERTY AND EQUIPMENT (Details) - Schedule of Property and Equipment - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 |
Property, Plant and Equipment [Line Items] | ||
Property and equipment | $ 216,033 | $ 216,033 |
Less: Accumulated depreciation | (205,533) | (199,570) |
Property and equipment, net | 10,500 | 16,463 |
Computer Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment | 25,120 | 25,120 |
Furniture and Fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment | 34,757 | 34,757 |
Lab Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment | 53,711 | 53,711 |
Telephone Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment | 12,421 | 12,421 |
Office Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment | 16,856 | 16,856 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment | $ 73,168 | $ 73,168 |
DUE FROM_TO OFFICERS (Details)
DUE FROM/TO OFFICERS (Details) - Deitsch [Member] - USD ($) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
DUE FROM/TO OFFICERS (Details) [Line Items] | ||
Due from Related Parties | $ 186,497 | $ 269,772 |
Debt Instrument, Interest Rate, Effective Percentage | 4.00% | 4.00% |
Repayments of Short-term Debt | $ 162,775 | $ 266,900 |
Proceeds from Short-term Debt | 105,900 | 330,350 |
Interest Income (Expense), Net | 7,674 | |
Accounts Receivable, Credit Loss Expense (Reversal) | $ 505,470 | |
Due to Related Parties | $ 134,549 | |
Series A Preferred Stock [Member] | ||
DUE FROM/TO OFFICERS (Details) [Line Items] | ||
Preferred Stock, Shares Issued (in Shares) | 3,000,000 | |
Preferred Stock, Value, Issued | $ 400,000 |
DEBTS (Details) - (1)
DEBTS (Details) - (1) - USD ($) | Feb. 15, 2019 | Oct. 12, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Mar. 31, 2012 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2010 | Oct. 31, 2017 | Aug. 31, 2016 | Aug. 30, 2013 | Aug. 02, 2011 |
DEBTS (Details) - (1) [Line Items] | ||||||||||||
Notes Payable | $ 3,389,986 | $ 3,466,403 | ||||||||||
Repayments of Notes Payable | 41,976 | 178,024 | ||||||||||
Deposit Liabilities, Accrued Interest | 141,808 | 126,036 | ||||||||||
Director [Member] | ||||||||||||
DEBTS (Details) - (1) [Line Items] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | |||||||||||
Short-term Debt, Interest Rate Increase | 12.00% | |||||||||||
Line of Credit Facility, Increase, Accrued Interest | 141,808 | 126,036 | ||||||||||
Interest Expense, Debt | 15,772 | 15,457 | ||||||||||
Director [Member] | ||||||||||||
DEBTS (Details) - (1) [Line Items] | ||||||||||||
Notes Payable | $ 200,000 | |||||||||||
Director Company[Member] | ||||||||||||
DEBTS (Details) - (1) [Line Items] | ||||||||||||
Notes Payable | $ 101,818 | $ 201,818 | 192,974 | 192,974 | $ 200,000 | |||||||
Line of Credit Facility, Increase, Accrued Interest | 40,033 | $ 16,876 | ||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 12.00% | |||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.008 | |||||||||||
Repayments of Notes Payable | $ 8,844 | $ 6,365 | ||||||||||
Debt Conversion, Converted Instrument, Rate | 12.00% | |||||||||||
Extinguishment of Debt, Nature of Restrictions on Assets Set Aside for Scheduled Payments | $21,023 | |||||||||||
Repayments of Lines of Credit | $ 104,000 | |||||||||||
Liquid Packaging Resources [Member] | ||||||||||||
DEBTS (Details) - (1) [Line Items] | ||||||||||||
Notes Payable | $ 281,772 | $ 350,000 | ||||||||||
Repayments of Notes Payable | $ 25,000 | |||||||||||
Liquid Packaging Resources [Member] | Being disputed in court [Member] | ||||||||||||
DEBTS (Details) - (1) [Line Items] | ||||||||||||
Notes Payable | 91,156 | |||||||||||
Related Party [Member] | ||||||||||||
DEBTS (Details) - (1) [Line Items] | ||||||||||||
Notes Payable | 12,000 | $ 12,000 | ||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 2,400 | $ 2,000 | ||||||||||
Pre Reverse Stock Split [Member] | Liquid Packaging Resources [Member] | Being disputed in court [Member] | ||||||||||||
DEBTS (Details) - (1) [Line Items] | ||||||||||||
Deposit Liabilities, Accrued Interest | $ 19,010 |
DEBTS (Details) - (2)
DEBTS (Details) - (2) - USD ($) | 1 Months Ended | 3 Months Ended | 7 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||
Jul. 31, 2019 | Aug. 30, 2018 | Jun. 30, 2018 | May 31, 2018 | Feb. 28, 2018 | Nov. 30, 2017 | May 31, 2016 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Sep. 30, 2020 | Nov. 30, 2018 | Jul. 31, 2018 | Apr. 30, 2018 | Jan. 31, 2018 | Oct. 31, 2017 | Sep. 30, 2017 | Jul. 31, 2017 | Jun. 30, 2017 | Apr. 30, 2017 | Dec. 31, 2016 | Oct. 31, 2016 | Sep. 26, 2016 | Aug. 30, 2016 | Jun. 30, 2016 | Apr. 30, 2016 | Mar. 19, 2014 | Aug. 30, 2013 | Dec. 31, 2012 | Jan. 26, 2012 | Aug. 02, 2011 | |
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | $ 3,389,986 | $ 3,389,986 | $ 3,466,403 | ||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 41,976 | $ 178,024 | |||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 4,046,746,110 | 4,046,746,110 | 2,032,233,701 | ||||||||||||||||||||||||||||||
Amortization of Debt Issuance Costs and Discounts | $ 32,146 | $ 28,815 | |||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 4,046,746 | 4,046,746 | 2,032,234 | ||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 378,754 | 117,325 | |||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 17,870 | 17,870 | 28,723 | ||||||||||||||||||||||||||||||
Non-Related Party [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | 1,469,690 | 1,469,690 | 1,337,470 | ||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 29,371 | 29,371 | 0 | ||||||||||||||||||||||||||||||
Liquid Packaging Resources [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | $ 281,772 | $ 350,000 | |||||||||||||||||||||||||||||||
Investment Owned, Balance, Principal Amount | $ 175,000 | ||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | $ 25,000 | ||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 25,000 | ||||||||||||||||||||||||||||||||
Sale of Stock, Number of Shares Issued in Transaction (in Shares) | 142,858 | ||||||||||||||||||||||||||||||||
Cash Settlement | $ 450,000 | ||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | $ 100,000 | ||||||||||||||||||||||||||||||||
Other Significant Noncash Transaction, Value of Consideration Received | $ 281,772 | ||||||||||||||||||||||||||||||||
Non-Related Party 2 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | 50,000 | 50,000 | $ 10,000 | ||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 10.00% | ||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 2,739 | 1,465 | |||||||||||||||||||||||||||||||
Non-Related Party 3 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | $ 75,000 | 50,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 62,950 | 62,950 | |||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 2.00% | ||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 37,801 | 25,567 | |||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 5,000,000 | ||||||||||||||||||||||||||||||||
Repayments of Debt | $ 25,000 | ||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | 6,542 | 6,542 | |||||||||||||||||||||||||||||||
Non-Related Party 4 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | 50,000 | 50,000 | $ 50,000 | ||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | 2.00% | |||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 31,000 | 18,767 | |||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 23,794 | ||||||||||||||||||||||||||||||||
Non-Related Party 5 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | 282,983 | 282,983 | 180,250 | $ 220,506 | $ 180,250 | $ 150,000 | |||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 3,616 | $ 3,616 | $ 2,765 | ||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 2.00% | 2.00% | 2.50% | 2.50% | 2.50% | ||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | $ 2,830 | 38,455 | |||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 10,000,000 | 10,000,000 | 5,000,000 | 2,000,000 | |||||||||||||||||||||||||||||
Amortization of Debt Issuance Costs and Discounts | $ 2,765 | ||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 5,500 | ||||||||||||||||||||||||||||||||
Notes Payable, Current | $ 282,983 | 282,983 | |||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | 3,945 | 3,945 | |||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 329 | ||||||||||||||||||||||||||||||||
Non-Related Party 6 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | $ 75,000 | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 10.00% | ||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 17,271 | 7,708 | |||||||||||||||||||||||||||||||
Non-Related Party 7 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | $ 120,000 | 120,000 | 120,000 | 120,000 | $ 50,000 | ||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 20,000 | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 2.00% | ||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 27,300 | 15,067 | |||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 10,000,000 | ||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 5,600 | ||||||||||||||||||||||||||||||||
Non-Related Party 8 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | $ 12,500 | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 10.00% | ||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 1,944 | 670 | |||||||||||||||||||||||||||||||
Non-Related Party 9 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | $ 170,402 | 135,426 | 135,426 | 191,329 | $ 200,000 | ||||||||||||||||||||||||||||
Repayments of Notes Payable | 34,976 | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 15.00% | ||||||||||||||||||||||||||||||||
Debt Issuance Costs, Gross | $ 5,500 | ||||||||||||||||||||||||||||||||
Gains (Losses) on Restructuring of Debt | 20,927 | ||||||||||||||||||||||||||||||||
Non-Related Party 10 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | 50,000 | 50,000 | 50,000 | 50,000 | |||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 10,000 | $ 10,000 | |||||||||||||||||||||||||||||||
Common Stock, Value, Issued | 1,500 | 1,500 | |||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | 3,300 | ||||||||||||||||||||||||||||||||
Non-Related Party 11 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | 0 | 0 | 42,500 | $ 51,000 | |||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 8,500 | ||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 42,500 | 8,500 | |||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 12.00% | ||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | $ 2,820 | ||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 187,500,000 | ||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 243,750 | $ 147,220 | $ 63,001 | ||||||||||||||||||||||||||||||
Gains (Losses) on Restructuring of Debt | $ 201,250 | ||||||||||||||||||||||||||||||||
Non-Related Party 20 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | 27,500 | 27,500 | 34,500 | $ 33,000 | 36,000 | ||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 6,000 | 6,000 | 4,000 | $ 3,000 | $ 6,000 | ||||||||||||||||||||||||||||
Repayments of Notes Payable | 7,000 | 1,500 | |||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 4,000 | 2,000 | |||||||||||||||||||||||||||||||
Non-Related Party 13 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | $ 61,746 | $ 61,746 | 60,000 | $ 60,000 | $ 60,000 | 50,000 | |||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 10,000 | $ 10,000 | $ 10,000 | ||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 10,000 | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | ||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 10,000,000 | 10,000,000 | 5,000,000 | 5,000,000 | 5,000,000 | ||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 3,000 | $ 3,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | 8,254 | 8,254 | $ 2,381 | $ 8,678 | $ 3,200 | ||||||||||||||||||||||||||||
Amortization of Debt Issuance Costs | 4,127 | ||||||||||||||||||||||||||||||||
Non-Related Party 15 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | 18,000 | $ 18,000 | $ 18,000 | ||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 3,000 | ||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 5,000,000 | 7,000,000 | 7,000,000 | ||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 5,600 | $ 5,600 | |||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 2,900 | ||||||||||||||||||||||||||||||||
Non-Related Party 16 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | $ 0 | $ 0 | 60,000 | ||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 10,000 | ||||||||||||||||||||||||||||||||
Investment Owned, Balance, Principal Amount | 150,000,000 | ||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 60,000 | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 12.00% | ||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 145,000,000 | ||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 101,500 | 180,000 | $ 16,040 | ||||||||||||||||||||||||||||||
Notes Payable, Current | $ 60,000 | ||||||||||||||||||||||||||||||||
Gains (Losses) on Restructuring of Debt | 41,500 | ||||||||||||||||||||||||||||||||
Notes Receivable, Related Parties | $ 60,000 | ||||||||||||||||||||||||||||||||
University Centre West Ltd [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Debt, Approximate | $ 55,410 | ||||||||||||||||||||||||||||||||
Monthly [Member] | Liquid Packaging Resources [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | $ 50,000 | ||||||||||||||||||||||||||||||||
Monthly [Member] | Non-Related Party 9 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Notes Payable | $ 7,000 | ||||||||||||||||||||||||||||||||
Pre Reverse Stock Split [Member] | Liquid Packaging Resources [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Sale of Stock, Number of Shares Issued in Transaction (in Shares) | 5,714,326 | ||||||||||||||||||||||||||||||||
Default Penalties [Member] | Non-Related Party 7 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 1,500,000 | ||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 2,250 | ||||||||||||||||||||||||||||||||
Default Penalties [Member] | Non-Related Party 13 [Member] | |||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 1,000,000 | ||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 1,700 |
DEBTS (Details) - (3)
DEBTS (Details) - (3) - USD ($) | Mar. 19, 2014 | Aug. 30, 2018 | Feb. 28, 2018 | Oct. 31, 2017 | Jan. 31, 2017 | Jul. 31, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Nov. 30, 2018 | Jun. 30, 2018 | Apr. 30, 2018 | Jul. 31, 2017 | May 31, 2016 | |
DEBTS (Details) - (3) [Line Items] | ||||||||||||||
Convertible Notes Payable | [1] | $ 1,156,341 | $ 1,925,365 | |||||||||||
Repayments of Convertible Debt | 3,000 | 40,000 | ||||||||||||
Deposit Liabilities, Accrued Interest | 141,808 | 126,036 | ||||||||||||
Amortization of Debt Discount (Premium) | 378,754 | 117,325 | ||||||||||||
Common Stock, Value, Issued | 4,046,746 | 2,032,234 | ||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 249,113 | $ 5,241 | ||||||||||||
Minimum [Member] | ||||||||||||||
DEBTS (Details) - (3) [Line Items] | ||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | 8.00% | ||||||||||||
Maximum [Member] | ||||||||||||||
DEBTS (Details) - (3) [Line Items] | ||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 12.00% | 12.00% | ||||||||||||
Non-Related Party [Member] | ||||||||||||||
DEBTS (Details) - (3) [Line Items] | ||||||||||||||
Convertible Notes Payable | $ 751,955 | $ 594 | ||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 29,371 | 0 | ||||||||||||
Non-Related Party 13 [Member] | ||||||||||||||
DEBTS (Details) - (3) [Line Items] | ||||||||||||||
Convertible Notes Payable | $ 500,000 | 27,000 | $ 594 | |||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 10,000 | $ 10,000 | $ 10,000 | |||||||||||
Repayments of Convertible Debt | $ 15,000 | 3,000 | ||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | |||||||||||||
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger | 0.20% | |||||||||||||
Deposit Liabilities, Accrued Interest | 11,412 | |||||||||||||
Debt Instrument, Unamortized Discount | 3,200 | 8,254 | $ 2,381 | 8,678 | ||||||||||
Common Stock, Value, Issued | 3,000 | |||||||||||||
Non-Related Party 19 [Member] | ||||||||||||||
DEBTS (Details) - (3) [Line Items] | ||||||||||||||
Convertible Notes Payable | $ 76,076 | $ 65,600 | $ 56,567 | $ 50,000 | 75,126 | |||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 3,800 | $ 4,035 | 950 | $ 65,000 | ||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 2.50% | 2.50% | 2.50% | 2.00% | 8.00% | 8.00% | ||||||||
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger | 0.05% | 0.05% | ||||||||||||
Deposit Liabilities, Accrued Interest | $ 10,476 | $ 65,600 | 8,177 | |||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 5,000,000 | 1,000,000 | ||||||||||||
Amortization of Debt Discount (Premium) | 2,850 | |||||||||||||
Debt Instrument, Unamortized Discount, Current | 105,334 | |||||||||||||
Non-Related Party 10 [Member] | ||||||||||||||
DEBTS (Details) - (3) [Line Items] | ||||||||||||||
Convertible Notes Payable | 60,000 | $ 60,000 | ||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 10,000 | $ 10,000 | ||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 5,000,000 | 1,000,000 | ||||||||||||
Debt Instrument, Unamortized Discount | $ 3,300 | |||||||||||||
Common Stock, Value, Issued | $ 1,500 | |||||||||||||
Non-Related Party 3 [Member] | ||||||||||||||
DEBTS (Details) - (3) [Line Items] | ||||||||||||||
Convertible Notes Payable | 589,829 | |||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 62,950 | |||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 2.00% | |||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 10,250,000 | |||||||||||||
Debt Instrument, Unamortized Discount | $ 6,542 | |||||||||||||
Convertible Notes Payable, Current | 618,250 | |||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 249,113 | |||||||||||||
Debt Instrument, Unamortized Discount (Premium), Net | 255,655 | |||||||||||||
Accumulated Amortization, Debt Issuance Costs, Noncurrent | 290,184 | |||||||||||||
Debt Instrument, Unamortized Discount, Current | $ 28,421 | |||||||||||||
Non-Related Party 3 [Member] | Minimum [Member] | ||||||||||||||
DEBTS (Details) - (3) [Line Items] | ||||||||||||||
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger | 0.0003% | |||||||||||||
Non-Related Party 3 [Member] | Maximum [Member] | ||||||||||||||
DEBTS (Details) - (3) [Line Items] | ||||||||||||||
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger | 0.001% | |||||||||||||
Currently in default and negotiation [Member] | ||||||||||||||
DEBTS (Details) - (3) [Line Items] | ||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 24,915 | |||||||||||||
Convertible Notes Payable, Current | $ 264,150 | |||||||||||||
[1] | At December 31, 2018 and 2017, the balance of $1,156,341 and $1,925,365, respectively, consisted of the following convertible loans: During December 2015, Mr. Deitsch, assigned $80,000 of his outstanding loan to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 4% and was due on December 7, 2016. The Note reverted back as the promissory note upon maturity date. On June 27, 2017, the Company owed principal balance of $80,000 plus accrued interest of $4,971. The total of $84,971 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note (See Note 7(2)). The note carries interest at 8% and was due on June 27, 2018, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of lowest closing bid prices of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. During July and August 2017, the Note holder made conversions of a total of 164,935,000 shares of our restricted common stock satisfying the principal balance of $55,325 with a fair value of $225,143. At December 31, 2017, the convertible note payable, at fair value, was recorded at $95,369. During February 2018, the Note holder made conversions of a total of 109,876,500 shares of our restricted common stock with a fair value of $462,625 in satisfaction of the remaining principal balance of $29,646 in full. On March 31, 2017, we issued a convertible denture in the amount of $80,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 8% and was due on March 30, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note into shares of Common Stock at a fifty-five percent (55%) of the of the lowest closing bid price of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. At December 31, 2017, the convertible note payable, at fair value, was recorded at $256,043. During February 2018, the Noteholder made a conversion of 70,123,500 shares of our restricted common stock with a fair value of $294,885 in satisfaction of a portion of the Note in the amount of $30,854 (See Note 7). The noteholder sold and assigned the remaining balance of $49,146 with accrued interest of $3,276 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During April and May 2018, the Note holder made conversions of a total of 65,885,713 shares of our restricted common stock with a fair value of $145,161 in satisfaction of the remaining principal balance of $49,146 and accrued interest in full (See Note 7). On July 18, 2017, we issued a convertible denture in the amount of $150,000 to Coventry. The note carries interest at 8% and was due on July 18, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note into shares of Common Stock at a fifty-five percent (55%) of the of the lowest closing bid price of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. At December 31, 2017, the convertible note payable, at fair value, was recorded at $483,092. During February 2018, the noteholder sold and assigned the balance of $150,000 with accrued interest of $6,000 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During May and June 2018, the Noteholder made conversions of a total of 120,891,284 shares of our restricted common stock with a fair value of $200,475 in partial satisfaction of the note in the amount of $70,000 (See Note 7). During July through September 2018, the Note holder made conversions of a total of 206,988,570 shares of our restricted common stock with a fair value of $176,655 in satisfaction of the remaining principal balance $86,000 and accrued interest in full (See Note 7). On March 28, 2016, we signed an expansion agreement with Brewer and Associates Consulting, LLC (“B+A”) to the original consulting agreement dated on October 15, 2015 for consulting services for twelve months for a monthly fee of $7,000. To relieve our cash obligation of $36,000 per original agreement, we issued three convertible notes for a total of $120,000 which includes the fees due under the original agreement and the new monthly fees due under the expansion agreement. The $40,000 and $60,000 of the Notes were paid in full as of December 31, 2016 and December 31, 2017, respectively. The remaining balance of $20,000 Notes is in default and negotiation of settlement. The conversion price is equal to 55% of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. At December 31, 2018 and 2017, the convertible notes payable with principal balance of $20,000, at fair value, were recorded at $47,481 and $52,948, respectively. During June 2016, we issued a Convertible Debenture in the amount of $72,000 to an unrelated third party as a result of debt sale. The Note carries interest at 8% and was due on June 20, 2017, unless previously converted into shares of restricted common stock. The convertible note holder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of the average of the three lowest volume weighted average prices (the VWAP) of our restricted common stock for the fifteen trading days preceding the conversion date. At December 31, 2017, the convertible notes payable, at fair value, was recorded at $237,121. During August 2018, a Note holder received a total of 300,000,000 shares of our restricted common stock in satisfaction of the principal balance of $72,000 with accrued interest in full (See Note 9). During June 2016, the notes payable of $50,000 originating in January 2016 with accrued interest of $4,800 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note (See Note 7(2)). The note carries interest at 8% and was due on June 16, 2017, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of the average of the three lowest VWAP prices of our restricted common stock for the fifteen trading days preceding the conversion date. At December 31, 2017, the balance of $54,800, at fair value, was recorded at $180,868. During May 2018, the Note holder made a conversion of 228,000,000 shares of our restricted common stock with a fair value of $319,200 in satisfaction of the principal balance of $54,800 in full (See Note 7). In April 2017, we issued a Convertible Promissory Note for $33,000 to an unrelated third party. The note carries interest at 12% annually and was due on January 30, 2018. The Holder has the right to convert the loan, beginning on the date which is one hundred eighty (180) days following the date of the Note, into common stock at a price of sixty percent (60%) of the average of the three lowest trading prices of our restricted common stock for the fifteen trading days preceding the conversion date. During October 2017, the Noteholder made the conversions of a total of 50,125,000 of our restricted common stock satisfying the principal balance of $16,040 with a fair value of $35,596. At December 31, 2017, the convertible note payable, at fair value, was recorded at $48,213. During June 2018, the Note holder made a conversion of 150,000,000 shares of our restricted common stock with a fair value of $180,000 in satisfaction of the remaining principal balance of $16,960 with accrued interest in full (See Note 7). During May and October 2017, we issued two Convertible Debenture for a total of $90,000 ($45,000 each) to Labrys. The notes carrie interest at 12% and were due on July 19, 2017 and November 3, 2017, respectively, unless previously converted into shares of restricted common stock. Labrys has the right to convert the notes into shares of Common Stock at sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty-five trading days preceding the conversion date. During November 2017, the Note holder made a conversion of 62,059,253 shares of stock satisfying the principal balance of $11,057 and accrued interest for a fair value of $51,732. At December 31, 2017, the convertible notes payable, at fair value, was recorded at $236,349. During February 2018, we issued 45,000,000 shares of our restricted common stock with a fair value of $247,500 to Labrys in settlement of the remaining balance of $78,943 and accrued interest in full (See Note 7). Based on the conversion methodology, the debt was valued at $1,206,081 prior to conversion, and the Company recorded a gain on settlement of $958,581, which is recorded within gain (loss) on settlement of debt, net, within the statement of operations. During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carries interest at 12% and matures on September 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 179,800,000 shares of stock satisfying the principal balance of $63,001 and accrued interest for a fair value of $298,575. At December 31, 2017, the convertible note payable, at fair value, was recorded at $147,314. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. During February and July, 2018, we issued a total of 105,157,409 shares of our restricted common stock to the original Note holder with a fair value of $147,220. At December 31, 2018, the Company owed additional shares to the original noteholder and recorded an accrual of $32,400 to account for the cost of the shares, and the shares were issued in January 2019. The new note of $49,819 carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During September 2018, the Noteholder made a conversions of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full (See Note 7). At December 31, 2018, the convertible note payable with principal balance of $34,819, at fair value, was recorded at $62,508. During May 2017, we issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. The note carries interest at 8% and was due on May 4, 2018, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty trading days preceding the conversion date. During November 2017, the Note holder made a conversion of our restricted common stocks satisfying the principal balance of $856 and penalty of $6,400 for a fair value of $21,399. At December 31, 2017, the convertible note payable, at fair value, was recorded at $185,765. During February 2018, the remaining balance of $63,144 with accrued interest and penalty of $12,442 was assigned and sold to three unrelated third parties. During June 2018, a Note holder made a conversion of 50,670,000 shares of our restricted common stock with a fair value of $70,938 in satisfaction of the balance of $34,060 plus accrued interest of $8,607 (See Note 7). At December 31, 2018, the remaining principal of $29,381 plus accrued interest of $7,138, at fair value, was recorded at $63,315. During February 2018, we issued a convertible denture in the amount of $200,000 to an unrelated third party. The note carries interest at 8% and is due in February 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $1,646,242. At December 31, 2018, the convertible note payable with principal balance of $200,000, at fair value, was recorded at $358,665. The note carries additional $200,000 “Back-end Note” ($100,000 each) with the same terms as the original note. During April 2018, $65,000 of one of the $100,000 Back-end Note was funded. The note carries interest at 8% and is due in February 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $110,700. At December 31, 2018, the convertible note payable, at fair value, was recorded at $115,165. During March 2018, we issued a convertible denture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and is due in March 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $48,418. At December 31, 2018, the convertible note payable, at fair value, was recorded at $107,329. The note carries an additional “Back-end Note” with the same terms as the original note that enables the lender to lend to us another $60,000. During June 2018, the $60,000 Back-end Note was funded. The note carries interest at 8% and is due in March 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $68,067. At December 31, 2018, the convertible note payable, at fair value, was recorded at $105,334. During May 2018, we issued a convertible denture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and is due in May 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $59,257. At December 31, 2018, the convertible note payable, at fair value, was recorded at $106,681. During August 2018, we issued a convertible denture in the amount of $31,500 to an unrelated third party. The note carries interest at 8% and is due in August 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $23,794. At December 31, 2018, the convertible note payable, at fair value, was recorded at $55,409. During July 2018, we issued a convertible denture in the amount of $50,000 to an unrelated third party. The note carries interest at 8% and is due in July 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $46,734. At December 31, 2018, the convertible note payable, at fair value, was recorded at $96,157. During August 2018, we issued a convertible denture in the amount of $20,000 to an unrelated third party. The note carries interest at 8% and is due in August 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $17,829. At December 31, 2018, the convertible note payable, at fair value, was recorded at $38,297. |
DEBTS (Details) - (4)
DEBTS (Details) - (4) - USD ($) | Feb. 13, 2019 | Feb. 28, 2018 | Oct. 10, 2017 | Oct. 09, 2017 | Mar. 28, 2016 | Oct. 31, 2020 | Aug. 31, 2020 | Dec. 31, 2019 | Feb. 28, 2019 | Sep. 30, 2018 | Aug. 30, 2018 | Jun. 30, 2018 | May 31, 2018 | May 30, 2018 | Apr. 30, 2018 | Feb. 28, 2018 | Nov. 30, 2017 | Oct. 31, 2017 | Apr. 30, 2017 | Jan. 31, 2017 | Dec. 31, 2016 | Jul. 31, 2016 | Jun. 30, 2016 | Jun. 30, 2012 | Sep. 30, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Aug. 31, 2018 | Jul. 31, 2018 | Sep. 30, 2017 | Jul. 31, 2017 | Jul. 18, 2017 | Jun. 27, 2017 | May 31, 2017 | Mar. 31, 2017 | Dec. 31, 2015 | |
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | [1] | $ 1,156,341 | $ 1,925,365 | |||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 4,046,746,110 | 2,032,233,701 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 4,046,746 | $ 2,032,234 | ||||||||||||||||||||||||||||||||||||
Assets | 141,417 | 389,570 | ||||||||||||||||||||||||||||||||||||
Notes Payable | 3,389,986 | 3,466,403 | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 59,760 | $ 40,501 | $ 9,497 | $ 22,879 | $ 7,370 | $ 8,147 | 174,535 | |||||||||||||||||||||||||||||||
Deposit Liabilities, Accrued Interest | 141,808 | 126,036 | ||||||||||||||||||||||||||||||||||||
Repayments of Convertible Debt | 3,000 | 40,000 | ||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | 41,976 | 178,024 | ||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 86,049,332 | 42,365,263 | ||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 1,156,341 | 1,925,959 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 249,113 | 5,241 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | $ 378,754 | 117,325 | ||||||||||||||||||||||||||||||||||||
Non-Related Party 1 [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 95,369 | $ 80,000 | $ 80,000 | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 4.00% | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 4,971 | |||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 109,876,500 | 109,876,500 | 164,935,000 | |||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 462,625 | $ 462,625 | $ 55,325 | |||||||||||||||||||||||||||||||||||
Assets | $ 225,143 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, If-converted Value in Excess of Principal | $ 29,646 | |||||||||||||||||||||||||||||||||||||
Coventry [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 80,000 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | 8.00% | 8.00% | 8.00% | ||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 120,891,284 | |||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 294,885 | $ 176,655 | $ 200,475 | $ 294,885 | $ 176,655 | |||||||||||||||||||||||||||||||||
Assets | $ 6,000 | 70,000 | 6,000 | $ 483,092 | ||||||||||||||||||||||||||||||||||
Notes Payable | $ 256,043 | |||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 70,123,500 | 206,988,570 | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | 30,854 | $ 86,000 | ||||||||||||||||||||||||||||||||||||
Short-term Debt | $ 150,000 | |||||||||||||||||||||||||||||||||||||
Deposit Liabilities, Accrued Interest | $ 150,000 | $ 150,000 | ||||||||||||||||||||||||||||||||||||
Non-Related Party 2 [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | 8.00% | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 145,161 | |||||||||||||||||||||||||||||||||||||
Assets | $ 49,146 | 65,885,713 | $ 49,146 | |||||||||||||||||||||||||||||||||||
Monthly Consulting Fee | $ 3,276 | 3,276 | ||||||||||||||||||||||||||||||||||||
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two and Three | $ 49,146 | |||||||||||||||||||||||||||||||||||||
Brewer And Associates Consulting LLC [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 120,000 | |||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 20,000 | |||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 47,481 | |||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Nature of Restrictions on Assets Set Aside for Scheduled Payments | $7,000 | |||||||||||||||||||||||||||||||||||||
Derivative, Collateral, Obligation to Return Cash | $ 36,000 | |||||||||||||||||||||||||||||||||||||
Repayments of Convertible Debt | 60,000 | $ 40,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 20,000 | |||||||||||||||||||||||||||||||||||||
Debt Conversion, Description | The conversion price is equal to 55% of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. | |||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | 52,948 | |||||||||||||||||||||||||||||||||||||
Non-Related Party 4 [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 34,819 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | |||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 37,011 | 37,011 | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 52,244,433 | |||||||||||||||||||||||||||||||||||||
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two and Three | $ 15,000 | $ 15,000 | ||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 62,508 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger | 49819.00% | |||||||||||||||||||||||||||||||||||||
Non-Related Party 8 [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | |||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 70,938 | |||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 50,670,000 | 856 | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 21,399 | 63,144 | ||||||||||||||||||||||||||||||||||||
Deposit Liabilities, Accrued Interest | 7,138 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | $ 12,442 | |||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | $ 185,765 | $ 29,381 | ||||||||||||||||||||||||||||||||||||
Fair Value, Debt Instrument, Valuation Techniques, Change in Technique, Quantification of Effect | $ 8,607 | |||||||||||||||||||||||||||||||||||||
Convertible Debt | 34,060 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Carrying Amount of Equity Component | $ 64,000 | |||||||||||||||||||||||||||||||||||||
Interest on Convertible Debt, Net of Tax | 6,400 | |||||||||||||||||||||||||||||||||||||
Long-term Debt, Contingent Payment of Principal or Interest | $63,315 | |||||||||||||||||||||||||||||||||||||
Non-Related Party 6 [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | 8.00% | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 1,646,242 | 200,000 | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 200,000 | |||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 358,665 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Carrying Amount of Equity Component | $ 200,000 | $ 200,000 | ||||||||||||||||||||||||||||||||||||
Non-Related Party 12 [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 96,157 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | 8.00% | 8.00% | |||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 300,000,000 | 46,734 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 72,000 | |||||||||||||||||||||||||||||||||||||
Notes Payable | 38,297 | $ 50,000 | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Description | The convertible note holder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of the average of the three lowest volume weighted average prices (the VWAP) of our restricted common stock for the fifteen trading days preceding the conversion date. | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 20,000 | $ 72,000 | 237,121 | |||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | $ 17,829 | |||||||||||||||||||||||||||||||||||||
Non-Related Party 14 [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | |||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | 319,200 | |||||||||||||||||||||||||||||||||||||
Notes Payable | 54,800 | |||||||||||||||||||||||||||||||||||||
Deposit Liabilities, Accrued Interest | $ 4,800 | |||||||||||||||||||||||||||||||||||||
Repayments of Convertible Debt | $ 54,800 | |||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 180,868 | |||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 228,000,000 | |||||||||||||||||||||||||||||||||||||
Non-Related Party 16 [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 33,000 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 12.00% | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 10,000 | |||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 145,000,000 | |||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 101,500 | 180,000 | $ 16,040 | |||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, If-converted Value in Excess of Principal | 16,960 | $ 35,596 | ||||||||||||||||||||||||||||||||||||
Notes Payable | 0 | 60,000 | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Description | The Holder has the right to convert the loan, beginning on the date which is one hundred eighty (180) days following the date of the Note, into common stock at a price of sixty percent (60%) of the average of the three lowest trading prices of our restricted common stock for the fifteen trading days preceding the conversion date. | |||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | 60,000 | |||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | 48,213 | |||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 50,125,000 | |||||||||||||||||||||||||||||||||||||
Investment Owned, Balance, Principal Amount | $ 150,000,000 | |||||||||||||||||||||||||||||||||||||
Notes Payable, Current | 60,000 | |||||||||||||||||||||||||||||||||||||
Labrys [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 90,000 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 12.00% | |||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | 247,500 | 247,500 | $ 11,057 | |||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 62,059,253 | |||||||||||||||||||||||||||||||||||||
Deposit Liabilities, Accrued Interest | $ 51,732 | |||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 236,349 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 45,000,000 | |||||||||||||||||||||||||||||||||||||
Fair Value, Debt Instrument, Valuation Techniques, Change in Technique, Quantification of Effect | 78,943 | |||||||||||||||||||||||||||||||||||||
Convertible Debt | 1,206,081 | 1,206,081 | ||||||||||||||||||||||||||||||||||||
Debtor Reorganization Items, Gain (Loss) on Settlement of Other Claims, Net | 958,581 | |||||||||||||||||||||||||||||||||||||
Non-Related Party 11 [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 12.00% | 12.00% | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 8,500 | |||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 187,500,000 | |||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 243,750 | $ 63,001 | $ 63,001 | 147,220 | ||||||||||||||||||||||||||||||||||
Notes Payable | 0 | 42,500 | $ 51,000 | |||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 179,800,000 | |||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 110,000 | |||||||||||||||||||||||||||||||||||||
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two and Three | 32,400 | |||||||||||||||||||||||||||||||||||||
Debt Conversion, Description | Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. | |||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 42,500 | $ 8,500 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 2,820 | |||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 147,314 | $ 105,157,409 | $ 298,575 | |||||||||||||||||||||||||||||||||||
Convertible Debt | 46,999 | 46,999 | ||||||||||||||||||||||||||||||||||||
Non-Related Party 19 [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 65,600 | $ 76,076 | $ 65,600 | $ 56,567 | $ 50,000 | 75,126 | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 2.50% | 2.50% | 8.00% | 8.00% | 2.50% | 2.50% | 2.00% | |||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 4,035 | $ 3,800 | $ 65,000 | $ 4,035 | 950 | |||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 115,165 | |||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 5,000,000 | 1,000,000 | ||||||||||||||||||||||||||||||||||||
Deposit Liabilities, Accrued Interest | 65,600 | $ 10,476 | $ 65,600 | 8,177 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger | 0.05% | 0.05% | ||||||||||||||||||||||||||||||||||||
Summary of Troubled Debt Restructuring Note, Debtor [Table Text Block] | $100,000 | |||||||||||||||||||||||||||||||||||||
Convertible Debt, Conversion Valuation | $ 110,700 | $ 110,700 | ||||||||||||||||||||||||||||||||||||
Notes Payable, Fair Value Disclosure | $ 60,000 | |||||||||||||||||||||||||||||||||||||
Other Significant Noncash Transaction, Value of Consideration Received | $ 68,067 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Current | 105,334 | |||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 2,850 | |||||||||||||||||||||||||||||||||||||
Non-Related Party 17 [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 60,000 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | 8.00% | ||||||||||||||||||||||||||||||||||||
Assets | $ 48,418 | |||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 60,000 | |||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | 107,329 | |||||||||||||||||||||||||||||||||||||
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two and Three | 106,681 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 60,000 | |||||||||||||||||||||||||||||||||||||
Notes Payable, Current | $ 59,257 | |||||||||||||||||||||||||||||||||||||
Non-Related Party 4 [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | 2.00% | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 23,794 | |||||||||||||||||||||||||||||||||||||
Notes Payable | $ 50,000 | 50,000 | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 31,500 | |||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | 55,409 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | $ 31,000 | $ 18,767 | ||||||||||||||||||||||||||||||||||||
Sold and Assigned [Member] | Non-Related Party 1 [Member] | ||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 84,971 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | |||||||||||||||||||||||||||||||||||||
[1] | At December 31, 2018 and 2017, the balance of $1,156,341 and $1,925,365, respectively, consisted of the following convertible loans: During December 2015, Mr. Deitsch, assigned $80,000 of his outstanding loan to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 4% and was due on December 7, 2016. The Note reverted back as the promissory note upon maturity date. On June 27, 2017, the Company owed principal balance of $80,000 plus accrued interest of $4,971. The total of $84,971 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note (See Note 7(2)). The note carries interest at 8% and was due on June 27, 2018, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of lowest closing bid prices of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. During July and August 2017, the Note holder made conversions of a total of 164,935,000 shares of our restricted common stock satisfying the principal balance of $55,325 with a fair value of $225,143. At December 31, 2017, the convertible note payable, at fair value, was recorded at $95,369. During February 2018, the Note holder made conversions of a total of 109,876,500 shares of our restricted common stock with a fair value of $462,625 in satisfaction of the remaining principal balance of $29,646 in full. On March 31, 2017, we issued a convertible denture in the amount of $80,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 8% and was due on March 30, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note into shares of Common Stock at a fifty-five percent (55%) of the of the lowest closing bid price of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. At December 31, 2017, the convertible note payable, at fair value, was recorded at $256,043. During February 2018, the Noteholder made a conversion of 70,123,500 shares of our restricted common stock with a fair value of $294,885 in satisfaction of a portion of the Note in the amount of $30,854 (See Note 7). The noteholder sold and assigned the remaining balance of $49,146 with accrued interest of $3,276 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During April and May 2018, the Note holder made conversions of a total of 65,885,713 shares of our restricted common stock with a fair value of $145,161 in satisfaction of the remaining principal balance of $49,146 and accrued interest in full (See Note 7). On July 18, 2017, we issued a convertible denture in the amount of $150,000 to Coventry. The note carries interest at 8% and was due on July 18, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note into shares of Common Stock at a fifty-five percent (55%) of the of the lowest closing bid price of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. At December 31, 2017, the convertible note payable, at fair value, was recorded at $483,092. During February 2018, the noteholder sold and assigned the balance of $150,000 with accrued interest of $6,000 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During May and June 2018, the Noteholder made conversions of a total of 120,891,284 shares of our restricted common stock with a fair value of $200,475 in partial satisfaction of the note in the amount of $70,000 (See Note 7). During July through September 2018, the Note holder made conversions of a total of 206,988,570 shares of our restricted common stock with a fair value of $176,655 in satisfaction of the remaining principal balance $86,000 and accrued interest in full (See Note 7). On March 28, 2016, we signed an expansion agreement with Brewer and Associates Consulting, LLC (“B+A”) to the original consulting agreement dated on October 15, 2015 for consulting services for twelve months for a monthly fee of $7,000. To relieve our cash obligation of $36,000 per original agreement, we issued three convertible notes for a total of $120,000 which includes the fees due under the original agreement and the new monthly fees due under the expansion agreement. The $40,000 and $60,000 of the Notes were paid in full as of December 31, 2016 and December 31, 2017, respectively. The remaining balance of $20,000 Notes is in default and negotiation of settlement. The conversion price is equal to 55% of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. At December 31, 2018 and 2017, the convertible notes payable with principal balance of $20,000, at fair value, were recorded at $47,481 and $52,948, respectively. During June 2016, we issued a Convertible Debenture in the amount of $72,000 to an unrelated third party as a result of debt sale. The Note carries interest at 8% and was due on June 20, 2017, unless previously converted into shares of restricted common stock. The convertible note holder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of the average of the three lowest volume weighted average prices (the VWAP) of our restricted common stock for the fifteen trading days preceding the conversion date. At December 31, 2017, the convertible notes payable, at fair value, was recorded at $237,121. During August 2018, a Note holder received a total of 300,000,000 shares of our restricted common stock in satisfaction of the principal balance of $72,000 with accrued interest in full (See Note 9). During June 2016, the notes payable of $50,000 originating in January 2016 with accrued interest of $4,800 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note (See Note 7(2)). The note carries interest at 8% and was due on June 16, 2017, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of the average of the three lowest VWAP prices of our restricted common stock for the fifteen trading days preceding the conversion date. At December 31, 2017, the balance of $54,800, at fair value, was recorded at $180,868. During May 2018, the Note holder made a conversion of 228,000,000 shares of our restricted common stock with a fair value of $319,200 in satisfaction of the principal balance of $54,800 in full (See Note 7). In April 2017, we issued a Convertible Promissory Note for $33,000 to an unrelated third party. The note carries interest at 12% annually and was due on January 30, 2018. The Holder has the right to convert the loan, beginning on the date which is one hundred eighty (180) days following the date of the Note, into common stock at a price of sixty percent (60%) of the average of the three lowest trading prices of our restricted common stock for the fifteen trading days preceding the conversion date. During October 2017, the Noteholder made the conversions of a total of 50,125,000 of our restricted common stock satisfying the principal balance of $16,040 with a fair value of $35,596. At December 31, 2017, the convertible note payable, at fair value, was recorded at $48,213. During June 2018, the Note holder made a conversion of 150,000,000 shares of our restricted common stock with a fair value of $180,000 in satisfaction of the remaining principal balance of $16,960 with accrued interest in full (See Note 7). During May and October 2017, we issued two Convertible Debenture for a total of $90,000 ($45,000 each) to Labrys. The notes carrie interest at 12% and were due on July 19, 2017 and November 3, 2017, respectively, unless previously converted into shares of restricted common stock. Labrys has the right to convert the notes into shares of Common Stock at sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty-five trading days preceding the conversion date. During November 2017, the Note holder made a conversion of 62,059,253 shares of stock satisfying the principal balance of $11,057 and accrued interest for a fair value of $51,732. At December 31, 2017, the convertible notes payable, at fair value, was recorded at $236,349. During February 2018, we issued 45,000,000 shares of our restricted common stock with a fair value of $247,500 to Labrys in settlement of the remaining balance of $78,943 and accrued interest in full (See Note 7). Based on the conversion methodology, the debt was valued at $1,206,081 prior to conversion, and the Company recorded a gain on settlement of $958,581, which is recorded within gain (loss) on settlement of debt, net, within the statement of operations. During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carries interest at 12% and matures on September 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 179,800,000 shares of stock satisfying the principal balance of $63,001 and accrued interest for a fair value of $298,575. At December 31, 2017, the convertible note payable, at fair value, was recorded at $147,314. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. During February and July, 2018, we issued a total of 105,157,409 shares of our restricted common stock to the original Note holder with a fair value of $147,220. At December 31, 2018, the Company owed additional shares to the original noteholder and recorded an accrual of $32,400 to account for the cost of the shares, and the shares were issued in January 2019. The new note of $49,819 carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During September 2018, the Noteholder made a conversions of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full (See Note 7). At December 31, 2018, the convertible note payable with principal balance of $34,819, at fair value, was recorded at $62,508. During May 2017, we issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. The note carries interest at 8% and was due on May 4, 2018, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty trading days preceding the conversion date. During November 2017, the Note holder made a conversion of our restricted common stocks satisfying the principal balance of $856 and penalty of $6,400 for a fair value of $21,399. At December 31, 2017, the convertible note payable, at fair value, was recorded at $185,765. During February 2018, the remaining balance of $63,144 with accrued interest and penalty of $12,442 was assigned and sold to three unrelated third parties. During June 2018, a Note holder made a conversion of 50,670,000 shares of our restricted common stock with a fair value of $70,938 in satisfaction of the balance of $34,060 plus accrued interest of $8,607 (See Note 7). At December 31, 2018, the remaining principal of $29,381 plus accrued interest of $7,138, at fair value, was recorded at $63,315. During February 2018, we issued a convertible denture in the amount of $200,000 to an unrelated third party. The note carries interest at 8% and is due in February 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $1,646,242. At December 31, 2018, the convertible note payable with principal balance of $200,000, at fair value, was recorded at $358,665. The note carries additional $200,000 “Back-end Note” ($100,000 each) with the same terms as the original note. During April 2018, $65,000 of one of the $100,000 Back-end Note was funded. The note carries interest at 8% and is due in February 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $110,700. At December 31, 2018, the convertible note payable, at fair value, was recorded at $115,165. During March 2018, we issued a convertible denture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and is due in March 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $48,418. At December 31, 2018, the convertible note payable, at fair value, was recorded at $107,329. The note carries an additional “Back-end Note” with the same terms as the original note that enables the lender to lend to us another $60,000. During June 2018, the $60,000 Back-end Note was funded. The note carries interest at 8% and is due in March 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $68,067. At December 31, 2018, the convertible note payable, at fair value, was recorded at $105,334. During May 2018, we issued a convertible denture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and is due in May 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $59,257. At December 31, 2018, the convertible note payable, at fair value, was recorded at $106,681. During August 2018, we issued a convertible denture in the amount of $31,500 to an unrelated third party. The note carries interest at 8% and is due in August 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $23,794. At December 31, 2018, the convertible note payable, at fair value, was recorded at $55,409. During July 2018, we issued a convertible denture in the amount of $50,000 to an unrelated third party. The note carries interest at 8% and is due in July 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $46,734. At December 31, 2018, the convertible note payable, at fair value, was recorded at $96,157. During August 2018, we issued a convertible denture in the amount of $20,000 to an unrelated third party. The note carries interest at 8% and is due in August 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $17,829. At December 31, 2018, the convertible note payable, at fair value, was recorded at $38,297. |
DEBTS (Details) - Schedule of O
DEBTS (Details) - Schedule of Other Debt - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 | |
Schedule of Other Debt [Abstract] | |||
Note payable and Convertible note payable, at fair value– Related Party (Net of discount of $2,000 and $0, respectively) | [1] | $ 12,000 | $ 202,974 |
Notes payable – Unrelated third parties (Net of discount of $17,870 and $28,73, respectively) | [2] | 1,469,690 | 1,337,470 |
Convertible notes payable – Unrelated third parties (Net of discount of $29,71 and $0, respectively) | [3] | 751,955 | 594 |
Convertible notes payable, at fair value | [4] | 1,156,341 | 1,925,365 |
Ending balances | 3,389,986 | 3,466,403 | |
Less: Current portion | (3,338,576) | $ (3,466,403) | |
Long-term portion-Notes payable-Unrelated third parties | $ 51,410 | ||
[1] | During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At December 31, 2018 and 2017, we owed this director accrued interest of $141,808 and $126,036. The interest expense for the years ended December 31, 2018 and 2017 was $15,772 and $15,457. In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by one of our directors. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At December 31, 2018 and 2017, we owed principal balance of $192,974, and accrued interest of $40,033 and $16,876, respectively. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020 (See Note 11). The remaining balance of the loan is in default and negotiation for settlement. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. At December 31, 2018 and 2017, the principal balance of the loan is $12,000. The Note was settled in June 2020. | ||
[2] | At December 31, 2018 and 2017, the balance of $1,469,690 and $1,337,470 net of discount of $17,870 and $28,723, respectively, consisted of the following loans: On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge is currently outstanding and carries no interest. In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $2,739 and $1,465. In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the outstanding principal balance is $50,000 and accrued interest is $37,801 and $25,567. In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2018 and 2017, the outstanding principal balance is $50,000 and accrued interest is $31,000 and $18,767. In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest were restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest were restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. The note is in default and negotiation of settlement. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018 (See Note 7). The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest were restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and will be due June 17, 2019. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $329 and the debt discount at December 31, 2018 is $3,616. At December 31, 2018 and 2017, the principal balance is $282,983 and $180,250, respectively, and the accrued interest is $2,830 and $38,455, respectively. On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $17,271 and $7,708. In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $27,300 and $15,067. In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $1,944 and $670. During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of December 31, 2018. At December 31, 2017, the principal balance of the loan was $191,329 and in negotiation of settlement. During June 2018, the loan was settled for $170,402 with scheduled repayments of approximately $7,000 per month through July 2020. We recorded a gain on settlement of debt in other income for $20,927. The Company repaid $34,976 during the third and fourth quarter of 2018. At December 31, 2018, the principal balance is $135,426. In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the principal balance of the note is $50,000. In September 2017, we issued a promissory note to an unrelated third party in the amount of $51,000 with original issue discount of $8,500. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The Company repaid $8,500 in cash in November 2017. In May 2018, the Noteholder received a total of 187,500,000 shares of our restricted common stock with a fair value of $243,750 in satisfaction of the remaining balance of $42,500. We recorded a loss on settlement of debt in other expense for $201,250 (See Note 7). As of December 31, 2018 and 2017, the principal balance of the note is $0 and $42,500. In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 each due in September 2019 and 2020, respectively. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and is due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the year ended December 31, 2018 and 2017 was $4,000 and $2,000, respectively. The debt discount at December 31, 2018 and 2017 is $6,000 and $4,000. Repayments of $1,500 and $7,000 have been made in 2017 and 2018, respectively. The Note is under personal guarantee by Mr. Deitsch. At December 31, 2018 and 2017, the principal balance of the note is $27,500 and $34,500, respectively. In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment (See Note 7). The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the year ended December 31, 2018 was $4,127. As of December 31, 2018, the amount due is $61,746, net of discount of $8,254. In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. 1,500,000 shares of common stocks were issued due to the default of repayments with a fair value of $2,250 (See Note 7). At December 31, 2018 and 2017, the principal balance of the loan is $120,000. In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600 (See Note 7). At December 31, 2018 and 2017, the principal balance of the note is $18,000. In December 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in one year from the execution and funding of the note. During August 2018, the Note holder sold the debt of $60,000 to a non-related party. The subsequent note holder received a total of 145,000,000 shares of our restricted common stock with a fair value of $101,500 in satisfaction of the Note of $60,000 in full. We recorded a loss on settlement of debt in other expense for $41,500 (See Note 7). As a result of the settlement of the note, the debt discount has been fully amortized as of December 31, 2018. At December 31, 2018 and 2017, the principal balance of the note is $0 and $60,000. | ||
[3] | At December 31, 2018 and 2017, the balance of $751,955 and $594 net of discount of $29,371 and $0, respectively, consisted of the following convertible loans: On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. The first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014. The notes carry interest at 8% and were due on March 19, 2018. The note holders have the right to convert the notes into shares of Common Stock at a price of $0.20. At December 31, 2017, these convertible notes payable, at fair value, was recorded at $594. During 2018, repayment of $3,000 was made. At December 31, 2018, the principal balance of the note is $27,000 and the accrued interest is $11,412. The two outstanding Notes were settled in connection with issuance of the convertible note in the amount of up to $1,000,000 in February 2019 (See Note 13). During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and is due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The note is under personal guarantee by Mr. Deitsch. At December 31, 2018, the convertible note payable was recorded at $75,126, net of discount of $950. The accrued interest as of December 31, 2018 is $8,177. In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500 (See Note 7). At December 31, 2018 and 2017, the principal balance of the note is $60,000. During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock (See Note 7). The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. Amortization for the year ended December 31, 2018 was $290,184. At December 31, 2018, the principal balance of the notes, net of discount of $28,421 is $589,829. $264,150 of the above mentioned convertible notes payable to nine of the unrelated third parties with original issue discount of $24,915 are in default and in negotiation of settlement. | ||
[4] | At December 31, 2018 and 2017, the balance of $1,156,341 and $1,925,365, respectively, consisted of the following convertible loans: During December 2015, Mr. Deitsch, assigned $80,000 of his outstanding loan to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 4% and was due on December 7, 2016. The Note reverted back as the promissory note upon maturity date. On June 27, 2017, the Company owed principal balance of $80,000 plus accrued interest of $4,971. The total of $84,971 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note (See Note 7(2)). The note carries interest at 8% and was due on June 27, 2018, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of lowest closing bid prices of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. During July and August 2017, the Note holder made conversions of a total of 164,935,000 shares of our restricted common stock satisfying the principal balance of $55,325 with a fair value of $225,143. At December 31, 2017, the convertible note payable, at fair value, was recorded at $95,369. During February 2018, the Note holder made conversions of a total of 109,876,500 shares of our restricted common stock with a fair value of $462,625 in satisfaction of the remaining principal balance of $29,646 in full. On March 31, 2017, we issued a convertible denture in the amount of $80,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 8% and was due on March 30, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note into shares of Common Stock at a fifty-five percent (55%) of the of the lowest closing bid price of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. At December 31, 2017, the convertible note payable, at fair value, was recorded at $256,043. During February 2018, the Noteholder made a conversion of 70,123,500 shares of our restricted common stock with a fair value of $294,885 in satisfaction of a portion of the Note in the amount of $30,854 (See Note 7). The noteholder sold and assigned the remaining balance of $49,146 with accrued interest of $3,276 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During April and May 2018, the Note holder made conversions of a total of 65,885,713 shares of our restricted common stock with a fair value of $145,161 in satisfaction of the remaining principal balance of $49,146 and accrued interest in full (See Note 7). On July 18, 2017, we issued a convertible denture in the amount of $150,000 to Coventry. The note carries interest at 8% and was due on July 18, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note into shares of Common Stock at a fifty-five percent (55%) of the of the lowest closing bid price of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. At December 31, 2017, the convertible note payable, at fair value, was recorded at $483,092. During February 2018, the noteholder sold and assigned the balance of $150,000 with accrued interest of $6,000 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During May and June 2018, the Noteholder made conversions of a total of 120,891,284 shares of our restricted common stock with a fair value of $200,475 in partial satisfaction of the note in the amount of $70,000 (See Note 7). During July through September 2018, the Note holder made conversions of a total of 206,988,570 shares of our restricted common stock with a fair value of $176,655 in satisfaction of the remaining principal balance $86,000 and accrued interest in full (See Note 7). On March 28, 2016, we signed an expansion agreement with Brewer and Associates Consulting, LLC (“B+A”) to the original consulting agreement dated on October 15, 2015 for consulting services for twelve months for a monthly fee of $7,000. To relieve our cash obligation of $36,000 per original agreement, we issued three convertible notes for a total of $120,000 which includes the fees due under the original agreement and the new monthly fees due under the expansion agreement. The $40,000 and $60,000 of the Notes were paid in full as of December 31, 2016 and December 31, 2017, respectively. The remaining balance of $20,000 Notes is in default and negotiation of settlement. The conversion price is equal to 55% of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. At December 31, 2018 and 2017, the convertible notes payable with principal balance of $20,000, at fair value, were recorded at $47,481 and $52,948, respectively. During June 2016, we issued a Convertible Debenture in the amount of $72,000 to an unrelated third party as a result of debt sale. The Note carries interest at 8% and was due on June 20, 2017, unless previously converted into shares of restricted common stock. The convertible note holder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of the average of the three lowest volume weighted average prices (the VWAP) of our restricted common stock for the fifteen trading days preceding the conversion date. At December 31, 2017, the convertible notes payable, at fair value, was recorded at $237,121. During August 2018, a Note holder received a total of 300,000,000 shares of our restricted common stock in satisfaction of the principal balance of $72,000 with accrued interest in full (See Note 9). During June 2016, the notes payable of $50,000 originating in January 2016 with accrued interest of $4,800 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note (See Note 7(2)). The note carries interest at 8% and was due on June 16, 2017, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of the average of the three lowest VWAP prices of our restricted common stock for the fifteen trading days preceding the conversion date. At December 31, 2017, the balance of $54,800, at fair value, was recorded at $180,868. During May 2018, the Note holder made a conversion of 228,000,000 shares of our restricted common stock with a fair value of $319,200 in satisfaction of the principal balance of $54,800 in full (See Note 7). In April 2017, we issued a Convertible Promissory Note for $33,000 to an unrelated third party. The note carries interest at 12% annually and was due on January 30, 2018. The Holder has the right to convert the loan, beginning on the date which is one hundred eighty (180) days following the date of the Note, into common stock at a price of sixty percent (60%) of the average of the three lowest trading prices of our restricted common stock for the fifteen trading days preceding the conversion date. During October 2017, the Noteholder made the conversions of a total of 50,125,000 of our restricted common stock satisfying the principal balance of $16,040 with a fair value of $35,596. At December 31, 2017, the convertible note payable, at fair value, was recorded at $48,213. During June 2018, the Note holder made a conversion of 150,000,000 shares of our restricted common stock with a fair value of $180,000 in satisfaction of the remaining principal balance of $16,960 with accrued interest in full (See Note 7). During May and October 2017, we issued two Convertible Debenture for a total of $90,000 ($45,000 each) to Labrys. The notes carrie interest at 12% and were due on July 19, 2017 and November 3, 2017, respectively, unless previously converted into shares of restricted common stock. Labrys has the right to convert the notes into shares of Common Stock at sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty-five trading days preceding the conversion date. During November 2017, the Note holder made a conversion of 62,059,253 shares of stock satisfying the principal balance of $11,057 and accrued interest for a fair value of $51,732. At December 31, 2017, the convertible notes payable, at fair value, was recorded at $236,349. During February 2018, we issued 45,000,000 shares of our restricted common stock with a fair value of $247,500 to Labrys in settlement of the remaining balance of $78,943 and accrued interest in full (See Note 7). Based on the conversion methodology, the debt was valued at $1,206,081 prior to conversion, and the Company recorded a gain on settlement of $958,581, which is recorded within gain (loss) on settlement of debt, net, within the statement of operations. During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carries interest at 12% and matures on September 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 179,800,000 shares of stock satisfying the principal balance of $63,001 and accrued interest for a fair value of $298,575. At December 31, 2017, the convertible note payable, at fair value, was recorded at $147,314. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. During February and July, 2018, we issued a total of 105,157,409 shares of our restricted common stock to the original Note holder with a fair value of $147,220. At December 31, 2018, the Company owed additional shares to the original noteholder and recorded an accrual of $32,400 to account for the cost of the shares, and the shares were issued in January 2019. The new note of $49,819 carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During September 2018, the Noteholder made a conversions of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full (See Note 7). At December 31, 2018, the convertible note payable with principal balance of $34,819, at fair value, was recorded at $62,508. During May 2017, we issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. The note carries interest at 8% and was due on May 4, 2018, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty trading days preceding the conversion date. During November 2017, the Note holder made a conversion of our restricted common stocks satisfying the principal balance of $856 and penalty of $6,400 for a fair value of $21,399. At December 31, 2017, the convertible note payable, at fair value, was recorded at $185,765. During February 2018, the remaining balance of $63,144 with accrued interest and penalty of $12,442 was assigned and sold to three unrelated third parties. During June 2018, a Note holder made a conversion of 50,670,000 shares of our restricted common stock with a fair value of $70,938 in satisfaction of the balance of $34,060 plus accrued interest of $8,607 (See Note 7). At December 31, 2018, the remaining principal of $29,381 plus accrued interest of $7,138, at fair value, was recorded at $63,315. During February 2018, we issued a convertible denture in the amount of $200,000 to an unrelated third party. The note carries interest at 8% and is due in February 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $1,646,242. At December 31, 2018, the convertible note payable with principal balance of $200,000, at fair value, was recorded at $358,665. The note carries additional $200,000 “Back-end Note” ($100,000 each) with the same terms as the original note. During April 2018, $65,000 of one of the $100,000 Back-end Note was funded. The note carries interest at 8% and is due in February 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $110,700. At December 31, 2018, the convertible note payable, at fair value, was recorded at $115,165. During March 2018, we issued a convertible denture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and is due in March 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $48,418. At December 31, 2018, the convertible note payable, at fair value, was recorded at $107,329. The note carries an additional “Back-end Note” with the same terms as the original note that enables the lender to lend to us another $60,000. During June 2018, the $60,000 Back-end Note was funded. The note carries interest at 8% and is due in March 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $68,067. At December 31, 2018, the convertible note payable, at fair value, was recorded at $105,334. During May 2018, we issued a convertible denture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and is due in May 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $59,257. At December 31, 2018, the convertible note payable, at fair value, was recorded at $106,681. During August 2018, we issued a convertible denture in the amount of $31,500 to an unrelated third party. The note carries interest at 8% and is due in August 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $23,794. At December 31, 2018, the convertible note payable, at fair value, was recorded at $55,409. During July 2018, we issued a convertible denture in the amount of $50,000 to an unrelated third party. The note carries interest at 8% and is due in July 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $46,734. At December 31, 2018, the convertible note payable, at fair value, was recorded at $96,157. During August 2018, we issued a convertible denture in the amount of $20,000 to an unrelated third party. The note carries interest at 8% and is due in August 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $17,829. At December 31, 2018, the convertible note payable, at fair value, was recorded at $38,297. |
DEBTS (Details) - Schedule of_2
DEBTS (Details) - Schedule of Other Debt (Parentheticals) - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 | |
Related Party [Member] | |||
DEBTS (Details) - Schedule of Other Debt (Parentheticals) [Line Items] | |||
[1] | $ 2,400 | $ 2,000 | |
Non-Related Party [Member] | |||
DEBTS (Details) - Schedule of Other Debt (Parentheticals) [Line Items] | |||
[2] | 17,870 | 28,723 | |
Convertible Notes Payable [Member] | |||
DEBTS (Details) - Schedule of Other Debt (Parentheticals) [Line Items] | |||
[3] | $ 29,371 | $ 0 | |
[1] | During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At December 31, 2018 and 2017, we owed this director accrued interest of $141,808 and $126,036. The interest expense for the years ended December 31, 2018 and 2017 was $15,772 and $15,457. In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by one of our directors. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At December 31, 2018 and 2017, we owed principal balance of $192,974, and accrued interest of $40,033 and $16,876, respectively. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020 (See Note 11). The remaining balance of the loan is in default and negotiation for settlement. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. At December 31, 2018 and 2017, the principal balance of the loan is $12,000. The Note was settled in June 2020. | ||
[2] | At December 31, 2018 and 2017, the balance of $1,469,690 and $1,337,470 net of discount of $17,870 and $28,723, respectively, consisted of the following loans: On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge is currently outstanding and carries no interest. In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $2,739 and $1,465. In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the outstanding principal balance is $50,000 and accrued interest is $37,801 and $25,567. In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2018 and 2017, the outstanding principal balance is $50,000 and accrued interest is $31,000 and $18,767. In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest were restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest were restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. The note is in default and negotiation of settlement. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018 (See Note 7). The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest were restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and will be due June 17, 2019. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $329 and the debt discount at December 31, 2018 is $3,616. At December 31, 2018 and 2017, the principal balance is $282,983 and $180,250, respectively, and the accrued interest is $2,830 and $38,455, respectively. On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $17,271 and $7,708. In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $27,300 and $15,067. In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the accrued interest is $1,944 and $670. During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of December 31, 2018. At December 31, 2017, the principal balance of the loan was $191,329 and in negotiation of settlement. During June 2018, the loan was settled for $170,402 with scheduled repayments of approximately $7,000 per month through July 2020. We recorded a gain on settlement of debt in other income for $20,927. The Company repaid $34,976 during the third and fourth quarter of 2018. At December 31, 2018, the principal balance is $135,426. In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. At December 31, 2018 and 2017, the principal balance of the note is $50,000. In September 2017, we issued a promissory note to an unrelated third party in the amount of $51,000 with original issue discount of $8,500. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The Company repaid $8,500 in cash in November 2017. In May 2018, the Noteholder received a total of 187,500,000 shares of our restricted common stock with a fair value of $243,750 in satisfaction of the remaining balance of $42,500. We recorded a loss on settlement of debt in other expense for $201,250 (See Note 7). As of December 31, 2018 and 2017, the principal balance of the note is $0 and $42,500. In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 each due in September 2019 and 2020, respectively. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and is due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the year ended December 31, 2018 and 2017 was $4,000 and $2,000, respectively. The debt discount at December 31, 2018 and 2017 is $6,000 and $4,000. Repayments of $1,500 and $7,000 have been made in 2017 and 2018, respectively. The Note is under personal guarantee by Mr. Deitsch. At December 31, 2018 and 2017, the principal balance of the note is $27,500 and $34,500, respectively. In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment (See Note 7). The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the year ended December 31, 2018 was $4,127. As of December 31, 2018, the amount due is $61,746, net of discount of $8,254. In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. 1,500,000 shares of common stocks were issued due to the default of repayments with a fair value of $2,250 (See Note 7). At December 31, 2018 and 2017, the principal balance of the loan is $120,000. In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600 (See Note 7). At December 31, 2018 and 2017, the principal balance of the note is $18,000. In December 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in one year from the execution and funding of the note. During August 2018, the Note holder sold the debt of $60,000 to a non-related party. The subsequent note holder received a total of 145,000,000 shares of our restricted common stock with a fair value of $101,500 in satisfaction of the Note of $60,000 in full. We recorded a loss on settlement of debt in other expense for $41,500 (See Note 7). As a result of the settlement of the note, the debt discount has been fully amortized as of December 31, 2018. At December 31, 2018 and 2017, the principal balance of the note is $0 and $60,000. | ||
[3] | At December 31, 2018 and 2017, the balance of $751,955 and $594 net of discount of $29,371 and $0, respectively, consisted of the following convertible loans: On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. The first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014. The notes carry interest at 8% and were due on March 19, 2018. The note holders have the right to convert the notes into shares of Common Stock at a price of $0.20. At December 31, 2017, these convertible notes payable, at fair value, was recorded at $594. During 2018, repayment of $3,000 was made. At December 31, 2018, the principal balance of the note is $27,000 and the accrued interest is $11,412. The two outstanding Notes were settled in connection with issuance of the convertible note in the amount of up to $1,000,000 in February 2019 (See Note 13). During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and is due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The note is under personal guarantee by Mr. Deitsch. At December 31, 2018, the convertible note payable was recorded at $75,126, net of discount of $950. The accrued interest as of December 31, 2018 is $8,177. In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500 (See Note 7). At December 31, 2018 and 2017, the principal balance of the note is $60,000. During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock (See Note 7). The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. Amortization for the year ended December 31, 2018 was $290,184. At December 31, 2018, the principal balance of the notes, net of discount of $28,421 is $589,829. $264,150 of the above mentioned convertible notes payable to nine of the unrelated third parties with original issue discount of $24,915 are in default and in negotiation of settlement. |
STOCKHOLDERS' DEFICIT (Details)
STOCKHOLDERS' DEFICIT (Details) $ / shares in Units, pure in Thousands | Oct. 30, 2017USD ($)$ / sharesshares | Aug. 31, 2018shares | Apr. 30, 2018shares | Sep. 30, 2017shares | Aug. 31, 2017shares | Jul. 31, 2017shares | Apr. 30, 2017shares | Feb. 28, 2018shares | Nov. 30, 2017shares | Dec. 31, 2018USD ($)shares | Mar. 07, 2018shares | Dec. 31, 2017USD ($) |
STOCKHOLDERS' DEFICIT (Details) [Line Items] | ||||||||||||
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased (in Shares) | 8,000,000,000 | |||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 5,000,000 | 5,000,000 | 4,000,000 | 300,000 | 2,000,000 | 500,000 | 4,250,000 | 25,000,000 | 25,500,000 | |||
Preferred Stock, Per Share Amounts of Preferred Dividends in Arrears (in Dollars per share) | $ / shares | $ 3,000,000 | |||||||||||
Preferred Stock, Value, Issued | $ | $ 3,000 | $ 3,000 | ||||||||||
Series A Preferred Stock [Member] | ||||||||||||
STOCKHOLDERS' DEFICIT (Details) [Line Items] | ||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 20,000,000 | |||||||||||
Votes Per Share | 1 | |||||||||||
Series A Preferred Stock [Member] | Deitsch [Member] | ||||||||||||
STOCKHOLDERS' DEFICIT (Details) [Line Items] | ||||||||||||
Preferred Stock, Value, Issued | $ | $ 400,000 | |||||||||||
Previous [Member] | ||||||||||||
STOCKHOLDERS' DEFICIT (Details) [Line Items] | ||||||||||||
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased (in Shares) | 2,000,000,000 |
STOCKHOLDERS' DEFICIT (Detail_2
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued with Indebtedness - USD ($) | 1 Months Ended | 2 Months Ended | 3 Months Ended | |||||||||||
Oct. 31, 2020 | Aug. 31, 2020 | Dec. 31, 2019 | Feb. 28, 2019 | Aug. 31, 2018 | Apr. 30, 2018 | Sep. 30, 2017 | Aug. 31, 2017 | Jul. 31, 2017 | Apr. 30, 2017 | Jan. 31, 2017 | Feb. 28, 2018 | Nov. 30, 2017 | Dec. 31, 2018 | |
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued with Indebtedness [Line Items] | ||||||||||||||
Debt Instrument, Face Amount | $ 51,000 | $ 56,567 | $ 50,000 | $ 180,250 | ||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 5,000,000 | 5,000,000 | 4,000,000 | 300,000 | 2,000,000 | 500,000 | 4,250,000 | 25,000,000 | 25,500,000 | |||||
Stock Issued During Period, Value, Other | $ 3,800 | $ 8,678 | $ 3,656 | $ 417 | $ 4,912 | $ 2,413 | $ 9,887 | $ 15,000 | $ 9,781 | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 1,000,000 | |||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 39,930,000 | 92,100,000 | 44,000,000 | 110,000,000 | 615,230 | |||||||||
Warrants Not Settleable in Cash, Fair Value Disclosure | $ 3,015 | |||||||||||||
Restated Note [Member] | ||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued with Indebtedness [Line Items] | ||||||||||||||
Debt Instrument, Face Amount | $ 56,567 | |||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 300,000 | |||||||||||||
Stock Issued During Period, Value, Other | $ 2,413 |
STOCKHOLDERS' DEFICIT (Detail_3
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt - USD ($) | Oct. 05, 2020 | Sep. 22, 2020 | Feb. 18, 2020 | Jan. 21, 2020 | Jun. 06, 2019 | May 31, 2019 | May 06, 2019 | Sep. 19, 2017 | Sep. 13, 2017 | Aug. 23, 2017 | Aug. 21, 2017 | Aug. 10, 2017 | Aug. 08, 2017 | Aug. 04, 2017 | Jul. 31, 2017 | Jul. 27, 2017 | Jul. 19, 2017 | Jul. 18, 2017 | Jul. 13, 2017 | Jul. 10, 2017 | Jul. 06, 2017 | Jul. 05, 2017 | Jun. 30, 2017 | Jun. 29, 2017 | Jun. 28, 2017 | Jun. 27, 2017 | Jun. 26, 2017 | Jun. 23, 2017 | Jun. 21, 2017 | Jun. 20, 2017 | Jun. 19, 2017 | Jun. 15, 2017 | Jun. 12, 2017 | Jun. 08, 2017 | Jun. 06, 2017 | May 25, 2017 | May 24, 2017 | May 11, 2017 | May 04, 2017 | Apr. 25, 2017 | Apr. 24, 2017 | Apr. 18, 2017 | Mar. 31, 2017 | Mar. 28, 2017 | Mar. 08, 2017 | Mar. 07, 2017 | Mar. 02, 2017 | Feb. 27, 2017 | Mar. 24, 2016 | Mar. 13, 2016 | Mar. 06, 2016 | Feb. 26, 2016 | Sep. 30, 2018 | Aug. 31, 2018 | Jun. 30, 2018 | May 31, 2018 | May 30, 2018 | Feb. 28, 2018 | Nov. 30, 2017 | Oct. 31, 2017 | Aug. 31, 2017 | Apr. 30, 2017 | Jun. 30, 2018 | May 31, 2018 | Aug. 31, 2017 | Jul. 31, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | May 31, 2017 | Jul. 31, 2017 | Oct. 31, 2017 |
Note Holder 1 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 17,935,000 | 60,000,000 | 37,000,000 | 50,000,000 | 50,125,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 16,040 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 35,596 | $ 35,596 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 14,732 | $ 73,159 | $ 56,236 | $ 81,016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 2 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 15,064,583 | 70,426,471 | 164,935,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 225,143 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 55,325 | 55,325 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 84,971 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 12,117 | $ 78,859 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 3 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 6,158,744 | 5,700,000 | 5,700,000 | 5,700,000 | 2,300,000 | 85,491,054 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 90,976 | 90,976 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 53,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 19,510 | $ 26,717 | $ 31,057 | $ 21,186 | $ 9,982 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
B+A [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 17,044,486 | 23,715,415 | 83,125,164 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 107,970 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 60,000 | 60,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 80,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 11,166 | $ 56,303 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 4 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 10,597,122 | 3,059,501 | 4,633,425 | 2,681,327 | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 75,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 39,700 | $ 16,016 | $ 20,760 | $ 18,381 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Coventry [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 16,511,483 | 15,000,000 | 15,500,000 | 47,011,483 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 214,795 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 69,886 | $ 66,000 | $ 78,909 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 5 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 23,167,481 | 8,603,866 | 11,473,225 | 25,558,744 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 108,452 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 45,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 25,343 | $ 25,108 | $ 55,549 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 6 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 69,574,422 | 37,138,936 | 20,971,375 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 94,857 | $ 94,857 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 52,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 53,338 | $ 42,923 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 7 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 5,323,258 | 8,000,000 | 6,250,000 | 43,244,572 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 106,000 | $ 106,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 52,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 17,742 | $ 38,234 | $ 42,171 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 8 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 33,199,136 | 26,171,885 | 27,429,750 | 27,429,600 | 10,679,950 | 13,631,346 | 106,713,358 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 96,261 | 96,261 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 52,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 39,839 | $ 28,789 | $ 30,173 | $ 38,401 | $ 20,949 | $ 60,202 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 9 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 82,122,533 | 9,711,900 | 21,275,000 | 50,650,959 | 19,573,258 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 98,147 | $ 98,147 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 51,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 65,229 | $ 5,062 | $ 23,486 | $ 117,179 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 10 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 50,000,000 | 53,800,000 | 19,000,000 | 19,000,000 | 19,000,000 | 19,000,000 | 138,541,668 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 218,353 | $ 218,353 | $ 218,353 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 66,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loss on Contract Termination for Default | 22,617 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 73,707 | $ 96,005 | $ 49,517 | $ 19,992 | $ 26,231 | $ 33,123 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 11 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 13,582,547 | 9,000,000 | 9,000,000 | 249,809,724 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 270,716 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 66,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loss on Contract Termination for Default | $ 5,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 15,056 | $ 11,872 | $ 27,051 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 12 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 42,221,167 | 32,252,381 | 30,352,771 | 11,560,500 | 62,059,253 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 51,732 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 11,057 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 45,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 36,849 | $ 43,664 | $ 32,450 | $ 10,158 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of Convertible Debt | $ 42,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note holder 13 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 23,747,390 | 45,000,000 | 42,960,000 | 33,000,000 | 30,000,000 | 28,000,000 | 20,000,000 | 31,532,125 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 21,399 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 856 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 64,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loss on Contract Termination for Default | $ 6,400 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 8,941 | $ 115,625 | $ 55,666 | $ 32,781 | $ 27,747 | $ 34,433 | $ 28,858 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of Convertible Debt | $ 60,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note holder 14 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 179,800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 298,575 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 63,001 | 63,001 | 63,001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 110,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note holder 15 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 31,582,547 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 53,979 | $ 53,979 | 53,979 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 22,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note holder 16 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 116,386,819 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 123,121 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 18 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 107,817,770 | 107,133,333 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 67,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 64,691 | $ 171,413 | $ 41,925 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 18 [Member] | Restricted Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 70,123,500 | 222,707,390 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 294,885 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 304,050 | 30,854 | $ 304,050 | 304,050 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 80,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 17 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 250,000,000 | 250,000,000 | 250,000,000 | 250,000,000 | 250,000,000 | 5,432,195 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 26,412 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 11,951 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 275,000 | $ 150,000 | $ 100,000 | $ 100,000 | $ 75,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 17 [Member] | Restricted Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 5,980,861 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 47,569 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 25,000 | 25,000 | $ 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 19 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 45,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 247,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 78,943 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 90,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 20 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 65,885,713 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 145,161 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 49,146 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 21 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 120,891,284 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 200,475 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 70,000 | 70,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 156,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 22 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 228,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 319,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 54,800 | $ 54,800 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 23 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 150,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 180,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 16,960 | 16,960 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 33,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 24 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 50,670,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 70,938 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 34,060 | 34,060 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deposit Liabilities, Accrued Interest | $ 6,476 | $ 6,476 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 25 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 206,988,570 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 176,655 | $ 176,655 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of Convertible Debt | 86,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 26 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 52,244,433 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 37,011 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 15,000 | $ 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 27 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Convertible Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 300,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ 300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 72,000 |
STOCKHOLDERS' DEFICIT (Detail_4
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Promissory Note - USD ($) | Jul. 31, 2017 | Jul. 13, 2017 | Jul. 10, 2017 | Jul. 05, 2017 | Jun. 30, 2017 | Jun. 29, 2017 | Jun. 28, 2017 | Jun. 27, 2017 | Jun. 23, 2017 | Jun. 19, 2017 | Aug. 31, 2018 | May 30, 2018 | Nov. 30, 2017 |
Note Holder 12 [Member] | |||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Promissory Note [Line Items] | |||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 42,221,167 | 32,252,381 | 30,352,771 | 11,560,500 | 62,059,253 | ||||||||
Conversion of Stock, Amount Converted | $ 51,732 | ||||||||||||
Repayments of Convertible Debt | $ 42,500 | ||||||||||||
Debt Securities, Gain (Loss) | $ 201,250 | ||||||||||||
Note Holder 12 [Member] | Restricted Stock [Member] | |||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Promissory Note [Line Items] | |||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 187,500,000 | ||||||||||||
Conversion of Stock, Amount Converted | $ 243,750 | ||||||||||||
Note holder 13 [Member] | |||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Promissory Note [Line Items] | |||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 23,747,390 | 45,000,000 | 42,960,000 | 33,000,000 | 30,000,000 | 28,000,000 | 20,000,000 | 31,532,125 | |||||
Conversion of Stock, Amount Converted | $ 21,399 | ||||||||||||
Repayments of Convertible Debt | $ 60,000 | ||||||||||||
Debt Securities, Gain (Loss) | $ 41,500 | ||||||||||||
Note holder 13 [Member] | Restricted Stock [Member] | |||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Conversion of Promissory Note [Line Items] | |||||||||||||
Conversion of Stock, Shares Converted (in Shares) | 145,000,000 | ||||||||||||
Conversion of Stock, Amount Converted | $ 101,500 |
STOCKHOLDERS' DEFICIT (Detail_5
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Account Payable - Note holder 14 [Member] | 1 Months Ended |
Aug. 31, 2018USD ($)shares | |
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Account Payable [Line Items] | |
Repayments of Long-term Loans from Vendors | $ 4,200 |
Debt Securities, Gain (Loss) | $ 1,400 |
Restricted Stock [Member] | |
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Account Payable [Line Items] | |
Conversion of Stock, Shares Issued (in Shares) | shares | 2,800,000 |
Conversion of Stock, Amount Issued | $ 2,800 |
STOCKHOLDERS' DEFICIT (Detail_6
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Settlement of Default Penalty - Note holder 16 [Member] - Restricted Stock [Member] | Jul. 31, 2018USD ($)shares |
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Settlement of Default Penalty [Line Items] | |
Common Stock, Shares, Issued (in Shares) | shares | 105,157,409 |
Common Stock, Value, Issued | $ | $ 147,220 |
STOCKHOLDERS' DEFICIT (Detail_7
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Default Payments - USD ($) | 1 Months Ended | 2 Months Ended | 9 Months Ended | ||||||
Apr. 30, 2018 | Apr. 30, 2017 | Mar. 31, 2017 | Jan. 31, 2017 | Nov. 30, 2017 | Dec. 31, 2018 | Sep. 30, 2017 | Aug. 31, 2017 | Jul. 31, 2017 | |
Note Holder 8 [Member] | |||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Default Payments [Line Items] | |||||||||
Debt Instrument, Face Amount | $ 96,261 | ||||||||
Note Holder 8 [Member] | Restricted Stock [Member] | |||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Default Payments [Line Items] | |||||||||
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings (in Shares) | 300,000 | ||||||||
Debt Instrument, Face Amount | $ 50,000 | ||||||||
Restricted Stock, Value, Shares Issued Net of Tax Withholdings | $ 2,520 | ||||||||
Note Holder 9 [Member] | |||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Default Payments [Line Items] | |||||||||
Debt Instrument, Face Amount | $ 98,147 | ||||||||
Note Holder 9 [Member] | Restricted Stock [Member] | |||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Default Payments [Line Items] | |||||||||
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings (in Shares) | 50,000 | ||||||||
Debt Instrument, Face Amount | $ 150,000 | ||||||||
Restricted Stock, Value, Shares Issued Net of Tax Withholdings | $ 275 | ||||||||
Labrys Fund [Member] | |||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Default Payments [Line Items] | |||||||||
Shares no longer obligated to be returned (in Shares) | 4,532,810 | ||||||||
Note Holder 10 [Member] | |||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Default Payments [Line Items] | |||||||||
Debt Instrument, Face Amount | $ 218,353 | ||||||||
Note Holder 10 [Member] | Restricted Stock [Member] | |||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Default Payments [Line Items] | |||||||||
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings (in Shares) | 350,000 | ||||||||
Debt Instrument, Face Amount | $ 50,000 | ||||||||
Restricted Stock, Value, Shares Issued Net of Tax Withholdings | $ 1,645 | ||||||||
Note Holder 11 [Member] | |||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Default Payments [Line Items] | |||||||||
Debt Instrument, Face Amount | $ 270,716 | ||||||||
Note Holder 11 [Member] | Restricted Stock [Member] | |||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Default Payments [Line Items] | |||||||||
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings (in Shares) | 450,000 | ||||||||
Restricted Stock, Value, Shares Issued Net of Tax Withholdings | $ 700 | ||||||||
Note Holder 12 [Member] | |||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Default Payments [Line Items] | |||||||||
Debt Instrument, Face Amount | 11,057 | ||||||||
Note Holder 12 [Member] | Restricted Stock [Member] | |||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Default Payments [Line Items] | |||||||||
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings (in Shares) | 1,000,000 | ||||||||
Debt Instrument, Face Amount | $ 50,000 | ||||||||
Restricted Stock, Value, Shares Issued Net of Tax Withholdings | $ 1,700 | ||||||||
Note holder 13 [Member] | |||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Default Payments [Line Items] | |||||||||
Debt Instrument, Face Amount | $ 856 | ||||||||
Note holder 13 [Member] | Restricted Stock [Member] | |||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Default Payments [Line Items] | |||||||||
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings (in Shares) | 33,625,000 | ||||||||
Restricted Stock, Value, Shares Issued Net of Tax Withholdings | $ 25,615 |
STOCKHOLDERS' DEFICIT (Detail_8
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Services - USD ($) | 1 Months Ended | 2 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||||
Aug. 31, 2018 | Jun. 30, 2018 | Apr. 30, 2018 | Sep. 30, 2017 | Aug. 31, 2017 | Jul. 31, 2017 | Apr. 30, 2017 | Feb. 28, 2017 | Jan. 31, 2017 | Feb. 28, 2018 | Nov. 30, 2017 | Dec. 31, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | |
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Services [Line Items] | ||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 5,000,000 | 5,000,000 | 4,000,000 | 300,000 | 2,000,000 | 500,000 | 4,250,000 | 25,000,000 | 25,500,000 | |||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 249,113 | $ 5,241 | ||||||||||||
Consultant 1 [Member] | ||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Services [Line Items] | ||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 1,500,000 | |||||||||||||
Share-based Goods and Nonemployee Services Transaction, Stockholders' Equity | $ 11,250 | |||||||||||||
Consultant 2 [Member] | ||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Services [Line Items] | ||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 1,000,000 | |||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 0.0087 | |||||||||||||
Share-based Goods and Nonemployee Services Transaction, Stockholders' Equity | $ 8,700 | |||||||||||||
Consultant 3 [Member] | ||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Services [Line Items] | ||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 100,000,000 | |||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 0.0012 | |||||||||||||
Share-based Goods and Nonemployee Services Transaction, Stockholders' Equity | $ 70,000 | |||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ 50,000 | $ 50,000 | ||||||||||||
Note Holder 9 [Member] | ||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Common Stock Issued for Services [Line Items] | ||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 0.0075 |
STOCKHOLDERS' DEFICIT (Detail_9
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock - USD ($) | Oct. 10, 2017 | Oct. 09, 2017 | Sep. 19, 2017 | Sep. 13, 2017 | Aug. 23, 2017 | Aug. 21, 2017 | Aug. 10, 2017 | Aug. 08, 2017 | Aug. 04, 2017 | Jul. 31, 2017 | Jul. 27, 2017 | Jul. 19, 2017 | Jul. 18, 2017 | Jul. 13, 2017 | Jul. 10, 2017 | Jul. 06, 2017 | Jul. 05, 2017 | Jun. 30, 2017 | Jun. 29, 2017 | Jun. 28, 2017 | Jun. 27, 2017 | Jun. 26, 2017 | Jun. 23, 2017 | Jun. 21, 2017 | Jun. 20, 2017 | Jun. 19, 2017 | Jun. 15, 2017 | Jun. 12, 2017 | Jun. 08, 2017 | Jun. 06, 2017 | May 25, 2017 | May 24, 2017 | May 11, 2017 | May 04, 2017 | Apr. 25, 2017 | Apr. 24, 2017 | Apr. 18, 2017 | Mar. 31, 2017 | Mar. 28, 2017 | Mar. 08, 2017 | Mar. 07, 2017 | Mar. 02, 2017 | Feb. 27, 2017 | Mar. 24, 2016 | Mar. 13, 2016 | Mar. 06, 2016 | Feb. 26, 2016 | Oct. 31, 2020 | Aug. 31, 2020 | Dec. 31, 2019 | Feb. 28, 2019 | Nov. 30, 2017 | Oct. 31, 2017 | Aug. 31, 2017 | Apr. 30, 2017 | Aug. 31, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Sep. 30, 2017 | May 31, 2017 | Jul. 31, 2017 | Oct. 31, 2017 | Dec. 31, 2018 |
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 86,049,332 | 42,365,263 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 59,760 | $ 40,501 | $ 9,497 | $ 22,879 | $ 7,370 | $ 8,147 | $ 174,535 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 1 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 17,935,000 | 60,000,000 | 37,000,000 | 50,000,000 | 50,125,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 14,732 | $ 73,159 | $ 56,236 | $ 81,016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 2 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 15,064,583 | 70,426,471 | 164,935,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 12,117 | $ 78,859 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
B+A [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 17,044,486 | 23,715,415 | 83,125,164 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 11,166 | $ 56,303 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Coventry [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 16,511,483 | 15,000,000 | 15,500,000 | 47,011,483 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 69,886 | $ 66,000 | $ 78,909 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 3 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 6,158,744 | 5,700,000 | 5,700,000 | 5,700,000 | 2,300,000 | 85,491,054 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 19,510 | $ 26,717 | $ 31,057 | $ 21,186 | $ 9,982 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 4 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 10,597,122 | 3,059,501 | 4,633,425 | 2,681,327 | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 39,700 | $ 16,016 | $ 20,760 | $ 18,381 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 5 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 23,167,481 | 8,603,866 | 11,473,225 | 25,558,744 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 25,343 | $ 25,108 | $ 55,549 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 6 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 69,574,422 | 37,138,936 | 20,971,375 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 53,338 | $ 42,923 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 7 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 5,323,258 | 8,000,000 | 6,250,000 | 43,244,572 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 17,742 | $ 38,234 | $ 42,171 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 8 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 33,199,136 | 26,171,885 | 27,429,750 | 27,429,600 | 10,679,950 | 13,631,346 | 106,713,358 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 39,839 | $ 28,789 | $ 30,173 | $ 38,401 | $ 20,949 | $ 60,202 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 9 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 82,122,533 | 9,711,900 | 21,275,000 | 50,650,959 | 19,573,258 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 65,229 | $ 5,062 | $ 23,486 | $ 117,179 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 10 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 50,000,000 | 53,800,000 | 19,000,000 | 19,000,000 | 19,000,000 | 19,000,000 | 138,541,668 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 73,707 | $ 96,005 | $ 49,517 | $ 19,992 | $ 26,231 | $ 33,123 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 11 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 13,582,547 | 9,000,000 | 9,000,000 | 249,809,724 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 15,056 | $ 11,872 | $ 27,051 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder 12 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 42,221,167 | 32,252,381 | 30,352,771 | 11,560,500 | 62,059,253 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 36,849 | $ 43,664 | $ 32,450 | $ 10,158 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note holder 13 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) - Schedule of Share Conversions of Restricted Stock [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares Converted | 23,747,390 | 45,000,000 | 42,960,000 | 33,000,000 | 30,000,000 | 28,000,000 | 20,000,000 | 31,532,125 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Debt Converted | $ 8,941 | $ 115,625 | $ 55,666 | $ 32,781 | $ 27,747 | $ 34,433 | $ 28,858 |
STOCK WARRANTS (Details)
STOCK WARRANTS (Details) - USD ($) | Apr. 04, 2016 | Mar. 03, 2016 | Sep. 21, 2013 | Sep. 12, 2013 | Sep. 03, 2013 | Oct. 31, 2020 | Aug. 31, 2020 | Dec. 31, 2019 | Feb. 28, 2019 | Apr. 30, 2017 | Oct. 31, 2016 | Mar. 31, 2016 | Jul. 31, 2015 | Apr. 30, 2015 | Apr. 30, 2014 | Mar. 31, 2013 | Mar. 31, 2017 | Dec. 31, 2018 | Dec. 31, 2017 |
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 39,930,000 | 92,100,000 | 44,000,000 | 110,000,000 | 615,230 | ||||||||||||||
Notes Payable (in Dollars) | $ 3,389,986 | $ 3,466,403 | |||||||||||||||||
Warrants Not Settleable in Cash, Fair Value Disclosure (in Dollars) | $ 3,015 | ||||||||||||||||||
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 1,000,000 | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested (in Dollars) | $ 0 | ||||||||||||||||||
Share Price | $ 0.0003 | ||||||||||||||||||
Warrant Repricing During October 2016 [Member] | |||||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 15,285,000 | ||||||||||||||||||
Warrants Granted March 2013 [Member] | |||||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 65,000 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.01 | ||||||||||||||||||
Investment Warrants Expiration Date | Mar. 22, 2018 | ||||||||||||||||||
Warrants Granted September 3rd 2013 [Member] | |||||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 500,000 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.025 | ||||||||||||||||||
Investment Warrants Expiration Date | Sep. 3, 2018 | ||||||||||||||||||
Warrants Granted September 12th 2013 [Member] | |||||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 375,000 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.01 | ||||||||||||||||||
Investment Warrants Expiration Date | Sep. 12, 2018 | ||||||||||||||||||
Warrants Granted March 31, 2017 [Member] | |||||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 6,000,000 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.005 | ||||||||||||||||||
Notes Payable (in Dollars) | $ 80,000 | ||||||||||||||||||
Warrants Not Settleable in Cash, Fair Value Disclosure (in Dollars) | $ 977 | $ 3,536 | |||||||||||||||||
Investment Warrants Expiration Date | Mar. 30, 2020 | ||||||||||||||||||
Warrants Granted March 3rd 2016 [Member] | |||||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 2,500,000 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.03 | ||||||||||||||||||
Warrants Not Settleable in Cash, Fair Value Disclosure (in Dollars) | $ 491 | 1,502 | |||||||||||||||||
Investment Warrants Expiration Date | Mar. 3, 2021 | ||||||||||||||||||
Warrants Granted April 4th 2016 [Member] | |||||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 4,000,000 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.05 | ||||||||||||||||||
Warrants Not Settleable in Cash, Fair Value Disclosure (in Dollars) | $ 0 | 862 | |||||||||||||||||
Investment Warrants Expiration Date | Apr. 4, 2019 | ||||||||||||||||||
Warrants Granted April 2014 [Member] | |||||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 100,000 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1 | ||||||||||||||||||
Warrants Not Settleable in Cash, Fair Value Disclosure (in Dollars) | $ 0 | $ 5 | |||||||||||||||||
Investment Warrants Expiration Date | Apr. 9, 2019 | ||||||||||||||||||
Warrants Granted July 2015 [Member] | |||||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 4,400,000 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.20 | $ 0.1009 | |||||||||||||||||
Notes Payable (in Dollars) | $ 59,000 | ||||||||||||||||||
Investment Warrants Expiration Date | Jun. 30, 2016 | ||||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 4,400,000 | ||||||||||||||||||
Common Stock, Par or Stated Value Per Share | $ 0.185 | ||||||||||||||||||
Warrants Granted July 2015 [Member] | Warrant Repricing During October 2016 [Member] | |||||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | 0.05 | ||||||||||||||||||
Investment Warrants Expiration Date | Mar. 31, 2017 | ||||||||||||||||||
Warrants Granted March 2016 [Member] | |||||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 916,667 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.10 | ||||||||||||||||||
Investment Warrants Expiration Date | Mar. 31, 2017 | ||||||||||||||||||
Warrants Greanted April 2015 [Member] | |||||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 1,000,000 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.35 | ||||||||||||||||||
Warrants Granted April 2017 [Member] | |||||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 615,230 | ||||||||||||||||||
Warrants Not Settleable in Cash, Fair Value Disclosure (in Dollars) | $ 3,015 | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 1,000,000 | ||||||||||||||||||
Original Exercise Price [Member] | Warrant Repricing During October 2016 [Member] | |||||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | 0.20 | ||||||||||||||||||
Current Exercise Price [Member] | Warrant Repricing During October 2016 [Member] | |||||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.05 | ||||||||||||||||||
Investment Warrants Expiration Date | Mar. 31, 2017 |
STOCK WARRANTS (Details) - Sche
STOCK WARRANTS (Details) - Schedule of Warrants Outstanding - $ / shares | 12 Months Ended | ||||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 30, 2016 | |
Schedule of Warrants Outstanding [Abstract] | |||||
Number of shares | 13,540,000 | 0.03 | |||
Weighted average exercise price | 12,600,000 | 13,540,000 | 12,600,000 | 13,540,000 | 29,141,667 |
Number of shares | 12,600,000 | 13,540,000 | |||
Weighted average exercise price (in Dollars per share) | $ 0.026 | $ 0.023 | |||
Number of shares, Exercised | (1,000,000) | ||||
Weighted average exercise price Exercised (in Dollars per share) | $ 0.35 | ||||
Number of shares, Issued | 6,000,000 | ||||
Weighted average exercise price Issued | 0.005 | ||||
Number of shares, Forfeited | (940,000) | (20,601,667) | |||
Weighted average exercise price Forfeited (in Dollars per share) | $ 0.015 |
STOCK WARRANTS (Details) - Sc_2
STOCK WARRANTS (Details) - Schedule of Fixed-Price Warrants Outstanding - Fixed-price Contract [Member] - $ / shares | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
STOCK WARRANTS (Details) - Schedule of Fixed-Price Warrants Outstanding [Line Items] | ||
Weighted Average Number Outstanding (in Shares) | 12,600,000 | 13,540,000 |
Weighted Average Contractual Life | 1 year 40 days | 1 year 9 months |
Weighted Average Exercise Price | $ 0.024 | $ 0.023 |
Minimum [Member] | ||
STOCK WARRANTS (Details) - Schedule of Fixed-Price Warrants Outstanding [Line Items] | ||
Exercise Price | 0.005 | 0.005 |
Maximum [Member] | ||
STOCK WARRANTS (Details) - Schedule of Fixed-Price Warrants Outstanding [Line Items] | ||
Exercise Price | $ 0.05 | $ 1 |
INCOME TAXES (Details)
INCOME TAXES (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
INCOME TAXES (Details) [Line Items] | ||
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | $ (3,748,415) | $ 803,561 |
Operating Loss Carryforwards, Expiration Date | Dec. 31, 2037 | |
Operating Loss Carryforwards | $ 35.8 | $ 35.4 |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% | 34.00% |
Corporate Tax Rate Prior to December 2017 [Member] | ||
INCOME TAXES (Details) [Line Items] | ||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 34.00% | |
Corporate Tax Rate After December 2017 [Member] | ||
INCOME TAXES (Details) [Line Items] | ||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% |
INCOME TAXES (Details) - Schedu
INCOME TAXES (Details) - Schedule of Tax Expense - USD ($) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Schedule of Tax Expense [Abstract] | ||
Federal tax rate | 21.00% | 34.00% |
Add: State taxes | 5.50% | 5.50% |
Permanent difference | (1.20%) | (1.90%) |
Valuation allowance and change in federal tax rate | (25.35%) | (37.63%) |
Computed “expected” tax expense (benefit) - Federal | $ (793,340) | $ (1,345,175) |
Computed “expected” tax expense (benefit) - State | (164,145) | (230,267) |
Permanent differences | 571,235 | 771,881 |
Change in federal tax rate | 4,134,665 | |
Change in valuation allowance | (3,748,415) | 803,561 |
Reserve for prepaid inventory | 12,104 | |
Accrued salary | 296,834 | 347,674 |
Net operating loss carryforwards | 9,083,135 | 12,792,814 |
Valuation allowance | (9,392,073) | (13,140,488) |
Net deferred income tax asset |
ACCRUED EXPENSES (Details) - Sc
ACCRUED EXPENSES (Details) - Schedule of Accrued Expenses - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 |
Schedule of Accrued Expenses [Abstract] | ||
Accrued consulting fees | $ 161,550 | $ 161,550 |
Accrued settlement expenses | 347,400 | 315,000 |
Accrued payroll taxes | 120,182 | 72,452 |
Accrued interest | 180,509 | 133,865 |
Accrued legal fees | 239,020 | |
Accrue others | 22,208 | 27,509 |
Total | $ 831,849 | $ 949,396 |
PREPAID EXPENSES (Details)
PREPAID EXPENSES (Details) - Prepaid Venom [Member] | 12 Months Ended |
Dec. 31, 2018USD ($) | |
PREPAID EXPENSES (Details) [Line Items] | |
SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease) | $ 47,757 |
Deferred Tax Assets, Valuation Allowance | $ 200,911 |
PREPAID EXPENSES (Details) - Sc
PREPAID EXPENSES (Details) - Schedule of Prepaid Expenses - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 |
Schedule of Prepaid Expenses [Abstract] | ||
Supplier advances for future purchases | $ 200,911 | $ 189,154 |
Reserve for supplier advances | (200,911) | (153,154) |
Net supplier advances | 36,000 | |
Prepaid professional fees | 13,000 | 16,500 |
Deferred stock compensation | 50,000 | |
Total | $ 63,000 | $ 52,500 |
COMMITMENTS AND CONTINGENCIES_2
COMMITMENTS AND CONTINGENCIES (Details) - Operating Leases - USD ($) | 1 Months Ended | 12 Months Ended | 61 Months Ended | ||
Feb. 29, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Aug. 31, 2017 | Jul. 31, 2012 | |
COMMITMENTS AND CONTINGENCIES (Details) - Operating Leases [Line Items] | |||||
Operating Leases, Rent Expense | $ 128,897 | $ 127,400 | |||
Recepto Pharm [Member] | |||||
COMMITMENTS AND CONTINGENCIES (Details) - Operating Leases [Line Items] | |||||
Lessor, Operating Lease, Term of Contract | 3 years | ||||
Operating Leases, Rent Expense, Monthly | $ 3,200 | $ 6,400 | |||
Lessor, Operating Lease, Renewal Term | 5 years | ||||
Lease Expiration Date | Aug. 1, 2017 | ||||
Increase (Decrease) in Prepaid Interest | 0.05 | ||||
Recepto Pharm [Member] | Lease Renewal [Member] | |||||
COMMITMENTS AND CONTINGENCIES (Details) - Operating Leases [Line Items] | |||||
Operating Leases, Rent Expense, Monthly | $ 6,900 | ||||
Lessor, Operating Lease, Renewal Term | 5 years |
COMMITMENTS AND CONTINGENCIES_3
COMMITMENTS AND CONTINGENCIES (Details) - Consulting Agreements - USD ($) | 1 Months Ended | ||||||||||
Dec. 31, 2018 | Dec. 31, 2016 | Oct. 31, 2015 | Jul. 31, 2015 | Aug. 31, 2012 | Dec. 31, 2017 | Sep. 30, 2017 | Aug. 31, 2017 | Jul. 31, 2017 | Apr. 30, 2017 | Feb. 29, 2016 | |
COMMITMENTS AND CONTINGENCIES (Details) - Consulting Agreements [Line Items] | |||||||||||
Common Stock, Shares, Issued (in Shares) | 4,046,746,110 | 2,032,233,701 | |||||||||
Debt Instrument, Face Amount | $ 51,000 | $ 56,567 | $ 50,000 | $ 180,250 | |||||||
Consultant Agreement 1 [Member] | |||||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Consulting Agreements [Line Items] | |||||||||||
Lessor, Operating Lease, Term of Contract | 5 years | 65 days | |||||||||
Common Stock, Shares, Issued (in Shares) | 500,000 | ||||||||||
Debt Instrument, Term | 1 year | ||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||||
Debt Instrument, Face Amount | $ 50,000 | ||||||||||
Consulting Fees [Member] | |||||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Consulting Agreements [Line Items] | |||||||||||
Common Stock, Shares, Issued (in Shares) | 2,500,000 | ||||||||||
Accrued expense | $ 19,150 | ||||||||||
Payments for Other Fees | $ 3,000 | ||||||||||
Deferred Compensation Equity | $ 31,750 | ||||||||||
Deferred Compensation Arrangement with Individual, Shares Issued (in Shares) | 1,000,000 | ||||||||||
Share Based Compensation, Shares Not Yet Issued (in Shares) | 1,500,000 | ||||||||||
Involuntary Petition of Bankruptcy [Member] | Original Claim [Member] | |||||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Consulting Agreements [Line Items] | |||||||||||
Accrued expense | $ 142,500 |
COMMITMENTS AND CONTINGENCIES_4
COMMITMENTS AND CONTINGENCIES (Details) - Litigation - USD ($) | Feb. 15, 2019 | Oct. 12, 2018 | Sep. 28, 2018 | Aug. 26, 2016 | Aug. 17, 2015 | Jul. 01, 2015 | Apr. 21, 2011 | Aug. 31, 2018 | Dec. 31, 2018 |
Patricia Meding, et. al. v. ReceptoPharm, Inc. [Member] | |||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Litigation [Line Items] | |||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 360,000 | ||||||||
Litigation Settlement Term Of Payments | 35 months | ||||||||
Payments for Legal Settlements | $ 20,000 | $ 20,000 | $ 10,000 | ||||||
Payment increase in event of default | 200,000 | ||||||||
Loss Contingency Accrual, Provision | 200,000 | ||||||||
Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik “Rik” Deitsch [Member] | |||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Litigation [Line Items] | |||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 350,000 | ||||||||
Litigation Settlement Term Of Payments | 7 years | ||||||||
Payments for Legal Settlements | $ 50,000 | ||||||||
Paul Reid et al. v. Nutra Pharma Corp. et al. [Member] | |||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Litigation [Line Items] | |||||||||
Loss Contingency, Damages Sought, Value | $ 315,000 | ||||||||
Get Credit healthy, Inc. v. Nutra Pharma Corp. and Rik Deitsch [Member] | |||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Litigation [Line Items] | |||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 104,000 | ||||||||
Loss Contingency, Damages Sought, Value | $ 100,000 | ||||||||
Loss Contingency, Settlement Agreement, Terms | We agreed to this request, and mediation took place on February 15, 2019. At December 31, 2018, we owed principal balance of $101,818 and accrued interest of $21,023 (See Note 6). At mediation, Get Credit Healthy, Inc. claimed that the individual that breached the binding memorandum of understanding with Nutra Pharma Corp. was never an owner of Get Credit Healthy, Inc., but rather, a close friend that encouraged Get Credit Healthy, Inc. to make the subject loan to Nutra Pharma Corp. Ultimately, the parties were able to reach a Confidential Settlement Agreement to resolve the dispute, and an Agreed Order was entered dismissing the lawsuit. The lawsuit was settled on February 15, 2019 for $104,000 with scheduled payments. The repayments were made in full as of November 2020 (See Note 13) | ||||||||
Long-term Debt | 101,818 | ||||||||
Debt Instrument, Increase, Accrued Interest | 21,023 | ||||||||
CSA 8411, LLC v. Nutra Pharma Corp [Member] | |||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Litigation [Line Items] | |||||||||
Loss Contingency, Damages Sought, Value | $ 100,000 | ||||||||
Loss Contingency, Settlement Agreement, Terms | Opposing counsel reached out to schedule mediation, and mediation was set for June 21, 2019 in Plantation, FL however the mediation was unsuccessful. At December 31, 2018, we owed principal balance of $91,156 and accrued interest of $19,010 (See Note 6) if the defenses and our new claims are deemed to be of no merit. | ||||||||
Long-term Debt | 91,156 | ||||||||
Debt Instrument, Increase, Accrued Interest | $ 19,010 | ||||||||
Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus [Member] | |||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Litigation [Line Items] | |||||||||
Private Placement Offerings, Amount Raised | $ 920,000 | ||||||||
Reimbursement for third party expenses [Member] | Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik “Rik” Deitsch [Member] | |||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Litigation [Line Items] | |||||||||
Loss Contingency, Damages Sought, Value | 359,826.85 | ||||||||
Punitive Damages [Member] | Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik “Rik” Deitsch [Member] | |||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Litigation [Line Items] | |||||||||
Loss Contingency, Damages Sought, Value | $ 500,000 |
COMMITMENTS AND CONTINGENCIES_5
COMMITMENTS AND CONTINGENCIES (Details) - Operating Leases | Dec. 31, 2018USD ($) |
Operating Leases [Abstract] | |
2019 | $ 84,765 |
2020 | 87,991 |
2021 | 99,163 |
2022 | 54,490 |
$ 326,409 |
SUBSEQUENT EVENTS (Details) - C
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable - USD ($) | 1 Months Ended | 2 Months Ended | 10 Months Ended | ||||||||
Aug. 31, 2020 | Jul. 31, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Jun. 30, 2019 | Feb. 28, 2019 | Mar. 31, 2020 | Feb. 28, 2020 | Oct. 31, 2020 | Nov. 30, 2019 | Jan. 31, 2019 | |
Note Holder 2 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Advance from Non-Related Party | $ 15,000 | ||||||||||
Promissory [Member] | Note Holder 1 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 55,000 | ||||||||||
Debt Instrument, Unamortized Discount | 5,000 | ||||||||||
Promissory [Member] | Note Holder 3 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 1,000,000 | ||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0005 | ||||||||||
Common Stock, Shares, Issued (in Shares) | 1,250,000,000 | ||||||||||
Convertible Notes Payable | $ 275,000 | ||||||||||
Stock Issued During Period, Value, Other | $ 700,000 | ||||||||||
Notes Payable | $ 114,572 | ||||||||||
Promissory [Member] | Note Holder 4 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 240,000 | ||||||||||
Debt Instrument, Unamortized Discount | $ 40,000 | ||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0005 | ||||||||||
Common Stock, Shares, Issued (in Shares) | 16,000,000 | ||||||||||
Amortization of Debt Issuance Costs and Discounts | $ 4,688 | ||||||||||
Promissory [Member] | Note Holder 5 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 137,500 | ||||||||||
Debt Instrument, Unamortized Discount | $ 12,500 | ||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.000275 | ||||||||||
Promissory [Member] | Note Holder 6 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Debt Instrument, Face Amount | 22,000 | ||||||||||
Debt Instrument, Unamortized Discount | $ 2,000 | ||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0002 | ||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 20,000 | ||||||||||
Promissory [Member] | Note Holder 7 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 68,750 | $ 68,750 | |||||||||
Debt Instrument, Unamortized Discount | $ 6,250 | $ 6,250 | |||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0005 | $ 0.0005 | |||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 5,500 | ||||||||||
Promissory [Member] | Note Holder 8 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 22,000 | 22,000 | |||||||||
Debt Instrument, Unamortized Discount | $ 2,000 | $ 2,000 | |||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0003 | $ 0.0003 | |||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 20,000 | ||||||||||
Promissory [Member] | Note Holder 9 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 5,500 | $ 5,500 | |||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0002 | $ 0.0002 | |||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 5,000 | ||||||||||
Promissory [Member] | Note Holder 10 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Debt Instrument, Face Amount | 5,500 | $ 5,500 | |||||||||
Debt Instrument, Unamortized Discount | $ 500 | $ 500 | |||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0005 | $ 0.0005 | |||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 3,300 | ||||||||||
Promissory [Member] | Note Holder 11 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 22,000 | ||||||||||
Debt Instrument, Unamortized Discount | $ 2,000 | ||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0005 | ||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 13,200 | ||||||||||
Promissory [Member] | Note Holder 12 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 20,900 | ||||||||||
Debt Instrument, Unamortized Discount | $ 1,900 | ||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.00052 | ||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 15,273 | ||||||||||
Promissory [Member] | Note holder 13 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Debt Instrument, Face Amount | 5,500 | ||||||||||
Debt Instrument, Unamortized Discount | $ 500 | ||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0005 | ||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 1,100 | ||||||||||
Note Holder 2 [Member] | Promissory [Member] | Note Holder 9 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Debt Instrument, Unamortized Discount | $ 500 | $ 500 | |||||||||
Restated Note [Member] | Promissory [Member] | Note Holder 1 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Debt Instrument, Unamortized Discount | 7,550 | $ 1,650 | |||||||||
Other Notes Payable | $ 38,500 | $ 22,000 | $ 16,500 | ||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0005 | ||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.001 | ||||||||||
Restated Note [Member] | Promissory [Member] | Note Holder 3 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Other Notes Payable | $ 389,572 | ||||||||||
Notes Eliminated [Member] | Promissory [Member] | Note Holder 3 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||
Other Notes Payable | 27,000 | ||||||||||
Debt Instrument, Increase, Accrued Interest | $ 11,412 |
SUBSEQUENT EVENTS (Details) - P
SUBSEQUENT EVENTS (Details) - PPP Loan - PPP Loan [Member] | May 30, 2020USD ($) |
SUBSEQUENT EVENTS (Details) - PPP Loan [Line Items] | |
Other Loans Payable, Long-term, Noncurrent | $ 64,895 |
Federal Loan, Interest Rate | 1.00% |
Loans Held-for-sale, Term | 24 months |
SUBSEQUENT EVENTS (Details) - E
SUBSEQUENT EVENTS (Details) - Economic Injury Disaster Loan - Economic Injury Disaster Loan [Member] | 3 Months Ended |
Jun. 30, 2020USD ($) | |
SUBSEQUENT EVENTS (Details) - Economic Injury Disaster Loan [Line Items] | |
Other Loans Payable, Long-term, Noncurrent | $ 154,900 |
Interest Accrual Rate Associated with Amortization Method of Present Value of Future Insurance Profits | 3.75% |
Payments for Loans | $ 731 |
Advance On Federal Loan | $ 5,000 |
SUBSEQUENT EVENTS (Details) -_2
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Services - USD ($) | 1 Months Ended | 2 Months Ended | 3 Months Ended | ||||||||||||||||
Oct. 31, 2020 | Sep. 30, 2020 | Jul. 31, 2020 | Jan. 31, 2020 | Sep. 30, 2019 | Aug. 30, 2019 | Jul. 31, 2019 | Jun. 30, 2019 | May 31, 2019 | Apr. 30, 2019 | Aug. 31, 2018 | Apr. 30, 2018 | Sep. 30, 2017 | Aug. 31, 2017 | Jul. 31, 2017 | Apr. 30, 2017 | Feb. 28, 2018 | Nov. 30, 2017 | Dec. 31, 2018 | |
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Services [Line Items] | |||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 5,000,000 | 5,000,000 | 4,000,000 | 300,000 | 2,000,000 | 500,000 | 4,250,000 | 25,000,000 | 25,500,000 | ||||||||||
Stock Issued During Period, Value, Other | $ 3,800 | $ 8,678 | $ 3,656 | $ 417 | $ 4,912 | $ 2,413 | $ 9,887 | $ 15,000 | $ 9,781 | ||||||||||
Default Payments [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Services [Line Items] | |||||||||||||||||||
Stock Issued During Period, Value, Other | $ 900 | $ 6,000 | $ 700 | $ 45,000 | $ 4,000 | $ 700 | $ 1,500 | $ 150 | $ 900 | ||||||||||
Stock Issued for Services [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Services [Line Items] | |||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 15,000,000 | 120,000,000 | |||||||||||||||||
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture | $ 24,000 |
SUBSEQUENT EVENTS (Details) -_3
SUBSEQUENT EVENTS (Details) - Promissory Notes - USD ($) | 1 Months Ended | 7 Months Ended | |||||||||||
Dec. 31, 2020 | Oct. 31, 2020 | Sep. 30, 2020 | Jul. 31, 2020 | Mar. 31, 2020 | Jan. 31, 2020 | Sep. 30, 2019 | May 31, 2019 | Aug. 31, 2018 | Jun. 30, 2020 | Dec. 31, 2019 | Aug. 31, 2019 | Jan. 31, 2019 | |
Restatement of Convertible Promissory Notes [Member] | |||||||||||||
SUBSEQUENT EVENTS (Details) - Promissory Notes [Line Items] | |||||||||||||
Debt Instrument, Face Amount | $ 148,225 | $ 60,000 | $ 36,000 | $ 24,000 | |||||||||
Debt Instrument, Unamortized Discount | $ 6,000 | 10,000 | 6,000 | 4,000 | |||||||||
Repayments of Convertible Debt | 6,000 | 2,400 | |||||||||||
Convertible Notes Payable | 36,000 | 166,926 | 148,225 | 36,000 | $ 24,000 | ||||||||
Common Stock, Shares, Issued (in Shares) | 3,000,000 | ||||||||||||
Amortization of Debt Issuance Costs and Discounts | 5,090 | $ 900 | |||||||||||
Repayments of Other Debt | $ 6,000 | ||||||||||||
Debt Instrument, Increase, Accrued Interest | $ 18,701 | $ 88,225 | |||||||||||
Accrued Interest Rate | 2.50% | ||||||||||||
Debt, Weighted Average Interest Rate | 2.00% | 2.00% | |||||||||||
Restatement of Convertible Promissory Notes [Member] | Note Holder 1 [Member] | |||||||||||||
SUBSEQUENT EVENTS (Details) - Promissory Notes [Line Items] | |||||||||||||
Debt Instrument, Face Amount | 48,000 | ||||||||||||
Debt Instrument, Unamortized Discount | 8,000 | ||||||||||||
Repayments of Convertible Debt | 8,000 | ||||||||||||
Convertible Notes Payable | $ 40,000 | ||||||||||||
Common Stock, Shares, Issued (in Shares) | 3,000,000 | ||||||||||||
Amortization of Debt Issuance Costs and Discounts | $ 900 | ||||||||||||
Restatement of Convertible Promissory Notes [Member] | Note Holder 3 [Member] | |||||||||||||
SUBSEQUENT EVENTS (Details) - Promissory Notes [Line Items] | |||||||||||||
Convertible Notes Payable | $ 333,543 | ||||||||||||
Common Stock, Shares, Issued (in Shares) | 20,000,000 | ||||||||||||
Restatement of Promissory Notes [Member] | Note Holder 3 [Member] | |||||||||||||
SUBSEQUENT EVENTS (Details) - Promissory Notes [Line Items] | |||||||||||||
Debt Instrument, Face Amount | $ 282,983 | ||||||||||||
Settlement of Convertible Promissory Notes [Member] | |||||||||||||
SUBSEQUENT EVENTS (Details) - Promissory Notes [Line Items] | |||||||||||||
Debt Instrument, Face Amount | $ 511,319 | $ 49,684 | $ 12,000 | ||||||||||
Debt Instrument, Unamortized Discount | $ 2,700 | $ 2,000 | |||||||||||
Repayments of Convertible Debt | $ 3,500 | ||||||||||||
Settlement of Notes Payable, Shares (in Shares) | 260,000,000 | 1,500,000 | 81,000,000 | ||||||||||
Common Stock, Value, Issued | $ 130,000 | $ 450 | $ 32,400 | ||||||||||
Settlement of Notes Payable | $ 12,000 | ||||||||||||
Settlement of Convertible Promissory Notes [Member] | Note Holder 8 [Member] | |||||||||||||
SUBSEQUENT EVENTS (Details) - Promissory Notes [Line Items] | |||||||||||||
Debt Instrument, Face Amount | 9,900 | ||||||||||||
Debt Instrument, Unamortized Discount | $ 900 | ||||||||||||
Settlement of Notes Payable, Shares (in Shares) | 40,000,000 | ||||||||||||
Common Stock, Value, Issued | $ 24,000 | ||||||||||||
Settlement of Convertible Promissory Notes [Member] | Note Holder 11 [Member] | |||||||||||||
SUBSEQUENT EVENTS (Details) - Promissory Notes [Line Items] | |||||||||||||
Convertible Notes Payable | $ 22,000 | 22,000 | |||||||||||
Debt Instrument, Increase, Accrued Interest | $ 10,345 | $ 10,140 | |||||||||||
Settlement of Notes Payable, Shares (in Shares) | 107,817,770 | 107,133,333 | |||||||||||
Settlement of Convertible Promissory Notes [Member] | Currently in default and negotiation [Member] | |||||||||||||
SUBSEQUENT EVENTS (Details) - Promissory Notes [Line Items] | |||||||||||||
Other Notes Payable | $ 8,500 | ||||||||||||
Settlement of Convertible Promissory Notes [Member] | Consulting Fees [Member] | |||||||||||||
SUBSEQUENT EVENTS (Details) - Promissory Notes [Line Items] | |||||||||||||
Debt Instrument, Face Amount | $ 46,500 | ||||||||||||
Settlement of Notes Payable, Shares (in Shares) | 5,000,000,000 | ||||||||||||
Accounts Payable, Current | $ 39,000 | ||||||||||||
Common Stock, Value, Outstanding | $ 300,000 | ||||||||||||
Settlement and Restatement of Promissory Notes [Member] | Note Holder 12 [Member] | |||||||||||||
SUBSEQUENT EVENTS (Details) - Promissory Notes [Line Items] | |||||||||||||
Debt Instrument, Face Amount | $ 120,000 | ||||||||||||
Debt Instrument, Unamortized Discount | $ 20,000 | ||||||||||||
Settlement of Notes Payable, Shares (in Shares) | 125,000,000 | ||||||||||||
Other Notes Payable | $ 50,000 | ||||||||||||
Settlement and Restatement of Promissory Notes [Member] | Note Holder 12 [Member] | Additional Shares Issued [Member] | |||||||||||||
SUBSEQUENT EVENTS (Details) - Promissory Notes [Line Items] | |||||||||||||
Debt Instrument, Unamortized Discount | $ 14,000 | ||||||||||||
Settlement of Notes Payable, Shares (in Shares) | 36,000,000 | ||||||||||||
Settlement of Notes Payable | $ 10,000,000 | ||||||||||||
Other Notes Payable | 70,000 | ||||||||||||
Stock Issued During Period, Value, Other | 119,700 | ||||||||||||
Settlement and Restatement of Promissory Notes [Member] | Currently in default and negotiation [Member] | Additional Shares Issued [Member] | |||||||||||||
SUBSEQUENT EVENTS (Details) - Promissory Notes [Line Items] | |||||||||||||
Other Notes Payable | $ 84,000 | ||||||||||||
Settlement of a Related-Party Note [Member] | |||||||||||||
SUBSEQUENT EVENTS (Details) - Promissory Notes [Line Items] | |||||||||||||
Debt Instrument, Face Amount | $ 14,400 | ||||||||||||
Debt Instrument, Unamortized Discount | $ 2,400 | ||||||||||||
Settlement of Notes Payable, Shares (in Shares) | 5,000,000 | ||||||||||||
Common Stock, Value, Issued | $ 3,000 | ||||||||||||
Settlement of Notes Payable | $ 14,400 | ||||||||||||
Sold to Non-Related Party [Member] | Settlement of Convertible Promissory Notes [Member] | Note Holder 11 [Member] | |||||||||||||
SUBSEQUENT EVENTS (Details) - Promissory Notes [Line Items] | |||||||||||||
Convertible Notes Payable | $ 467,000 | ||||||||||||
Debt Instrument, Increase, Accrued Interest | 166,168 | ||||||||||||
Debt Securities, Held-to-maturity, Sold at Par Value | $ 250,000 |
SUBSEQUENT EVENTS (Details) - A
SUBSEQUENT EVENTS (Details) - Advances | May 30, 2020USD ($) |
Subsequent Events [Abstract] | |
Investments in and Advance from Affiliates, Subsidiaries, Associates, and Joint Ventures | $ 175,000 |
SUBSEQUENT EVENTS (Details) -_4
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments - Default Payments [Member] - USD ($) | 1 Months Ended | ||||||||
Oct. 31, 2020 | Sep. 30, 2020 | Jul. 31, 2020 | Jan. 31, 2020 | Sep. 30, 2019 | Aug. 30, 2019 | Jul. 31, 2019 | Jun. 30, 2019 | May 31, 2019 | |
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments [Line Items] | |||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 1,500,000 | 10,000,000 | 1,000,000 | 75,000,000 | 10,000,000 | 2,000,000 | 5,000,000 | 500,000 | 3,000,000 |
Debt Instrument, Face Amount | $ 84,000 | $ 333,543 | $ 22,000 | $ 148,225 | $ 60,000 | $ 282,983 | $ 12,000 | $ 48,000 | |
Stock Issued During Period, Value, Other | $ 900 | $ 6,000 | $ 700 | $ 45,000 | 4,000 | $ 700 | $ 1,500 | $ 150 | 900 |
Debt Instrument, Unamortized Discount | $ 10,000 | ||||||||
Notes Originated in November 2018 [Member] | |||||||||
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments [Line Items] | |||||||||
Debt Instrument, Face Amount | $ 24,000 |
SUBSEQUENT EVENTS (Details) - S
SUBSEQUENT EVENTS (Details) - Schedule of Warrants Issued - USD ($) | Oct. 10, 2017 | Oct. 09, 2017 | Oct. 31, 2020 | Aug. 31, 2020 | Dec. 31, 2019 | Feb. 28, 2019 | Apr. 30, 2017 | Dec. 31, 2018 |
Schedule of Warrants Issued [Abstract] | ||||||||
Number of Warrants | 39,930,000 | 92,100,000 | 44,000,000 | 110,000,000 | 615,230 | |||
Fair Value of Warrants | $ 59,760 | $ 40,501 | $ 9,497 | $ 22,879 | $ 7,370 | $ 8,147 | $ 174,535 | |
Month of Expiration | 2022-10 | 2021-08 | 2020-08 | 2019-08 |
SUBSEQUENT EVENTS (Details) -_5
SUBSEQUENT EVENTS (Details) - Schedule of Shares Converted - USD ($) | Oct. 05, 2020 | Sep. 22, 2020 | Feb. 18, 2020 | Jan. 21, 2020 | Jun. 06, 2019 | May 31, 2019 | May 06, 2019 | Jul. 31, 2017 |
Note Holder 17 [Member] | ||||||||
SUBSEQUENT EVENTS (Details) - Schedule of Shares Converted [Line Items] | ||||||||
Number of Shares Converted | 250,000,000 | 250,000,000 | 250,000,000 | 250,000,000 | 250,000,000 | 5,432,195 | ||
Fair Value of Debt Converted | $ 275,000 | $ 150,000 | $ 100,000 | $ 100,000 | $ 75,000 | |||
Note Holder 18 [Member] | ||||||||
SUBSEQUENT EVENTS (Details) - Schedule of Shares Converted [Line Items] | ||||||||
Number of Shares Converted | 107,817,770 | 107,133,333 | ||||||
Fair Value of Debt Converted | $ 64,691 | $ 171,413 | $ 41,925 |